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      Combination chemotherapy is commonly used to treat cancer, because such a therapy 
regimens usually involve sequential administration of multiple drugs and allow targeting 
different cell signaling pathway. The co-delivery of drug combination at a controlled 
ratio via the same vehicle is offering the advantages such as spatial-temporal 
synchronization of drug exposure, synergistic therapeutic effects and suppression of drug 
resistance. Undoubtedly, there are several molecular and pharmacological factors that 
determine the effectiveness of drug combinations. A rationally designed drug 
combination is required since certain drug ratios and the definitive exposure to the targets 
of interest can only be synergistic while others are additive or even antagonistic. Cisplatin 
(CDDP) and paclitaxel (PTX) combination has resulted in improvement in the ovarian 
cancer treatment compare to individual drug with limited side effects. Multiple clinical 
trials studied the overall efficacy of CDDP and PTX and found significant benefit over 
the pre-existing treatments. Since then, this combination has been the treatment of choice 
for both early stage as well as advanced cases of ovarian cancer. However, administration 
of two different agents comes with the inconvenience of repeated or extended duration of 
drug infusion in patients. Moreover, the most extensively used conventional formulation 
of paclitaxel, Taxol®, utilizes Cremophor EL (polyethoxylated castor oil) that has been 
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linked to significant toxicities including allergic, hypersensitivity and anaphylactic 
reactions during infusion that require premedication and prolonged peripheral 
neuropathy. Combining such drugs in one delivery carrier is therefore a well-suited and 
convenient strategy for controlling the pharmacokinetics and co-delivery of the desired 
drug ratio in vivo, to maximize the therapeutic potency and minimize drug-associated 
toxicities. In an attempt to develop such multidrug vehicle, we designed a functional 
biodegradable and biocompatible polypeptide-based polymeric nanogels. Triblock 
copolymers containing the blocks of ethylene glycol, glutamic acid and phenylalanine 
(PEG–PGlu–PPhe) were successfully synthesized via NCA-based ring-opening 
copolymerization and their composition was confirmed by 
1
H NMR. Self-assembly 
behavior of PEG–PGlu90–PPhe25 was utilized for the synthesis of hybrid micelles with 
PPhe hydrophobic core, cross-linked ionic PGlu intermediate shell layer, and PEG 
corona. Cross-linked micelles (nanogels, NG) were about 90 nm in diameter (ξ-potential 
= − 20 mV), uniform (narrow size distribution), and exhibited nanogels-like behavior. 
Degradation of NG was observed in the presence of proteolytic enzymes (cathepsin B). 
The resulting NG can incorporate the combination of drugs with very different physical 
properties such as CDDP (15 w/w% loading) and PTX (9 w/w% loading). Binary drug 
combination in NG exhibited synergistic cytotoxicity against human ovarian A2780 
cancer cells and exerted a superior antitumor activity by comparison to individual drug-
loaded NGs or free cisplatin in cancer xenograft model in vivo. However, this system 
relies solely on the enhanced permeation and retention (EPR) effect to facilitate the 
delivery of the drug combination to the tumor site.  Regardless of the importance and 
popularity of EPR effect-based drug delivery, this strategy has some limitations related to 
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the inter- and intra-tumor heterogeneity, variations in the density as well as permeability 
of the tumor vasculature that can affect the accumulation of nanocarriers. One of the 
popular approaches to circumvent these problems is by surface-functionalization of the 
drug carrier with ligands that can target receptors with differential expression on the 
cancer cell surface, which helps in increasing the mean residence time of the delivery 
system at the tumor site and improving target cell uptake.  
      One such receptor of interest is the folate receptor (FR). Its natural ligand, FA, comes 
with the advantages of high binding affinity, stability and a simple chemical structure 
together with ease of availability, making it a suitable targeting ligand for ovarian cancer 
therapy. FA can thus be successfully conjugated to macromolecular systems without loss 
of binding affinity to its receptor. Our group has previously demonstrated a tumor-
specific delivery and improved anti-cancer effect in vivo of CDDP-loaded NGs decorated 
with FA targeting groups. In the next part of our study, we designed FA-linked NGs 
incorporating platinum-taxane combination, and examined whether FR-targeted 
concurrent delivery of synergistic combination of CDDP and PTX can lead to enhanced 
therapeutic efficacy compared to nontargeted NG system. FA-decorated NGs 
significantly suppressed the growth of intraperitoneal ovarian tumor xenografts 
outperforming their nontargeted counterparts without extending their cytotoxicity to the 
normal tissues. We also confirmed that synchronized co-delivery of the platinum-taxane 
drug combination via single carrier to the same targeted cells is more advantageous than a 
combination of targeted single drug formulations administered at the same drug ratio. 
Lastly, we demonstrated that the same platform can also be used for localized 
chemotherapy. Our data indicate that intraperitoneal administration can be more effective 
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in the context of targeted combination therapy. Our findings suggest that multifunctional 
NGs are promising drug delivery carriers for improvement of current treatment for 
ovarian cancer. 
      Combination chemotherapy is also very common in the treatment of breast cancer. 
Trastuzumab (Herceptin™), in combination with chemotherapy is currently used for 
treatment of ErbB2-overexpressing breast cancers, following surgical removal of the 
primary tumor. However, patients either do not respond to Trastuzumab based therapies 
or relapse during the course of the treatment, necessitating the development of newer 
therapeutics. ErbB2 depends on heat shock protein 90 (HSP90) association for stability 
and, among client proteins of the chaperone, ErbB2 is perhaps the most sensitive to 
HSP90 inhibition. HSP90 inhibitors (such as the ansamycin antibiotic, Geldanamycin and 
related molecules like 17-AAG) have shown significant promise in pre-clinical models of 
ErbB2-driven breast cancer as well as initial phase I/II clinical trials. The mechanism 
involves attenuation of oncogenic signaling via degradation of ErbB2 as well as other 
critical downstream signaling mediators in the pathway, which include phospho-Akt and 
c-Raf. In a cancer cell, these signaling molecules are strongly dependent on HSP90 to 
maintain their stability. In a recently completed phase II study of 17-AAG and 
trastuzumab, an overall clinical benefit (including stable disease) was seen in 57% of the 
patients with ErbB2-positive metastatic breast cancer progressing on trastuzumab. We 
therefore hypothesized that HSP90-inhibition will enhance ErbB2-targeted drug delivery 
by promoting the endocytic uptake of ErbB2-bound nano-encapsulated cargo and 
facilitating its re-routing from a recycling pathway to the lysosomes. Using Trastuzumab-
conjugated NGs (Trast-NG) encapsulating the DNA-damaging drug Doxorubicin (DOX) 
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as a model chemotherapeutic, we demonstrate through both in vitro and in vivo studies 
that HSP90-inhibition can indeed lead to an enhancement of targeted delivery of DOX 
specifically into ErbB2-overexpressing breast cancer cells. As a consequence, a sub-
therapeutic and non-toxic dose of the HSP90 inhibitor 17AAG markedly improves the 
efficacy of ErbB2-targetd nanogels in vivo. In a follow up study, we attempted to co-
encapsulate DOX and 17-AAG since combining drugs in one delivery carrier is a well-
suited strategy for controlling the pharmacokinetics and co-delivery of the desired drug 
ratio in vivo. However, co-incorporation of drug molecules with different 
physicochemical properties, such as hydrophilic DOX and hydrophobic 17-AAG, has 
been challenging. We have recently described biodegradable polymeric nanogels (NGs) 
based on poly(ethylene glycol)-b-poly(L-glutamic acid) (PEG-b-PGA) with pendant 
phenylalnine functionalities [23]. Such NGs have multiple hydrophobic domains formed 
by phenylalanine moieties within the cross-linked PGA polyion cores surrounded by a 
hydrophilic PEG shell.  Herein, we explored these novel NGs for co-encapsulation of 17-
AAG and DOX. The potency of this co-delivery system was evaluated in a panel of 
human breast cancer lines and in an ErbB2-driven orthotopic xenograft model. We 
demonstrate that NGs-based co-delivery of synergistic combination of 17-AAG and DOX 
exhibited superior antitumor efficacy compared to a combination of free drugs. The 
implications of our results may support a new platform for delivery of combinations of 
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PEG-b-PGlu-b-PPhe   Polyethylene Glycol-block-poly(L-glutamic acid)-block-poly(L-                 
                                     phenylalanine) 
PME   L-phenylalanine Methyl Ester 
PBS    Phosphate Buffered Saline 
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PMA    Poly(sodium methacrylic acid) 
RBC    Red Blood Cells 
RI    Refractive Index 
RPMI   Roswell Park Memorial Institute medium 
RP-HPLC   Reverse Phase-high Pressure Liquid Chromatography 
ROIs   Regions of Interest 
SD    Standard Deviation 
SEC    Size Exclusion Chromatography 
SEM    Standard Error of the Mean 
TEM    Transmission Electron Microscopy 
THF   Tetrahydrofuran 
T/C     (Vt - Vo) treated tumor/ (Vt - Vo) control tumor, where Vt and Vo  
represent the mean tumor volume on the evaluation day and at the  
start of the treatment, respectively. 
TBME    tert-butyl Methyl Ether 
Trast-NG    Trastuzumab-conjugated Nanogels 
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      Cancer is a major health problem and the second leading cause of illness-related 
death. The six essential changes in cell physiology suggested to collectively contribute to 
the malignant growth are self-sufficiency in growth signals, insensitivity to anti-growth 
signals, tissue invasion and metastasis, limitless replicative potential, sustained 
angiogenesis and evading apoptosis [1]. Currently available chemotherapeutic agents 
have played a significant role in reducing mortality/morbidity and in increasing patient’s 
overall lifespan [2]. Most of the chemotherapeutic agents have relatively narrow 
therapeutic index; develop resistance and leads to off-target biodistribution upon 
intravenous administration leading to severe side effects to healthy tissues. These 
limitations of conventional chemotherapeutic strategies frequently result in suboptimal 
dosing, treatment delay or discontinuance and reduced patient compliance to therapy [3]. 
Despite the recent advances in early diagnosis and cancer treatment, the development of 
chemotherapeutic agents which can effectively deliver on efficacy, safety and 
convenience for the patient remains a great challenge [3].  
1.2. Combination chemotherapy  
      Combination chemotherapy is medicine’s best attempt to address aforementioned 
issues. In combination chemotherapy, cancer cells are attacked by drugs with synergistic 
cytotoxicity by disrupting different stages of the cell reproduction cycle. Majority of 
chemotherapeutic drugs act on a specific phase of the cell cycle, so it is logical to attack 
multiple phases of the cell replication cycle to prevent mutation and resistance. The 
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primary goals of drug combination in anticancer treatment are to overcome tumor 
heterogeneity, reduce chemo-resistance and achieve additive or more desirable 
synergistic anticancer efficacy without overlapping toxicity. Frei et al. proved in 1965 
that a combination therapy consisting of two cytotoxic agents was therapeutically more 
effective than monotherapy in children with acute leukemia [4]. Since then, clinically 
effective drug combinations, that would improve the efficacy of oncology treatment, have 
been widely researched. The fundamentals of combination chemotherapy development 
have remained mostly unchanged over the last few decades. The general principles have 
been to: i) use drugs with non-overlapping toxicities so that each drug can be 
administered at near-maximal dose; ii) combine agents with different mechanisms of 
action and minimal cross-resistance in order to inhibit the emergence of broad spectrum 
drug resistance; iii) preferentially use drugs with proven activity as single drugs and iv) 
administer the combination at early stage disease and at a schedule with a minimal 
treatment-free period between cycles but still allowing the recovery of sensitive target 
tissues [5-7]. In combination therapy the overall therapeutic benefit of the drugs in 
combination were found to be greater than the sum of the effects of the drugs 
individually. The best drug combination with maximal antitumor efficacy can be 
calculated by combination index (CI) analysis, an effective way to demonstrate that drugs 
are working synergistically [8]. Unlike single agent therapy, synergistic combinations of 
two or more agents proved to overcome toxicity and other side-effects associated with 
high doses of single drugs [9, 10]. The use of combination therapy for cancer treatment 




Figure 1.1. Schematic representation depicting various advantages shown by 
combination drug delivery for cancer therapy. Adapted from [11]. 
 
The widely investigated drug combinations for effective cancer treatment are the 
combination of multiple chemotherapeutic agents, chemotherapy with radiotherapy, 
chemotherapy with hormone therapy and immunotherapy with chemotherapy [11]. 
Hormone therapy which involves administration of specific steroid hormones or drugs is 
often given to patients with early stages of breast cancer and it act by 
blocking/downregulating the estrogen receptor or by reducing the estrogen concentration 
around or within the cancer cell [12, 13]. Combination of chemotherapy and radiotherapy 
is one of the most promising strategies for current cancer therapeutics. It has been shown 
to improve patient survival and the locoregional control of various cancers when 
compared with radiotherapy alone [14-16]. Cancer treatment using different monoclonal 
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antibodies is another practiced strategy for the current treatment of cancer. Antibodies 
have the unique capacity to target and kill tumor cells while simultaneously activating 
immune effectors to kill tumor cells through the complement cascade or antibody-
dependent cellular cytotoxicity. This multifaceted antibody-mediated killing mechanism 
combined with chemotherapy has been taken up by various investigators to achieve 
enhanced antitumor activity [17-19]. Among different combination therapies the most 
practiced and well researched therapy method is co-treatment with multiple 
chemotherapeutic drugs. Therefore, current trends in anticancer research have 
progressively concentrated on the development of new combinations of anticancer drugs 
with a view to overcoming the limitations frequently associated with conventional 
chemotherapy. Considering the scope of this work, we have focused on combination 
chemotherapy in leading gynecologic cancers which are ovarian and breast cancer. 
1.3. Combination chemotherapy in ovarian cancer   
      Ovarian cancer is the most lethal gynecologic malignancy in women and it is the 
leading cause of death from gynecologic cancer. Approximately 60% of patients will 
experience a relapse after the standard first-line treatment including cytoreductive surgery 
and adjuvant chemotherapy [20]. At this time, when relapse occurs, the chance of cure 
decreases drastically and treatment is solely palliative. Surgery is not sufficiently 
validated due to the lack of phase III clinical trials, and there are no approved targeted 
therapies in relapsed ovarian cancer. Therefore, chemotherapy is the only option to 
achieve these objectives. Management of ovarian cancer has evolved from single agent to 
combination chemotherapy. Clinical trials performed in the late 1970s demonstrated that 
cisplatin (CDDP) is an active chemotherapy in advanced or recurrent ovarian cancer with 
5 
 
a response rate in the range of 13–30% [21]. Subsequently, CDDP became the primary 
choice for many clinical trials in ovarian cancer. Early trials also identified the toxicity 
profile of this platinum agent including the risk of myelosupression and nephrotoxicity. 
The next generation of ovarian cancer treatment regimens included the combination 
therapy of CDDP plus other chemotherapeutic drug. One of such a research study 
evaluating combination chemotherapy with CDDP plus cyclophosphamide revealed that 
the tumor progression and survival were markedly improved compared with CDDP only 
[22]. As a result, the standard combination chemotherapy in the late 1980s and early 
1990s was CDDP plus cyclophosphamide. Discovery of paclitaxel (PTX) changed the 
standard of care in ovarian cancer yet again. Clinical trials comparing cyclophosphamide 
and CDDP with PTX and CDDP demonstrated that the platinum/taxane treatment 
regimens had an improved outcome compared with standard combination of 
cyclophosphamide and CDDP [23, 24]. After decades of clinical trials, intravenous 
treatment regimens were accepted in the 1990s as the standard of care for advanced 
ovarian cancer [25]. Till today, this combination is considered as standard chemotherapy 
regimen in advanced ovarian cancer and suggested that a plateau has been reached for IV 
chemotherapy. The typical course of platinum/taxane regimen for epithelial ovarian 
cancer involves 3 to 6 cycles. A cycle is a schedule of regular doses of a drug, followed 
by a rest period. In patients with advanced ovarian cancer (stages III–IV), six cycles of 
chemotherapy are recommended [26]. In an attempt to deliver increased concentrations of 
drugs to the ovarian tumors, intraperitoneal (IP) route of administration of chemotherapy 
has been investigated which involves administration of drugs through surgically placed 
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IP catheters (Fig. 1.2). The IP administration allows very large concentrations of active 
agents to reach the tumor while attempting to minimize systemic toxicity.  
 
Figure 1.2 IP administration of chemotherapy in ovarian cancer 
The IP administration of CDDP resulted in a 10–20 fold greater concentration in the 
tumor space compared with IV [27-29], while for paclitaxel the IP pharmacokinetics 
demonstrate a 1000-fold greater IP versus IV concentration [30, 31]. Three randomized 
phase III trials have demonstrated a major improvement in the treatment of advanced 
ovarian cancer through the utilization of IP chemotherapy [32-34]. A phase III study 
reported by Markman and colleagues in 2001 in stage III ovarian cancer patients who had 
undergone optimal debulking surgery to less than 1 cm residual tumor [33]. The standard 
chemotherapy arm used IV PTX and CDDP. The investigational arm utilized IV 




 in the IV arm). This study 
demonstrated an improvement in progressive free survival (22 versus 28 months, 
p = 0.01) and a borderline improvement in overall survival (52 versus 63 months, 
p = 0.05) in the investigational arm. The increased toxicity associated with the IP arm 
prevented the routine use of this regimen despite its proven efficacy. Later a phase III 
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study reported by Armstrong and colleagues in 2006 in optimally debulked stage III 
ovarian cancer patients with less than 1 cm residual tumor [32], established a new 
standard of care. This study randomized patients to IV PTX (135 mg/m
2
) over 24 h on 
day 1 followed by IV CDDP (75 mg/m
2
) on day 2 versus IP CDDP (100 mg/m
2
) on day 2 
and IP paclitaxel (60 mg/m
2
) on day 8. This study demonstrated a significant 
improvement in overall survival (49.7 versus 65.6 months, p = 0.03). Significant 
neurotoxicity was also observed in this study (19% in IP versus 9% in the IV group) (Fig. 
1.3).  
 
Figure 1.3. Overall survival among the 415 patients with stage III ovarian cancer who 
were randomly assigned to treatment with intravenous PTX and CDDP or to treatment 
with intravenous PTX, intraperitoneal CDDP, and intraperitoneal PTX. Adapted from 
[32]. 
 
      Although increased toxicity was noted during and following IP chemotherapy in this 
study, the quality-of-life measurements returned to baseline 1 year following treatment. 
Despite these phase III trials demonstrating a significant survival advantage with IP 
compared with IV chemotherapy and a National Cancer Institute clinical alert supporting 
IP chemotherapy, controversies regarding the use of IP chemotherapy still exist and this 
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route of administration has not gained overwhelming support by the gynecologic and 
medical oncology community [35]. Some of the barriers to utilizing IP therapy include IP 
therapy-related side effects, complexity of IP administration, and controversies still 
related to the clinical survival advantage of IP therapy.  
1.4. Combination chemotherapy in breast cancer 
      Breast cancer is the most frequently diagnosed cancer and the leading cause of 
cancer-related death among females worldwide. The latest world cancer statistics 
available from the International Agency for Research on Cancer showed that 1,677,000 
women were diagnosed with breast cancer and 577,000 women died in 2012 [36]. 
Despite the success in early detection, up to five percent of women diagnosed with breast 
cancer in the United States have metastatic disease at the time of first presentation. In 
addition, up to 30 percent of women with early-stage, non-metastatic breast cancer at 
diagnosis will develop distant metastatic disease [12]. Advancement in chemotherapy, 
surgery, lymph node evaluation and hormone receptor blocking therapy have improved 
the survival of breast cancer patients [37]. Genetic and molecular profiling of breast 
cancer has revealed its profound complexity and heterogeneity [38, 39]. Such complexity 
makes it challenging for clinicians to find the optimal treatment regimen in the treatment 
of breast cancer. The cell surface receptors of the ErbB family including EGFR, ErbB2 
(also known as Her2/neu) and ErbB3 (Her3) are over-expressed or deregulated in many 
types of cancers, including breast cancers. The past two decades have seen an explosion 
of activity in the development of ErbB-receptor targeted therapeutics. EGFR and ErbB2 
have been the primary targets for therapeutic development. For example, the humanized 
monoclonal antibodies Trastuzumab (Herceptin™; Genentech; against ErbB2) or 
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Cetuximab (Erbitux™; Eli Lilly and Company; against EGFR) and the tyrosine kinase 
inhibitors, Lapatinib (Tykerb; Glaxo Smithkline; dual EGFR/Her2 inhibitors) or Erlotinib 
(Tarceva; Genentech; against ErbB2) are currently used clinically. However, de novo and 
acquired resistance to treatment necessitate continued exploration of novel strategies. 
One emerging approach is the use of antibody-drug conjugates, such as Trastuzumab-
DM1 (also developed by Genentech), which is an anti-mitotic fungal toxin chemically 
conjugated to anti-ErbB2 monoclonal antibody. An alternative strategy involves targeted 
delivery of conventional chemotherapeutic drugs (such as Doxorubicin, Paclitaxel or 
Campothecin) encapsulated in anti-ErbB2 or anti-EGFR antibodies or ligands conjugated 
liposomal or polymer micelle based nanoparticles are being explored at a laboratory and 
pre-clinical stage. Both approaches use the overexpression of EGFR and ErbB2 as 
addresses to specifically deliver cytotoxic cargo. This may be particularly useful as a 
strategy for overcoming resistance to currently approved ErbB-directed targeted 
therapies. However, for both antibody-drug conjugates as well as targeted nanoparticulate 
drug-delivery systems, the extent of endocytosis of the receptor and its distribution 
between recycling versus lysosomal pathways can limit successful delivery of the 
chemotherapeutic payload into ErbB2 or EGFR overexpressing breast cancers. 
Considering a scope of thesis, this section is intended to focus on use of clinical 
combination therapy for the treatment of ErbB2-driven breast cancer. Although, 
Trastuzumab in combination with chemotherapy has shown effectiveness in many 
patients, challenges due to intrinsic or acquired therapeutic resistance have prompted the 
development of  Trastuzumab-MCC-DM1 (T-DM1; Genentech), which is an antibody-
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drug conjugate (ADC). DM1 is a Maytansanoid (a derivative of Maytansine; a Vinca 
alkaloid), which functions as an antimitotic drug (Fig. 1.4) [40]. 
 
Figure 1.4. Schematic representation of T-DM1. The maytansine skeleton is shown in 
black at left. The thioether group that makes mertansine is shown in red. The linker group 
that makes emtansine is shown in blue at right, bound to the amino group (NH–) of a 
lysine residue in the trastuzumab molecule (–mab). 
 
DM1 is chemically conjugated to Trastuzumab via a non-reducible Succinimidyl-4-(N-
maleimidomethyl) cyclohexane-1-carboxylate (MCC) crosslinker, which was optimized 
based on a systematic comparison of various reducible and non-reducible crosslinkers in 
in vitro studies (intracellular drug release) and in vivo pharmacokinetics and toxicity 
studies [41-43]. While the mechanism(s) of Trastuzumab resistance remains unclear, 
several studies indicate that it is not due to loss of ErbB2 overexpression [44, 45]; 
consequently the rationale for T-DM1 design was to use ErbB2 as an address to deliver 
the cytotoxic drug specifically to ErbB2-overexpressing breast cancers. T-DM1 
demonstrated potent and selective activity against a panel of ErbB2 overexpressing breast 
cancer cell lines (including several Trastuzumab-resistant model cell lines) as compared 
to normal or ErbB2-low cancer cell lines [46, 47]. Most importantly, the drug exhibited 
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favorable pharmacokinetics, low toxicity in mice and also inhibited growth of 
Trastuzumab-sensitive as well as resistant ErbB2-overexpressing human breast cancer 
cell xenografts in mice [46]. Although it was presumed that the cytotoxicity was a result 
of internalization of the ADC direct data demonstrating internalization of the ADC was 
lacking. The importance of this is underscored by recent studies that have shown that 
ErbB2 receptor is not efficiently internalized [48, 49]. Given the numerous studies, which 
suggest that ErbB2 receptor is either internalization resistant or rapidly recycles back to 
the cell surface [48], data on the site of action of T-DM1 is critical in order to improve 
designs for optimizing the intracellular delivery of the Maytansanoid. This will especially 
become important in cases where patient-specific mutations or alterations in the activities 
of regulators of endocytic trafficking (discussed above) could potentially cause 
refractoriness or reduce the efficacy of T-DM1. For example, one factor that is 
hypothesized to contribute to the low rate of endocytosis is the constitutive association of 
ErbB2 with Heat Shock Protein 90 (HSP90) [49]. It has been demonstrated that HSP90 
ATPase inhibitors such as 17-allylaminodemethoxy geldanamycin (17-AAG) induced 
rapid downregulation of cell surface ErbB2 which is mediated by ubiquitin modification 
of ErbB2 [50, 51]. Subsequent work has shown that 17-AAG indeed promotes the 
delivery of surface ErbB2 to the lysosome [52, 53], an organelle where molecules such as 
T-DM1 are intended to go. Several HSP90 inhibitors are currently in phase I and II 
clinical trials and could potentially be combined with T-DM1.       
1.5. Nanocarrier-based approach for combination chemotherapy 
      Despite the fact that combination chemotherapeutic strategies have helped toward the 
better treatment of cancer, their clinical success is largely hindered as a result of the 
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inadequate accessibility of chemotherapeutic agents to tumor tissue, requiring high doses, 
rapid abolition, poor solubility and inconsistent bioavailability. While in vitro cellular 
studies have generated many leads for combinatorial regimens, their clinical results are 
often met with little improvement in efficacy and at times higher toxicity [54-56]. One 
major factor that separates in vitro success from in vivo clinical outcomes is the varying 
pharmacokinetics among different drugs. Controlling the therapeutic cocktail that reach 
the diseased cells and tissues therefore become a major clinical challenge. One strategy 
toward more effective combination therapies thus is devising a better scheme for precise 
and control delivery of multiple therapeutic agents. Thus, to mitigate the limitations 
associated with conventional combination chemotherapy, there is an urgent need for 
developing a drug delivery system that could enhance the delivery of drugs to the tumor 
site while reducing toxic side effects.  
      Advances in nanotechnology have opened up infinite opportunities in controlled drug 
delivery and novel combination strategies. Nano-formulated drugs have now come of age 
in the clinic and are inspiring innovative investigations in drug delivery [57]. 
Nanoparticle therapies provide improved drug solubility, reduced systemic toxicity, 
longer circulation times in the blood, controllable release profiles, and the potential to 
target specific cells and tissues [58-60]. Recently, nanocarriers are gaining increasing 
attention for their ability to co-encapsulate multiple therapeutic agents and to synchronize 
their delivery to the diseased cells. Various nanoparticle platforms such as liposomes, 
dendrimers, micelles, carbon nanotubes (CNTs), polymer–drug conjugates and nanogels 
have been used to carry broad classes of therapeutics including cytotoxic agents, 




      Liposomes are spherical vesicles consisting of amphiphilic phospholipid bilayers. 
Phosphatidylcholine and phosphatidylethanolamine are the common building blocks for 
liposomal preparation whereas cholesterol is a frequent additive that serves to modify the 
rigidity of the lipid membranes. Liposomes have been pharmaceutical carriers of choice 
for drug delivery applications and several liposomal drug formulations have already been 
approved, and many more are under clinical evaluation [61]. One major advantage of 
liposomes as a drug carrier is its ability to work with both hydrophobic and hydrophilic 
drugs; hydrophobic drugs can be enclosed within the phospholipid bilayers, while 
hydrophilic can drugs reside in the aqueous cavity [62]. Liposomes are typically prepared 
by rehydrating lipid films to form multilamellar vesicles, which subsequently undergo 
mechanical extrusions to form unilamellar vesicles [63]. Multidrug-loaded liposomes can 
be prepared using either active extrusion or passive diffusion followed by filtration of 
unloaded drugs. CPX-351 (cytarabine/daunorubicin liposome injection) is a liposomal 
formulation of cytarabine and daunorubicin for intravenous infusion. [64]. In preparing 
CPX-351, cytarabine was hydrated and extruded with the lipid components yielding 
cytarabine-loaded liposomes. These liposomes were then incubated with daunorubicin to 
achieve dual-drug encapsulation. The two drugs contained within the liposome in a 5:1 
molar ratio, showed synergistic cytotoxicity in vitro and in murine models of 
hematological malignancies Liposome-encapsulated curcumin and resveratrol were 
prepared by film hydration method. Systemic administration of this formulation inhibited 
prostate cancer by increasing their bioavailability synergistically and enhanced the 
anticancer effects. Combination therapy of liposomal paclitaxel and cisplatin as 
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neoadjuvant chemotherapy in locally advanced cervical cancer was evaluated by Li et al 
[65]. Patients were administered with intravenous dose of 175 mg/m
2
 PTX and 75 mg/m
2
 
CDDP. The total response rate was 86.1% (62/72) including a complete response and 
partial response rate of 27.8% (20/72) and 58.3% (42/72). The study showed that 
liposomal paclitaxel with cisplatin as an additional chemotherapy regimen is efficacious 
and tolerable in the NACT of cervical cancer. Transferrin-conjugated liposome co-
encapsulating doxorubicin and varapamil proved to be effective in doxorubicin-resistant 
K562 cells and showed enhanced cytotoxicity caused by overcoming P-gp-mediated 
multidrug resistance [66]. A Phase I study was performed by taking a liposomal 
formulation entrapped with irinotecan and floxuridine in the ratio of 1:1 and the 
maximum tolerated dose and pharmacokinetic parameters of the liposomal formulation 
were determined in patients with advanced solid tumors. The results demonstrated the 
dual-drug-loaded liposomal formulation was well tolerated showing enhanced anticancer 
activity in patients [67]. Co-delivery of the P-gp inhibitor, tariquidar, and cytotoxic drug, 
paclitaxel, into tumor cells to reverse the multi-drug resistance using long-circulating 
liposomes [68]. Anticancer drug combinations can act synergistically or antagonistically 
in vivo against tumor cells depending on the ratios of the individual agents comprising the 
combination. Mayer et al examined the liposomes for loading of various drug 
combinations (irinotecan/floxuridine, cytarabine/daunorubicin, and 
cisplatin/daunorubicin) at different ratios (1:1, 5:1, and 10:1) [69]. The liposomes not 
only maintained drug ratios in the plasma after injection, but also delivered the 
formulated drug ratio directly to tumor tissue. Apart from small molecule therapeutic 
combination, liposomes have been also reported to encapsulate combination of small 
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molecule and oligodeoxynucleotides/siRNAs. Cationic liposomes targeted with a 
monoclonal antibody against the disialoganglioside GD2 co-encapsulating c-myc 
antisense oligodeoxynucleotides and doxorubicin led to the most pronounced delay in 
tumor growth when administered in a sequential manner. As a result, their combination 
translates into a statistically significant suppression of blood vessel density and an 
enhanced apoptosis, compared to all treatments given separately. Saad et al showed an 
efficient encapsulation of doxorubicin and siRNA targeted to MRP1 and BCL2 mRNA 
(suppressors of pump and non-pump cellular-resistance, respectively) into the cationic 
liposomes which led to enhanced cell-death induction and suppression of cellular 
resistance in multi-drug resistant lung cancer cells.  
      Two liposomal drug combinations have entered clinical trials. First is small molecules 
combinations in Phase II clinical trials, CPX-351 (cytarabine and daunorubicin) in 
patients with newly diagnosed acute myeloid leukemia [70], and CPX-1 (irinotecan 
HCI:floxuridine) in patients with colorectal cancer 
(http://www.celatorpharma.com/new/products.html). 
1.5.2. Polymer-dug conjugates 
      Covalently attaching therapeutic agents to water-soluble polymers is another 
approach that improves the drugs systemic circulation lifetime and reduces their exposure 
to normal tissues. The advantages of polymer–drug conjugates include passive tumor 
targeting by EPR effect due to its leaky vasculature which allows selective extravasation 
of the conjugate in tumor tissue and retained for longer period due to its poor lymphatic 
drainage [54]. Polyethylene glycol, poly (l-glutamic acid) (PGA), and N-(2-
hydroxypropyl)methacrylamide (HPMA) are examples of polymers that have been 
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accepted into clinical practice [71]. Currently, more than fourteen polymer–drug 
conjugates have undergone clinical evaluation and a polyglutamic acid (PGA)-paclitaxel 
conjugate (CT-2103, OPAXIO
®
, previously known as Xyotax
®
) is expected to enter the 
market in the near future [71, 72]. Since these polymers have the multivalent functional 
groups, recent research efforts have synthesized conjugates with a combination of drugs 
to the polymer chains and demonstrated synergistic efficacy. HPMA copolymer carrying 
the combination of the aromatase inhibitor aminoglutethimide and doxorubicin was the 
first report of these types of conjugates [73]. Drugs were linked through a biodegradable 
linker and a loading capacity was approximately 5% w/w for aminoglutethimide and 7% 
w/w for doxorubicin. The data suggested that the conjugate carrying both drugs was more 
active than the combination of two polymer conjugates each carrying a single drug [73]. 
A follow on study investigated the mechanism of synergy and suggested that such 
increased activity could be due to a variety of factors, including drug release rate, 
conjugate conformation in solution and possibly, activation of certain molecular 
pathways (induction of apoptosis)[74]. Santucci et al used PEG to conjugate the 
chemotherapeutic agent epirubicin (EPI) and the diffusible messenger nitric oxide (NO). 
Authors build a dendronised structure to one terminus of the PEG chain since unmodified 
PEG has a maximum loading capacity of two drug molecules per polymer chain [75]. 
This strategy also allowed to obtain two chemically distinct termini i.e. a carboxylic acid 




Figure 1.5. Structure of dendronized EPI-PEG-(NO)8 conjugate [75].  
In cancer cells, EPI and NO act synergistically, conversely, in cardiomyocytes NO 
counterbalances EPI induced cardio-toxicity. In vivo studies confirmed that this 
conjugate displayed anticancer activity but was less cardio-toxic [75, 76]. 
Minko group synthesized a six-branched luteinizing hormone secreting hormone-targeted 
conjugate containing equimolecular amounts of camptothecin and BH3. In vitro studies 
showed that such multicomponent conjugate was almost 100 times more cytotoxic than 
the single conjugates and displayed enhanced antitumour activity in vivo when compared 
with monotherapy [77]. 
      Segal et al. developed an HPMA copolymer containing antiangiogenic agent, TNP-
470 (Caplostatin) and the aminobiisphosphonate alendronate [78]. In this combination, 
alendronate has the double function of targeting moiety (to promote bone targeting) and 
of pharmacologically active agent. In vitro evaluation of this combination conjugate 
confirmed its synergy and in vivo results showed almost complete tumour regression 
observed in a human osteosarcoma model [78]. In another study, the same group 
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developed HPMA conjugate of alendronate and paclitaxel. Prostate and breast cancer 
cells showed anticancer and antiangiogenic activity in in vitro experiments and suggest 
promising applications in bone metastasis. 
      Lammers et al synthesized and evaluated an HPMA-based polymer–drug conjugate 
carrying 6.4 wt% of gemcitabine and 5.7 wt% of doxorubicin [79]. The resulting 
construct had able to effectively kill cancer cells in vitro, to circulate for prolonged 
period of time, to localize to tumors relatively selectively, and to inhibit tumor growth. 
As compared to free drug, polymer-dug conjugate increased the efficacy of the 
combination of gemcitabine and doxorubicin without increasing its toxicity, and it more 
strongly inhibited angiogenesis and induced apoptosis [79]. Another HPMA-conjugate 
carrying the doxorubicin and the anti-inflammatory agent dexamethasone was reported 
[80]. The conjugate with a combination of two drugs showed better therapeutic activity 
that the individual drug conjugates. Doxorubicin and a phosphatidylinositol-3 kinase 
inhibitor wortmannin were conjugated alone or combination onto poly(ethylene glycol)-
poly(aspartate hydrazide) block copolymers through a hydrazone bond [81]. Polymer–
drug conjugates assembled into a unimodal micelle structure with a < 100 nm particle 
size. Wortmannin enhanced the efficacy of doxorubicin through an efficient combination 
delivery accompanied by synergistic drug action.  
1.5.3. Polymeric micelles  
      Amphiphilic block or graft copolymers comprised of two or more chains with 
different hydrophobicity have been used extensively in pharmaceutical applications 
ranging from sustained-release technologies to gene delivery. These copolymers are 
known to spontaneously self-assemble in an aqueous solution into nanoscopic polymeric 
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micelles (10 to 100 nm) having fairly narrow size distribution. The nature of the self-
assembly process allows for significant versatility in the chemical composition of the 
polymeric micelles and thus permits fine tuning of the material properties, morphology 
and sizes. These micelles have unique core-shell architectures with hydrophobic polymer 
chains segregating into a micelle core surrounded by a shell of hydrophilic chains. 
Hydrophobic drugs can be entrapped into the micelle core non-specifically through 
hydrophobic interactions or specifically by chemical conjugation to the core-forming 
block of the copolymer via a carefully designed pH- or enzyme-sensitive linker that can 
be cleaved to release a drug in its active form. A variety of drugs with diverse 
physicochemical properties can be incorporated into the core by engineering the structure 
of the core-forming segment of the copolymer to attain sufficiently strong interaction 
with drug molecules. These polymeric micelle systems can also be used for co-delivery 
of two or more drugs with similar or different properties for combination therapy, or to 
combine multiple modalities within a single carrier (Fig. 1.6).  
 
Figure 1.6. Multi-drug polymeric micelles for drug delivery. Adapted from [82]. 
Simultaneous delivery of chemotherapeutic drugs by polymeric micelles improves safety, 
and may permit anticancer agents to act at solid tumors at the same time, aiming for 
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synergistic drug interaction [83-85]. Multi-drug delivery is very often realized by the 
step-wise physical loading of an anticancer agents in a polymeric micelle. Multi-drug 
polymeric micelles may release physically loaded drug(s) by disassembly of polymeric 
micelles in blood and/or by diffusion. Drug release tends to be rapid in vivo, and in vitro 
results must be interpreted with caution due to poor in vitro/in vivo correlation. Thus, 
while EPR targeting of solid tumors is feasible with physically loaded drug, it is regarded 
as challenging, and research on multidrug polymeric micelles for tumor targeting 
deserves more attention. Another way for multi-drug loading is via chemical conjugation, 
a reversible covalent linkage is required between an anticancer agent and a block 
copolymer. Drug release from multi-prodrug polymeric micelles may occur by simple 
hydrolysis or stimuli- /environment dependent release and may be tuned by choice of 
chemical linkage, e.g., esters, and spacer groups [54, 86]. Shin et al attempted to 
physically co-incorporate three hydrophobic drugs, PTX, rapamycin, and 17-AAG in 
Poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles using a simple 




Figure 1.7. PEG-b-PLA micelles for the delivery of PTX, rapamycin, and 17-AAG. 
Adapted from [87]. 
Three drug-loaded PEG-b-PLA micelles had a 10–10,000-fold increase in aqueous 
solubility of PTX, rapamycin, and 17-AAG (up to 7.2, 3.3, and 7.3 mg/mL, respectively). 
PEG-b-PLA micelles delayed release of three drugs compared to single drug-loaded 
micelles in vitro. Simultaneous delivery of PTX, rapamycin, and 17-AAG via 3-in-1 
PEG-b-PLA micelles (particle size of ca. 30–40 nm) at 60, 30, and 60 mg/kg, 
respectively IV injection caused durable antitumor responses in A549 human non-small 
cell lung cancer and MDA-MB-231 human breast cancer xenograft models with 
acceptable acute toxicity [84]. Na et al studied the antitumor effects of 5-fluorouracil, 
CDDP, CPT-11, oxaliplatin, etoposide, mitomycin-C, doxorubicin and PTX by 
determination of in vitro cytotoxicity to CT-26 colorectal tumor cells or in vivo following 
a subcutaneous transplant in BALB/c mice [88]. Single agent and combination in vivo 
studies were performed using drug-loaded polymeric micelles composed of poly(γ-benzyl 
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l-glutamate) and poly(ethylene oxide) (GEG) or poly(l-lactide)/poly(ethylene glycol) 
(LE) diblock copolymer. When tumor cells were exposed to doxorubicin concurrently 
with etoposide or paclitaxel, evidence of synergy was observed in CT-26 cells in vitro. 
Doxorubicin and paclitaxel loaded into GEG or LE copolymers at a high concentration 
(19.5 and 16.7 wt%, respectively) were almost completely released (83.2% and 93.7%, 
respectively) by day 3. When tumor-bearing mice were treated in combination with 
doxorubicin–paclitaxel or doxorubicin–etoposide, substantial antitumor activity was 
evident compared with single therapy. These data suggest that chemotherapy using 
micelle-loaded anticancer drugs represents a promising potential as a carrier system in 
modulating drug delivery. In another study, wang at al reported core-shell-type micelles 
that were doubly emulsified from an amphiphilic copolymer methoxy poly(ethylene 
glycol)-poly(lactide-co-glycolide) (mPEG-PLGA) [89]. These micelles offered 
advantages over other nanocarriers, as they were easy to fabricate by improved double 
emulsion method, biocompatible, and showed high loading efficacy. More importantly, 
these micelles could co-deliver hydrophilic doxorubicin and hydrophobic PTX. The drug-
loaded micelles possessed a better polydispersity, indicating that they are more readily 
subject to controlled size distribution. Co-delivery nanocarrier suppressed tumor cells 
growth more efficiently than the delivery of either doxorubicin or PTX at the same 
concentrations, indicating a synergistic effect. Moreover, the drug-loaded micelles with a 
DOX/PTX concentration ratio of 2:1 showed the highest anti-tumor activity to three 
different types of tumor cells. Kabanov and collaborators reported amphiphilic poly(2-
oxazoline)s (POx)-based micelles as a promising high capacity delivery platform for 
multidrug cancer chemotherapy [85]. A variety of binary and ternary drugs combinations 
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of PTX, docetaxel, 17-AAG, etoposide and bortezomib were solubilized in defined 
polymeric micelles achieving unprecedented high total loading capacities of up to 50 wt 
% drug per final formulation. Multi-drug loaded POx micelles showed enhanced stability 
in comparison to single-drug loaded micelles. Drug ratio dependent synergistic 
cytotoxicity of micellar etoposide /17-AAG was observed in MCF-7 cancer cells and of 
micellar bortezomib /17-AAG in MCF-7, PC3, MDA-MB-231 and HepG2 cells.        
      Katragadda et al developed a micellar nanocarriers for concomitant delivery of PTX 
and 17-AAG for cancer therapy [90]. PTX and 17-AAG were simultaneously loaded into 
polymeric micelles by a solvent evaporation method. Two candidate nanocarrier 
constructs, PEG–PLA-based micelles and PEG-
distearoylphosphatidylethanolamine/tocopheryl polyethylene glycol 1000 (PEG-
DSPE/TPGS)-based mixed micelles, were assessed for the release kinetics of the loaded 
drugs. Compared to PEG–PLA micelles, entrapment of paclitaxel and 17-AAG into PEG-
DSPE/TPGS mixed micelles resulted in significantly prolonged release half-lives. 
Paclitaxel/17-AAG-loaded PEG-DSPE/TPGS mixed micelles were as effective in 
blocking the proliferation of human ovarian cancer SKOV-3 cells as the combined free 
drugs. There are plenty of other examples of use of micelles a carrier of drug 
combinations. This section only covers the most relevant examples. For detailed 
information about the application of polymeric micelles as a multi-drug vehicles, please 
see the review by cho et al [82]. 
1.5.4. Nanogels  
      Nanogels are three-dimensional hydrogel materials in the nanoscale size range 
formed by crosslinked swellable polymer networks with a high capacity to hold water, 
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without actually dissolving into the aqueous medium. Nanogels can be composed of a 
variety of naturally occurring polymers, synthetic polymers or a combination thereof. 
Their characteristics such as size, charge, porosity, amphiphilicity, softness, and 
degradability can be fine-tuned by varying the chemical composition of the nanogels. 
They are mostly spherical particles but the current advancement in synthetic strategies 
allow for the fabrication of nanogels of different shapes [91, 92]. They can be also 
designed to have either a core-shell or a core-shell-corona structure, with at least one of 
the layers crosslinked for structural integrity. Being mostly hydrophilic in nature, 
nanogels are highly biocompatible with a high loading capacity for guest molecules and 
their unique physical properties offer them distinct advantages over other types of 
nanomaterials for biomedical applications. Nanogels not only protect the cargo from 
degradation and elimination but also participate actively in the delivery process due to 
their characteristic properties like stimuli-responsive behavior, softness and swelling to 
help achieve a controlled, triggered response at the target site [93-95]. The versatility of 
their architecture allows for incorporation of a plethora of guest molecules ranging from 
inorganic nanoparticles to biomacromolecules like proteins and DNA with suitable 
modifications of the materials used for their construction, without compromising their 
gel-like behavior [96-99]. This multifunctionality and stability is hard to find in other 
types of nanoparticulate systems [100, 101]; especially the ability to incorporate entities 
with very different physical properties within the same carrier. Inorganic nanomaterials 
have distinct material properties like optical activity, electrical conductivity and magnetic 
properties that make them suitable for in vivo diagnostic and imaging applications, but 
they suffer from limitations of poor colloidal stability, low aqueous solubility and rapid 
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elimination by the mononuclear phagocytic system (MPS). Polymeric nanogels can be 
used as carriers for such imaging probes by imparting stability and increasing their utility. 
This lead to the evolution of a new class of agents termed ‘nanohybrids’ which are 
nanogels incorporating inorganic materials [102, 103]. Such nanohybrids can contain a 
wide variety of diagnostic and imaging agents for different types of medical conditions. 
Nanogels prevent biomolecules like enzymes and genetic material from degradation 
while their own macromolecular properties help increase the circulation half-lives of 
small molecules, and serve as a highly convenient platform for combination delivery of 
therapeutic molecules. They can be targeted specifically to the site of interest by 
conjugation with a targeting ligand or due to the passive targeting that is a characteristic 
feature of their nanoscale size. Despite such diversity in their applications, nanogels are 
not yet a part of clinical use. Many comprehensive and more specialized review articles 
on synthesis and application of nanogels were recently published.  
1.5.4.1. Synthesis of nanogels 
      Nanogels can be synthesized by a number of techniques. Since an in-depth discussion 
of all the available techniques is beyond the scope of this review, a brief overview of the 
techniques is given, along with reference to more detailed sources. Traditionally, 
nanogels have been classified based on the method of crosslinking as either physically or 
chemically (covalently) crosslinked nanogels. Chemical crosslinking involves formation 
of covalent bonds between the polymer chains during polymerization of low molecular 
weight monomers or crosslinking of polymer precursors. The most extensively employed 
methods for preparing chemically crosslinked nanogels utilize heterogeneous 
polymerization reactions in the presence of either bifunctional or multifunctional 
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crosslinkers [104, 105]. Conventional and controlled/living radical polymerization 
techniques allow for preparation of nanogels with different composition, dimensions, and 
architectures including core-shell and hollow nanogel particles [106, 107]. The use of 
functional initiators and macroinitiators further allows the incorporation of functionalities 
in the interior or on the surface of nanogels, which facilitate multivalent bioconjugation 
[108]. A variety of other crosslinking approaches including click chemistry, Schiff-base 
reactions, thiol-disulfide exchange, amide crosslinking, photo-induced crosslinking, 
enzyme-mediated crosslinking etc., have been developed for the synthesis of nanogels 
from the polymer precursors. In addition, the crosslinking reactions carried out on 
preformed core-shell self-assemblies such as polymer micelles allow introducing a high 
degree of spatial organization into the nanogels [109]. For a comprehensive look into 
crosslinking strategies, the reader is directed to excellent review written by Haag and 
colleagues [110]. Recent advances in nanoscale fabrication methods provided further 
unique opportunities to fabricate well-defined nanogels with precise control over size, 
shape, deformability and surface chemistry in a high-throughput manner [111-113]. 
Physically crosslinked systems though formed under the mild conditions, tend to be more 
fragile than their covalently crosslinked counterparts since they are stabilized by 
relatively weak interactions between polymer chains such as hydrogen bonding, 
hydrophobic interactions or ionic interactions. The use of hydrophobically-modified 
polymers and other associating polymers for preparing functional nanogels has recently 
been reviewed by Sasaki and Akiyoshi [114]. One of the challenges in the formation of 
nanogels by such polymers is a control over the particle size, which requires fine-tuning 
of the polymer concentrations or environmental parameters such as temperature, pH, and 
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ionic strength. A study by Nielsen and co-workers has demonstrated that these challenges 
can be addressed by utilizing a microfluidics-based approach [115]. Overall, the advances 
in polymer chemistry led to the exceptional diversity and control over the composition, 
architecture and functionality of crosslinked nanogels, which in turn provide more 
flexibility to tune their properties to comply with targeted biomedical applications. 
1.5.4.2. Stimuli-responsive behavior  
      Stimuli-responsive behavior of nanogels is a sequence of events initiated by an 
external cue that comes either from the specific environment within the body like change 
in pH, temperature, redox conditions or enzyme concentration, or a stimulus that can be 
applied externally such as light, magnetic field, etc. This stimulus then causes a 
conformational or structural change in the nanogel, which is mediated by various factors 
including, but not limited to, transition in the temperature below or above its lower 
critical solution temperature (LCST) or the ionization of acidic or basic functional groups 
on the polymer chains. These changes also alter the hydrophilicity and/or hydrophobicity 
of the nanogels or, in other words, the extent of interaction of the system with water 
molecules [116-118] and is mostly manifested in the form of swelling or deswelling of 
the nanogel network, which in turn causes responses like release of the entrapped cargo 
[119, 120]. One of the considerable advantages of nanogels over the macroscopic gels is 
their very rapid response to a change in environmental conditions [121]. The 
responsiveness of nanogels to the external physical or chemical signals can be tightly 
regulated by controlling the structure of the materials used for preparation of the nanogels 
[93, 122]. For example, in the case of polyelectrolyte nanogels pH-dependent ionization 
of functional groups results in an increase of osmotic pressure inside the nanogel due to 
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entrapped counterions and ultimately results in the swelling of the nanogels [122-124]. It 
is well recognized that a balance between the osmotic pressure and the polymer elasticity 
sets the physical dimensions of a hydrogel particle [125]. Thus, the extent of swelling 
also depends on structural characteristics of the nanogel like the chemical composition, 
hydrophilicity of crosslinkers, and the degree of crosslinking of the nanogel network, 
which controls the freedom of conformational mobility of the polymer chains [126, 127]. 
Tan et al. studied pH-responsive polyampholyte nanogels with different fractions of 
methacrylic acid (MAA) and 2-diethylaminoethyl methacrylate (DEAM) units in the 
crosslinked polymer cores that were sterically stabilized by poly(ethylene glycol), PEG, 
shell [128] The MAA segment in this nanogel is a weak acid and DEAM is a weak base 
(pKa = 5.4 for MAA and pKa = 7.3 for DEAM).  The DEAM segments could be 
protonated at low pH, imparting a positive charge to this segment, whereas the MAA 
units are negatively charged at high pH. As a result, these nanogels exhibited marked 
swelling at both high and low pH values, but shrunk in the vicinity of isoelectric point 
due to overall charge neutralization. It was demonstrated that swelling-deswelling 
transition can be tuned by varying the composition of MAA and DEAM in the nanogels. 
The unique charge-switching properties of amphoteric nanogels based on poly(N-
isopropylacrylamide) functionalized with aminophenylboronic acid (PBA) were explored 
by Hoare and Pelton to regulate the release of preloaded insulin in glucose-dependent 
manner [129]. The binding of glucose to the PBA residues shifts the boronic acid 
ionization equilibrium, increases the anionic charge density on the gel and drives a gel 
swelling response. These nanogels were designed to both swell and deswell in response 
to glucose according to the pH of the medium, the concentration of PBA groups grafted 
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to the nanogel, and the relative concentrations of the cationic and anionic functional 
groups in the platform nanogel.  Such PBA-nanogels had a high capacity for insulin 
uptake and selectively released insulin under physiological conditions in an “on-off” 
manner with fluctuating glucose level. Similar approach was adapted by Wu et al. for the 
design of a nanogel-based glucose sensor, which comprised of a core of Ag nanoparticle 
encapsulated within a glucose-recognizing crosslinked shell containing PBA residues. 
The swelling of the gel in response to glucose binding causes a change in the refractive 
index of the medium around Ag nanoparticle that leads to change in its fluorescence 
properties. The response rate is reported to be on the order of 100 ns, and the detection 
sensitivity for change in glucose concentration was reported to be ± 0.1 mM [130]. Thus, 
both sensitivity and rate of response of the nanogels can be programmed and fine-tuned 
by alterations in the structure of the building blocks [93, 122]. Accordingly, the cargo 
(mostly drugs) can either be conjugated chemically to the nanogels or merely entrapped 
physically into its core [15], depending on the stimulus that is most feasible for utilization 
at the targeted site of disease. Often multifunctional nanogels, which respond to a 
combination of more than one external signal, can also be fabricated for more site-
specific response [131-133]. These stimuli are frequently disease- or organ-specific, since 
different pathological conditions are associated with changes in pH, temperature and 
redox balance or expression levels of certain biomolecules as compared to the normal 
physiological conditions [134]. The reversible crosslinks containing disulfide bonds that 
are stable in extracellular milieu but are cleaved in the reductive intracellular 
environments due to the differences in the reductive potential between the extracellular 
and intracellular compartments, are successfully utilized in design of redox-responsive 
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nanogels [132, 135, 136]. The nanogels with disulfide links are stable during circulation 
in the blood but labile while internalized in cells, thus, facilitating the release of the drug. 
Matyjaszewski et al. have prepared biodegradable nanogels with disulfide-functionalized 
dimethacrylate crosslinkers that degraded into individual polymeric chains in the 
presence of glutathione and enabled both the release of encapsulated cargos and the 
removal of the carriers [137]. Thayumanavan and coworkers reported the preparation of 
redox-sensitive nanogels based on random amphiphilic copolymer that contains 
hydrophilic oligoethyleneglycol (OEG) and hydrophobic pyridyldisulfide (PDS) units as 
side-chain functionalities [138]. Self-assembled nanostructures formed by this polymer 
were crosslinked by initiating a thiol-disulfide exchange reaction among the PDS groups 
using dithiothreitol (DTT). The size of the resulting nanogels can be tuned by varying the 
copolymer molecular weight, composition and concentration, while the extent of 
crosslinking can be controlled by the amount of added DTT. The release of the 
encapsulated doxorubicin (DOX) was triggered by glutathione treatment and the release 
rate can be tuned by adjusting the crosslinking density. 
1.5.4.3. Nanogels as a therapeutic drug carrier  
      Nanogels are highly swollen and can incorporate 30% wt. or more of biological 
molecules and drugs through electrostatic, van der Waals and/or hydrophobic interactions 
or covalent bonding with the polymer chains. These loading capacities are unusually high 
and exceed those of liposomes and polymeric micelles. As a result of drug loading, the 
nanogels collapse forming stable nanoparticles, in which biological agent becomes 
entrapped. Introducing dispersing hydrophilic polymers (e.g., PEG) in a nanogel structure 
can prevent their aggregation. During the collapse of the drug-nanogel complex 
hydrophilic polymer chains become exposed at the surface and form a protective layer 
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around the nanogel. The control and versatility of polymer chemistry allows designing a 
broad range of drug formulations and inclusion of multiple therapeutic cargos within the 
same nanogel carrier. Stimuli-responsive drug release via temperature or pH-induced 
volume collapse can also be very attractive for drug delivery applications. The 
functionalization of the nanogel surface can further facilitate their selective accumulation 
in the target tissue or cells. Development of nanogels that can carry, protect, target and 
release therapeutic agents in spatially and temporally controlled manner is actively 
ongoing and their rational design can provide a platform for multiple applications. The 
group of Wang took advantage of the activity of bacterial lipases, which are abundant in 
microbial flora, to construct a nanogel for the on-demand release of antibiotics [134]. In 
this approach, the triple-layered nanogel contains a hydrophobic lipase-sensitive poly(ε-
caprolactone) (PCL) interlayer between the crosslinked polyphosphoester core and the 
PEG shell. Prior to reaching sites of bacterial infection, the antibiotics are protected 
inside the polyphosphoester core and are not released due to the compacted PCL 
molecular fence. However, rapid drug release was observed in the presence of lipase or 
lipase-secreting bacteria.     
1.5.4.3.1. Nanogels for small therapeutic molecule delivery 
      Over the past few years, significant progress has been achieved in application of 
nanogels as a delivery carrier for small biologically active molecules. Nanogels can be a 
versatile platform for the incorporation of various small drug molecules through the 
combination of electrostatic and hydrophobic interactions as well as hydrogen-bond 
formation [139]. The swelling of nanogels in an aqueous environment allows for easy 
permeation of the cargos. The rational design of the nanogels might be an effective tool 
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to tune the drug release rates, to affect carrier-cell interactions, and achieve desirable 
therapeutic effect of the drugs. One of the most important features of weakly-crosslinked 
polyelectrolyte nanogels is their ability to incorporate molecules of the opposite charge. 
For example, cationic crosslinked PEG-polyethyleneimine (PEG-PEI) nanogels were 
explored for immobilization of negatively charged biologically active compounds such as 
retinoic acid, indomethacin or valproic acid [139, 140]. These drug formulations formed 
stable colloidal dispersions at physiological pH and ionic strength, could be lyophilized 
and then redispersed.  Similar nanogels and complexation strategy has been successfully 
utilized for incorporation of various nucleoside analog 5′-triphosphates [141, 142]. It was 
reported that these drug-loaded nanogels could improve the delivery of the active 
triphosphates of therapeutic nucleoside analogs into cancer cells and inhibited tumor 
growth in the mammary carcinoma animal model [142]. Recently, the same group 
demonstrated the significant advantage of active 5′-triphosphates of nucleoside reverse 
transcriptase inhibitors encapsulated in cationic nanogels over free drugs in the antiviral 
therapy of HIV-1 infection in the central nervous system (CNS) [143]. Our group utilized 
a controlled template synthesis of nanogels by polyion complexation and crosslinking of 
doubly hydrophilic block ionomers, such as PEG-b-poly(methacrylic acid) (PEG-b-
PMA) [123, 144]. The resulting nanogels have swollen cores of a crosslinked PMA 
network surrounded by a shell composed of PEG chains. This synthetic approach allows 
versatile control of the macroscopic properties of nanogels (size, degree of swelling, drug 
loading) by changing the number and the chemical structure of the crosslinks [144]. 
Notably, in contrast to many nanoparticles these anionic nanogels exhibited very low 
nonspecific adhesion to nontargeted surfaces, which can minimize their off target effect 
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and facilitate target-specific delivery [145]. Such core-shell nanogels can incorporate 
very large amounts (up to 50% wt.) of weakly basic drug DOX through electrostatic 
coupling with carboxylic groups in the cores. DOX-loaded nanogels were stable for a 
prolonged period of time, exhibited noticeable pH-sensitive behavior with accelerated 
release of DOX in acidic environment due to the protonation and swelling of the nanogel 
crosslinked cores, and demonstrated cytotoxic activities in cancer cell lines [146]. 
Introduction of reversible crosslinks with disulfide bonds in the PMA ionic cores 
(cystamine was used as a biodegradable crosslinker) allowed developing nanogels that 
are degradable in the presence of the reducing agent (glutathione, cysteine), which in turn 
facilitated the release of the incorporated DOX [146]. This difference in the release 
kinetics led to considerable increase of cytotoxicity: degradable DOX-loaded nanogels 
displayed nearly six-fold higher cytotoxic activity than non-degradable nanogels. Shi et 
al. used PEG-poly(L-glutamic acid-co-L-cystine) copolymers to prepare nanogels 
stabilized by disulfide bridges and also demonstrated that DOX release was accelerated in 
intracellular reductive and acidic conditions [147]. DOX was loaded into these 
polypeptide-based nanogels, and an accelerated release was observed in glutathione 
monoester pretreated HeLa cells.  Anionic PEG-b-PMA nanogels were further used to 
encapsulate hydrophilic drug cisplatin through coordination interactions with COOH 
functionalities [123]. Cisplatin-loaded nanogels displayed pH-sensitive release of Pt 
species in sustained manner that can be effectively controlled by adjusting the degree of 
crosslinking of the crosslinked cores. The released platinum species retained their activity 
and were able to form Pt adducts with nuclear DNA in the cancer cells [123]. It was 
shown that loading of cisplatin into the nanogels greatly improved drug therapeutic index 
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by improving PK, enhancing tumor delivery, increasing antitumor efficacy, and 
mitigating the cisplatin-mediated nephrotoxicity in a mouse model of ovarian cancer 
[148]. When the same cispaltin-loaded nanogels were also decorated with targeting 
ligands (e.g. folate or LHRH peptide), tumor growth inhibition could be even further 
enhanced [149, 150]. Peng et al. described dual pH- and temperature-responsive nanogels 
based on N-isopropylacrylamide, MAA, and PEG methylether methacrylate (NIPAAm-
MAA-PEGMA) for the entrapment and release of cisplatin. It was shown that cisplatin 
release can be accelerated at acidic pH, and could be additionally controlled by the 
temperature change due to the deswelling behavior of these nanogels at the body 
temperature [151]. Small molecules usually contain only limited number of ionic groups, 
which are able to interact with oppositely charged nanogels, and complementary 
hydrophobic, hydrogen or coordination bonding between drug molecules and nanogels 
can further stabilize the electrostatic pairing [139]. Recently, our laboratory demonstrated 
that microenvironment formed by the hydrophobic domains in the nanogel ionic cores 
influences solubilization capacity and release characteristics of the nanogels [152]. 
Diblock copolymer, PEG-b-poly(L-glutamic acid), hydrophobically-modified with L-
phenylalanine methyl ester moieties was used for the synthesis of nanogels with small 
size (ca. 70nm in diameter) and narrow particle size distribution. Stable DOX-loaded 
hybrid nanogels were prepared at high DOX capacity (30% wt.). It was shown that the 
release rates of DOX from hydrophobically-modified carriers were substantially less 
compared to nonmodified nanogels: a burst release of over 85% of the incorporated drug 
within 8h for nonmodified nanogels was observed while only ~20% of the incorporated 
DOX was released from hydrophobically-modified nanogels during the same period of 
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time. These results suggested that intermolecular interactions in combination with more 
compact crosslinked core could account for the delayed and controlled release of DOX 
from hydrophobically-modified polyelectrolyte nanogels. It was also found that these 
DOX-loaded nanogels exhibited an improved antitumor efficacy compared to free DOX 
in an ovarian tumor xenograft mouse model.  
      Nanogels have also been explored as a carrier for poorly water-soluble drugs. Wang 
et al. introduced thermoresponsive nanogels based on chitosan–poly(NIPAAm-co-
acrylamide) for the delivery of paclitaxel (PTX) [153]. Loading capacity of these 
nanogels for PTX was around 9% wt. and drug-nanogel formulation showed very good 
colloidal stability. This nanogel released PTX in a temperature-dependent manner 
wherein significantly faster drug release was achieved at higher temperature. Moreover, 
PTX-loaded nanogels demonstrated improved antitumor efficacy in mice bearing HT-29 
colon carcinoma tumors after intravenous administration. In another study by Gref and 
coworkers, hydrophobic molecule benzophenone (widely used as sunscreen agent) was 
solubilized into nanogels formed spontaneously upon the association of a lauryl-modified 
dextran and a β-cyclodextrin polymer in aqueous media [154]. The highest benzophenone 
loadings (about 2.5 % wt.) were obtained by solubilizing it in both polymer solutions 
before mixing them to form nanogels. Such nanogel-based formulations present a 
compelling future opportunity for the application in the cosmetic field as sun screen 
carriers prepared by a simple “green” technology. The use of nanogels for the 
development of long-lasting formulations of local anesthetics has recently been reviewed 
by Tan et al [155]. Eckmann and colleagues explored biocompatible physically 
crosslinked hybrid nanogels consisting of a partially denaturated lysozyme cores and 
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dextran shells for the local delivery of dexamethasone to alleviate acute pulmonary 
inflammation [156]. To target the pulmonary vasculature, nanogels were coated with 
antibodies directed to endothelial determinant, Intercellular Adhesion Molecule-1 
(ICAM). The synthesized ICAM- targeted nanogels were loaded with dexamethasone at 
5% wt. In vivo studies in animal model of LPS-induced lung injury showed that nanogels 
targeted to lungs succeeded in delivering encapsulated dexamethasone, as was indicated 
by drastic reduction in pulmonary vasculature inflammation to levels found in naïve 
mice. In other work, similar dextran-lysozyme nanogels were utilized as scaffolds for the 
in situ synthesis of silver nanoparticles [157, 158]. Such hybrid nanogels exhibited 
bactericidal properties towards E. coli and bacteriostatic properties towards S. aureus, and 
their antibacterial activity can be tuned by varying lysozyme content. The tunability of 
the hybrid nanogels makes it possible to optimize release of the bactericidal agent for 
specific clinical use and type of infection. Nagasaki’s group used the protonated 
crosslinked poly(2-[N,N-diethylamino]ethyl methacrylate) (PEAMA) cores of the 
stimuli-responsive PEGylated nanogels for the synthesis of gold nanoparticles without 
any reducing agents (“gold nanogels”) [159]. It was shown that the tertiary amino groups 
in the PEAMA gel core play a crucial role in the reduction of the Au(III) ions 
(nanoreactor) as well as the immobilization of the resulting gold nanoparticles 
(nanomatrix) to attain large payloads of gold nanoparticles. The resulting gold-containing 
nanogels showed a remarkable photothermal efficacy in response to laser-irradiation 
resulting in selective cytotoxicity in cancer cells. In other studies, a potential of the 




1.5.4.3.1.1. Nanogels for combination drug delivery 
      Drug combinations directed simultaneously at multiple pharmacological targets have 
the potential to dramatically improve the response to treatment and are already a standard 
clinical practice in the treatment of cancer and infectious diseases [161].  However, the 
difference in pharmacokinetic and pharmacodynamic profiles among diverse drug 
molecules makes dosing and scheduling optimization very challenging. Combining drugs 
in one delivery carrier is a well-suited strategy for controlling the pharmacokinetics and 
co-delivery of the desired drug ratio in vivo, and a variety of nanoscale carriers, including 
nanogels, have been investigated in terms of their ability to deliver multiple drugs [162, 
163]. As highlighted in previous sections, the nanogel structure can be readily adjusted to 
integrate features of different materials and, thus, offer advantages for combinatorial 
encapsulation of drugs with varying physicochemical properties such as small molecules, 
proteins and nucleic acids. Fahmy and coworkers developed liposomal nanogels of drug-
complexed cyclodextrins and cytokine-encapsulating biodegradable polymers that can 
deliver small hydrophobic molecular TGF-β inhibitor and water-soluble protein cytokine 
(IL-2) in a sustained fashion to the tumor microenvironment [164]. They demonstrated 
that synergistic effects of simultaneously delivered IL-2 and TGF-β inhibitor on 
activation of the innate arm of the immune system led to delayed tumor growth and 
enhanced survival of melanoma tumor-bearing mice after systemic administration. 
Akiyoshi and colleagues evaluated nanogels based on acrylate group–modified CHP for 
co-delivery of prostaglandin E2 receptor–specific agonist EP4A (small molecule) in 
combination with bone morphogenic proteins (BMP-2) for bone regeneration [165]. In 
this study, EP4A-containing nanogels and BMP-2-containing nanogels were crosslinked 
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with thiol-bearing PEG to obtain disc-like scaffolds for the implantation into large bone 
defects.  Combination treatment with EP4A and low-dose BMP-2 efficiently activated 
bone cells to regenerate calvarial bone by forming both outer and inner cortical plates as 
well as bone marrow tissue and resulted in the formation of enough bone to cover the 
defects in calvarial bone. In another study, cationic physically-crosslinked nanogels 
composed of a hexadecyl group-bearing cycloamylose and spermine-modified 
cycloamylose to complex and co-deliver plasmid DNA along with phospholipaseA2 
(PLA2) [166]. As a lipolytic enzyme, PLA2 catalyzes hydrolysis of a variety of different 
phospholipids. Thus, being delivered into endosomes by nanogel it could disrupt the lipid 
membrane and subsequently trigger the release of the co-encapsulated DNA into the 
cytoplasm. Transfection experiments confirmed that DNA expression level was enhanced 
when complexed with PLA2. Similarly, pDNA and proteins were successfully co-
encapsulated using pH- and temperature-sensitive carbohydrate-based nanogels [167]. 
The nanogels had a core-shell structure with a crosslinked hydrophobic core that could be 
loaded with proteins and the shell contained carbohydrate residues that allowed for the 
complexation of DNA. These nanogels were capable of loading larger-than-normal 
amounts of cargo by using a heating and cooling cycle. Altogether, these studies may 
open new avenues for the development of the carrier-mediated combination therapies. 
1.6. Conclusion 
      Combination chemotherapy is preferred over treatment with single agents to combat 
most cancers as it targets multiple cell-survival pathways at the same time and delays the 
onset of resistance. This helps in achieving long-term tumor remission and increases 
median survival. Cisplatin (CDDP)-based therapy has been the standard treatment for 
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ovarian cancer since its discovery. After paclitaxel (PTX) was shown to be effective in 
ovarian cancer, multiple clinical trials studied the overall efficacy of CDDP and PTX and 
found significant benefit over the pre-existing treatments. Since then, this combination 
has been the treatment of choice for both early stage as well as advanced cases of ovarian 
cancer. However, administration of two different agents comes with the inconvenience of 
repeated or extended duration of drug infusion in patients. Moreover, the most 
extensively used conventional formulation of paclitaxel, Taxol®, utilizes Cremophor EL 
(polyethoxylated castor oil) that has been linked to significant toxicities including 
allergic, hypersensitivity and anaphylactic reactions during infusion that require 
premedication and prolonged peripheral neuropathy. Combining such drugs in one 
delivery carrier is therefore a well-suited and convenient strategy for controlling the 
pharmacokinetics and co-delivery of the desired drug ratio in vivo, to maximize the 
therapeutic potency and minimize drug-associated toxicities.  
      Cross-linked nanogels have been found to be promising drug carriers to achieve this 
goal. Being mostly hydrophilic in nature, nanogels are highly biocompatible with a high 
loading capacity for guest molecules. The nanogel structure can be readily adjusted to 
integrate features of different materials and, thus, offer advantages for combinatorial 
encapsulation of drugs with varying physicochemical properties. One of the widespread 
synthetic techniques for the synthesis of nanogels is the crosslinking of preformed core-
shell self-assemblies such as polymer micelles that allows introducing a high degree of 
spatial organization into the nanogels. Cross-linking is known to impart control over the 
swelling behavior of the nanogels and thus helps in achieving controlled release of the 
incorporated cargo, which is an added advantage over the structural integrity imparted to 
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the carrier system upon in vivo administration. The enhanced stability also makes the 
prolonged circulation of the nanogels possible, which in turn allows for increased drug 
accumulation at the target site by enhanced permeability and retention effect (EPR). We 
report a design of multi-compartment cross-linked nanogels based on hybrid triblock 
copolymers, poly(ethylene glycol)-block-poly(L-glutamic acid)-block-poly(L-
phenylalanine) (PEG-b-PGlu-b-PPhe) for simultaneous loading and delivery of binary 
CDDP and PTX combination. Such nanogels have 1) a hydrophobic core formed by PPhe 
chains, which serves as a reservoir for PTX solubilization, 2) an anionic layer, which 
incorporates CDDP through coordination with the carboxylic groups of PGlu, and 3) an 
outer PEG shell stabilized, which stabilizes micelles in aqueous dispersion. The 
crosslinks incorporated into PGlu block layer ensure that the PEG-b-PGlu-b-PPhe 
micelles remain stable until they encounter proteases, which degrade the micelles by 
cleaving the polypeptide chains of the block copolymers. This work demonstrates that 
such biodegradable hybrid micelles carrying CDDP and PTX drug combination exert 
superior antitumor efficacy in treatment of ovarian cancer in xenograft mouse tumor 
model. However, our system relied solely on the EPR effect to facilitate the delivery of 
the drug combination to the tumor site.  Regardless of the importance and popularity of 
EPR effect-based drug delivery, this strategy has some limitations related to the inter- and 
intra-tumor heterogeneity, variations in the density as well as permeability of the tumor 
vasculature that can affect the accumulation of nanocarriers. One of the popular 
approaches to circumvent these problems is by surface-functionalization of the drug 
carrier with ligands that can target receptors with differential expression on the cancer 
cell surface, which helps in increasing the mean residence time of the delivery system at 
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the tumor site and improving target cell uptake. One such receptor of interest is the folate 
receptor (FR). Malignant cells, due to their high rate of cell division, have an increased 
requirement of folic acid (FA), since it is essential component of cell metabolism and 
DNA synthesis and repair. To fulfill this higher need of FA, FR is known to be over-
expressed in a large number of malignant tissues, including ovarian cancer, compared to 
normal tissues with the exception of the kidney and choroid plexus. Furthermore, this 
receptor becomes accessible via the plasma compartment only after the cells lose their 
polarity owing to malignant transformation which makes it a differential target for cancer 
tissue that is easily accessible for intravenously administered FA conjugated systems. Its 
natural ligand, FA, comes with the advantages of high binding affinity, stability and a 
simple chemical structure together with ease of availability, making it a suitable targeting 
ligand for ovarian cancer therapy. FA can thus be successfully conjugated to 
macromolecular systems without loss of binding affinity to its receptor. Many different 
agents targeting the folate pathway are currently in clinical development. To date, FA-
targeted agents showed significant promise in phase II clinical trials but it has not been 
confirmed in phase III studies. Accordingly, there is a need for further identification of 
new therapeutic combinations and refinement of patient selection. To this end, FA-
conjugated imaging agents could be used for pre-selection of patients based on the 
expression of FR and several methods have been already developed for this purpose.  
      Our group has previously demonstrated a tumor-specific delivery and improved anti-
cancer effect in vivo of CDDP-loaded nanogels decorated with FA targeting groups. In 
our further study, we designed FA-linked nanogels incorporating platinum-taxane 
combination, and examined whether FR-targeted concurrent delivery of synergistic 
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combination of CDDP and PTX can lead to enhanced therapeutic efficacy compared to 
nontargeted NG system. 
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BIODEGRADABLE HYBRID NANOGELS FOR COMBINATION DRUG 
THERAPY IN OVARIAN CANCER
1
 
2.1 Introduction.  
Ovarian cancer is the most lethal gynecologic malignancy in women, which causes 
nearly 15,000 deaths in the United States every year. Its high death rate is a result of the 
fact that most patients (>75%) are diagnosed at an advanced stage of disease at which 
point the 5-year survival rate is less than 30% [1, 2]. The vast majority of ovarian cancers 
are epithelial in origin and characterized by the rapid growth and spread of solid 
intraperitoneal tumors and formation of large volumes of ascitic fluid. The standard 
treatment for patients with advanced ovarian cancer is maximal surgical cytoreduction 
followed by systemic platinum-based chemotherapy [2]. Cytotoxic action of platinum 
compounds such as cisplatin (cis-dichlorodiamminoplatinum (II), CDDP) is mediated 
through the formation of platinum-DNA adducts, which in turn inhibits DNA replication 
and/or transcription and results in apoptosis and necrosis [3, 4]. Despite its success, use 
of CDDP is greatly limited by severe dose limiting side effects, rapid elimination, and 
development of acquired drug resistance. No new small molecule platinum drug have 
gained international marketing approval since 1999 indicating a shift in focus in the last 
decade away from drug design and towards drug delivery [5]. Among drug delivery 
systems, those based on self-assembled block copolymer micelles have great potential for 
delivery of anticancer drugs [6]. The advantages of polymer micelles include their small 
                                                             
1 Reproduced with permission from Desale SS, Cohen SM, Zhao Y, Kabanov AV, and Bronich TK, 
Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer, J Control Release 
171.3 (2013): 339-348. Copyright 2013 Elsevier B.V. 
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size, long circulation times, and ability to circumvent renal excretion and extravasate at 
sites of enhanced vascular permeability. However, disintegration of the polymer micelles 
is a major drawback for their application in drug delivery. In order to overcome this 
limitation, we have proposed hydrophilic polyelectrolyte micelles with core composed of 
a network of cross-linked polyanion chains and PEG shell that can encapsulate CDDP 
with high capacity (up to 35 w/w%) [7, 8]. We have demonstrated significant 
improvement of drug safety and drug delivery using such CDDP-loaded cross-linked 
micelles. However, single drug therapy agents directed to individual targets frequently 
show limited efficacies. Hence, multi-component therapies and multi-targeted drug 
combinations are key to most cancer treatments [9]. Combination chemotherapy using 
sequential administration of paclitaxel (PTX) with a platinum-based regimen is currently 
the standard first-line therapy for ovarian cancer resulting in increased success rates in 
eradicating tumors and/or longer remission periods [10]. These clinical benefits of the 
combination therapy can be possibly maximized by controlled delivery of the desired 
drug ratio to the in vivo target. Combining drugs in one delivery carrier is well-suited 
strategy for controlling the pharmacokinetics and co-delivery of the desired drug ratio in 
vivo. The drug loading and structure of such carriers can be tuned to control the drug 
release rates, maximize the therapeutic potency and minimize drug-associated toxicities. 
Nanoscale delivery carriers such as liposomes, nanoparticles, polymeric micelles have 
been explored for co-delivery of anticancer drugs [11-13]. However, co-incorporation of 
drug molecules with different physicochemical properties, such as hydrophilic CDDP and 
hydrophobic PTX, has been challenging. As an attempt to address this challenge, we 
report a design of multi-compartment cross-linked micelles, also known as nanogels 
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(NG) based on hybrid triblock copolymers, poly(ethylene glycol)-block-poly(L-glutamic 
acid)-block-poly(L-phenylalanine) (PEG-b-PGlu-b-PPhe) for simultaneous loading and 
delivery of binary CDDP and PTX combination. Such NGs have 1) a hydrophobic core 
formed by PPhe chains, which serves as a reservoir for PTX solubilization, 2) an anionic 
layer, which incorporates CDDP through coordination with the carboxylic groups of 
PGlu, and 3) an outer PEG shell stabilized, which stabilizes NGs in aqueous dispersion. 
The crosslinks incorporated into PGlu block layer ensure that the PEG-b-PGlu-b-PPhe 
NGs remain stable until they encounter proteases, which degrade the NGs by cleaving the 
polypeptide chains of the block copolymers. This work demonstrates that such 
biodegradable hybrid NGs carrying CDDP and PTX drug combination exert superior 
antitumor efficacy in treatment of ovarian cancer in xenograft mouse tumor model. 
2.2 Material and Methods 
2.2.1 Materials 
PEG-b-PGlu-b-PPhe block copolymers with different ratios of glutamic acid and 
phenylalanine units (90:7 and 90:25) were synthesized as described below. α-Amino-ω-
methoxy poly(ethylene glycol) (mPEG-NH2 , Mw = 5,000 g mol
-1
,  Mw / Mn = 1.05) was 
purchased from Creative PEGWorks Inc., (NC, USA). CDDP was purchased from Acros 
Organics. L-glutamic acid γ-benzyl ester (BGlu), L-phenylalanine (Phe), 1,2-
ethylenediamine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), 
paclitaxel, and other chemicals were purchased from Sigma-Aldrich (St Louis, MO) and 
were used without further purification. Fetal bovine serum (FBS), RPMI 1640 medium, 
penicillin, streptomycin, Trypsin–ethylenediaminetetraacetic acid (EDTA) (0.5% trypsin, 
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5.3 mM EDTA tetra-sodium) and other chemicals were purchased from Invitrogen 
(Carlsbad, CA, USA). 
2.2.2 N-carboxyanhydrides (NCA) of BGlu and Phe 
BGlu (0.020 mole) or Phe (0.026 mole) and anhydrous tetrahydrofuran (THF) were 
added into a dried glass reactor to form a suspension. Triphosgen (0.023mole) was 
separately dissolved in fresh anhydrous THF and injected drop wise into reaction 
mixture. Nitrogen was bubbled through the mixture during synthesis. The mixture was 
heated at about 40
o
C with constant stirring till mixture became transparent. The solution 
was precipitated in n-hexane and then stored at -20
o
C overnight in order to allow 
complete precipitation of γ-benzyl L-glutamate-N-carboxyanhydride (BGlu-NCA) or L-
phenulalanine –N-carboxyanhydride (Phe-NCA). The white solids obtained were 
collected and purified further by repeated precipitation with n-hexane. The resulting NCA 






2.2.3 PEG-b-PGlu-b-PPhe block copolymer 
Monoaminomethoxypoly(ethylene glycol) (mPEG-NH2) (0.02 mmol) was dissolved 
under stirring  in 10 mL of anhydrous dimethylformamide (DMF) in nitrogen atmosphere 
at 40
o
C. BGlu-NCA (2 mmol, the feed molar ratio of mPEG-NH2 to BGlu-NCA was 1: 
100) dissolved in 5 mL of anhydrous DMF was added dropwise and the solution was 
stirred for 24 hrs. The aliquot of the reaction mixture was precipitated using excess of 
diethyl ether, dried under vacuum, and the composition of PEG-PBGlu diblock 
copolymer was determined by 
1
H-NMR from the peak intensity ratios of the methylene 
protons of PEG and the phenyl protons of the γ-benzyl groups (400 MHz in CDCl3: δ = 
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3.5 (s, 4H, -OCH2CH2-), 5.0 (m, 2H, benzyl), 7.3 (m, 5H, aryl)). The calculated amount 
of the monomer for the third block, Phe-NCA, dissolved in anhydrous DMF was then 
injected dropwise and mixture was stirred under a N2 atmosphere at 40 °C for additional 
24 hrs. The product (PEG-b-PBGlu-b-PPhe) was precipitated by diethyl ether, purified by 
repeated precipitation in diethyl ether and dried in a vacuum. The benzyl groups of PEG-
b-PBGA-b-PPhe were removed in the presence of NaOH to obtain PEG-b-PGlu-b-PPhe.  
Polymer sample was dissolved in 10 mL of THF followed by addition of 5 mL of 1N 
NaOH. After stirring for 10 hrs at 40
o
C THF was removed at reduced pressure, the 
residual solution was neutralized by 1M HCl and dialyzed using a dialysis membrane 
(MWCO 3,500 Da) against distilled water for 24 hrs. After dialysis the product was 
dried, washed 2-3 times with ethanol followed by lyophilization. By varying the feed 
molar ratio of mPEG-NH2 to Phe-NCA (1:10 and 1:30), two copolymers with targeted 
compositions PEG-b-PBGlu(100)-b-PPhe(10) and PEG-b-PBGlu(100)-b-PPhe(30) were 
synthesized. The concentration of carboxylate groups in the copolymer samples was 
estimated by potentiometric titration. Self-assembly behavior of PEG-b-PGlu-b-PPhe 
copolymers was examined using pyrene as a hydrophobic fluorescence probe [14]. 
2.2.4 Pyrene assay and fluorescence spectroscopy 
      Self-assembly studies of PEG-PGlu90-PPhe25 and PEG-PGlu90-PPhe7 using pyrene as 
fluorescent probe were performed using a spectrofluorometer system (Flourlog®, 
HORIBA Jobin Yvon Inc., NJ, USA). Known amounts of pyrene in acetone were added 
to empty vials, followed by acetone evaporation. Subsequently, the pyrene film was 
incubated with varying concentrations (ranging from 3.9 to 2000mg/L) of polymer 
overnight on shaker at room temperature. The pyrene concentration in the final solution 
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was 6 x 10-7 M (MW 202.25). Fluorescence spectra were recorded on a microplate 
reader (SpectraMax M5, MDS, CA) with samples in a 1.0 cm quartz cuvette. Emission 
spectra were recorded for PEG-PGlu90-PPhe25 and PEG-PGlu90-PPhe7 solutions in 
water (1mg/mL) from 250 to 350 nm using an excitation wavelength λex=265 nm. 
2.2.5 Preparation of NGs 
NGs were prepared by directly dissolving PEG-b-PGlu-b-PPhe copolymer in aqueous 
media at a concentration of about 1 mg/mL. EDC in water (0.2 eq with respect to the 
amount of carboxylate groups) was added dropwise to this solution and allowed to stir for 
additional 10 min at r.t.. An aqueous solution of cross-linker, 1,2-ethylenediamine (0.1 
eq) was then added to the dispersion of micellar aggregate to achieve 20% of cross-
linking degree. This degree represents the maximum theoretical amount of cross-linking 
that could take place, rather than the precise extent of amidation. The reaction mixture 
was allowed to stir overnight at r.t. Byproducts of the cross-linking reaction were 
removed by exhaustive dialysis of the reaction mixtures against distilled water.  




H NMR spectra for the monomers and copolymers were acquired in CDCl3 or 
D2O at 25 °C using a Bruker 400 MHz spectrometer. Effective hydrodynamic diameters 
(Deff) and ζ-potential of NGs were determined by dynamic light scattering (DLS) using a 
Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK). All measurements were 
performed in automatic mode at 25°C. Software provided by the manufacturer was used 
to calculate the size, polydispersity indices (PDI), and ζ-potential of NGs. All 
measurements were performed at least in triplicate to calculate mean values ± SD. 
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Morphology of the NGs was characterized by transmission electron microscopy (TEM) 
and atomic force microscopy (AFM) as previously described [24]. NGs (ca. 1 mg/mL) 
were incubated with cathepsin B from human liver (10 units/mL) in phosphate buffered 
saline (PBS, pH 6.5, 0.14 M NaCl) at 37
0
C for various time points (0, 12, 24 hrs) and 
analyzed by size exclusion chromatography (SEC) using an  KTA  PLC (Amersham 
Biosciences) system and Sepharose CL-6B column (300 mm × 10 mm; flow rate 0.5 
mL/min; mobile phase PBS, r.t.).  Detection was performed at 280 nm. 
2.2.7 Drug loading 
A solution of PTX in ethanol (2 mg/mL) was added dropwise into the aqueous 
dispersion of NGs (1 mg/mL) and the mixture was stirred at r.t. overnight in an open-air 
system to allow slow evaporation of ethanol [15]. The residual ethanol was then removed 
at reduced pressure. The precipitate of unbound PTX was removed by centrifugation. The 
aqueous dispersion of PTX-loaded NGs were mixed with an aqueous solution of CDDP 
(1 mg/mL) at pH 9.0 at 0.5 molar ratio of CDDP to carboxylate groups followed by 
incubation at 37°C for 48 h. Unbound CDDP was removed by Ultracon filter units 
(MWCO 10,000 Da, Millipore). Pt content in NGs (Pt194/Pt195) was assayed on Nexion 
ion coupled plasma-mass spectrometer (NexION 300Q, PerkinElmer) calibrated with Pt 
(2-100 ng/ml) and Holmium as the internal standard. Samples were diluted in 0.1 N HCl. 
PTX levels were determined by high-performance liquid chromatography (HPLC) 
analysis under isocratic conditions using an Agilent 1200 HPLC system a diode array 
detector set at 227 nm. As stationary phase a Nucleosil C18 column was used (250 mm  
4.6 mm), a mobile phase of acetonitrile/water mixture (55/45, v/v) was applied at a flow 
rate of 1 mL/min. 
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2.2.8 Release studies  
Drug release from the NGs was examined in PBS (pH 7.4), acetate buffered saline 
(ABS, pH 5.5, 0.14 M NaCl), and ABS in presence of cathepsin B (10 units/mL) by 
dialysis method using a membrane with 3,500 Da cutoff. The concentrations of PTX and 
Pt(II) released were determined by HPLC and inductively coupled plasma mass 
spectrometry (ICP-MS), respectively, and expressed as a percentage of the total PTX or 
Pt(II) available vs. time. 
2.2.9 Cell culture and cytotoxicity assay 
A2780 human ovarian carcinoma cells were provided by Dr. P. Rogers (Institute of 
Cancer Research, University of Bristol, UK). Cells were maintained in RPMI 1640 
medium with 2 mM glutamine supplemented with 10% (v/v) FBS in the presence of 
penicillin and streptomycin (100 U/ml and 0.1 mg/ml, respectively) at 37°C in a 
humidified atmosphere containing 5% CO2. Cells were harvested with trypsin-EDTA 
(Life Technologies) after 80% confluence. Cells seeded in 96-well plates (5,000 
cells/well) 24 h prior the experiment were exposed to various doses (0-10 μg/mL on 
CDDP or PTX basis) of CDDP alone, polymeric NGs alone, CDDP-loaded NGs, PTX-
loaded NGs and (CDDP+PTX)-loaded NGs for 72 h at 37 °C, followed by washing with 
PBS, and maintaining in RPMI 1640 medium with 10% FBS for additional 24 h. 
Cytotoxicity of drug-loaded NGs was assessed by a standard MTT assay [16] and the 
IC50 values were calculated using GraphPad Prism software. Combination index (CI) 
analysis based on Chou and Talaly method [17] was performed using CompuSyn 
software for CDDP and PTX combinations, determining synergistic, additive, or 
antagonistic cytotoxic effects against A2780 breast cancer cells. Values of CI < 1 
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demonstrate synergism while CI = 1 and CI > 1 values represent additive and 
antagonistic effects of drug combination, respectively. 
2.2.10 Animal studies 
Upon arrival, animals were placed in a facility accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care. Food and reverse osmosis 
water were available ad libitum throughout the study. Treatments were administered by 
tail vein injection. Drug amount was calculated based on the average animal body weight. 
The University of Nebraska Medical Center Institutional Animal Care and Use 
Committee approved all animal protocols. A xenograft human ovarian carcinoma model 
was used as previously described [8, 18]. Briefly, A2780 cells (5 x 10
6
 cells/site) were 
subcutaneously transplanted into the flanks, one above each hind limb, of four-week-old 
female athymic (Ncr-nu/nu) mice (National Cancer Institute). When the tumors reached a 
size of about 200-400 mm
3
 (12-15 days after transplantation) animals were randomized 
(5 treatment groups, n = 8) and treated with free CDDP or CDDP/NGs or PTX/NGs or 
(CDDP+PTX)/NGs at an equivalent dose of 4 mg/kg CDDP, or 1mg/kg PTX or (4 mg/kg 
CDDP+1 mg/kg PTX) or 5% dextrose solution. Treatments were administered via tail 
vein injections at 4-day intervals. Animal body weight and tumor volume were monitored 
every second day. Tumor volume (V = 0.5 x L x W
2
) was estimated by measuring two 
orthogonal diameters (longer dimension: L, and smaller dimension: W) of the tumor 
using electronic calipers. Animals were sacrificed when tumor volume exceeded 3000 
mm
3
, greatest tumor dimension exceeded 20 mm, tumor became necrotic, or animal 
exhibited a body weight loss of more than 20%. Euthanasia was performed by CO2 
asphyxiation. All other animals were sacrificed by day 45. 
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2.2.11 Apoptosis and proliferation 
Tumors from mice that received different treatments were excised at day 14 (2-3 mice 
per group). The tumors were dissected and fixed in 10% neutral buffered formalin. Then, 
the tissues were processed routinely into paraffin, sectioned at a thickness of 4 μm. 
Proliferating and apoptotic cells were detected using an antibody against Ki-67 and 
caspase-3, respectively. Visualization was done by incubation with DAB+ (brown, for 
Ki-67) and Permanent red (for caspase-3) (DAKO) for 2 min. After being rinsed with 
distilled water, the sections were counterstained with hematoxylin. For quantification of 
Ki-67 and caspase-3 expression, the area of positive cells was determined (Image J) in 5 
random high power fields (20X magnification) and divided by the total area of cells for 
each field of slice. 
2.2.12 Sample preparation and drug content measurement in tissue. 
Known weights of thawed tissue, collected from the animals sacrificed at different 
days during treatment, were decomposed by wet-ashing in screw-capped vials with six 
volumes of concentrated nitric acid, overnight heating, and stirring at 65°C. An iridium 
internal standard was added prior to digestion. Total platinum concentrations were 
determined by ICP-MS using iridium correction. Calibration range for the assay was 
platinum 2–100 ng/mL with extrapolation to platinum 1000 ng/mL. Necessary dilutions 
were made when the platinum concentration exceeded the calibration range. Assay 
sensitivity was 0.8 ng of Pt/mL, with inter- and intraday assay variability not exceeding 
5%. For PTX measurements, tissue sample (200 mg) was spiked with 50 uL diazepam 
(internal standard, I.S.) to achieve a final concentration about 25 ug/mL, then 2mL of 
tert-butyl methyl ether (TBME) was added and tissue was homogenized. Homogenized 
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samples were centrifuged at 3000g for 10 min, 1mL of supernatant TBME layer was 
collected and dried under air. Residue was reconstituted using 1mL of mobile phase and 
20uL of it was injected into HPLC system. Samples of PTX was prepared by directly 
dissolving PTX and I.S. in mobile phase and measured in HPLC system to calculate 
recovery rate.  
2.2.13 Blood chemistry and histopathology  
Blood from the sacrificed animals was collected in EDTA tubes and analyzed for 
blood cell count and liver enzymes using Vetscan VS (Abaxis). Fixed tissues were 
processed, sectioned, inserted into tissue cassettes, dehydrated in 70% ethanol overnight, 
and paraffin embedded (UNMC Tissue Sciences  acility, Omaha, NE). Serial 5 μm 
sections were stained with either hematoxylin and eosin (H&E) or by 
immunohistochemistry (IHC). For histopathological diagnosis, H&E-stained slides were 
examined by light microscopy and photomicrographs were taken using a Nikon camera 
mounted on a Nikon Eclipse 600 microscope (both Nikon Instruments, Melville, NY) 
with Adobe Elements 3.0 software (Adobe Systems, San Jose, CA). For IHC detection of 
NGs in tissues, rabbit monoclonal antibody to PEG (anti-PEG methoxy group; Epitomics, 
Burlingame, CA) was used. Goat anti-rabbit secondary antibody conjugated with 
fluorescence label AF 488 was used for the detection followed by counterstaining with 
Mayer’s hematoxylin. Stained slides were visualized using confocal imaging (Carl Zeiss 
LSM 510). 
2.2.14 Statistical analysis 
Statistical comparisons except animal studies were carried out using Student t-test. 
For the antitumor study and toxicity studies, group means for tumor volume and body 
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weights were evaluated using repeated measures analysis of variance with the Bonferroni 
post test. Survival was estimated using Kaplan–Meier analysis and compared using log-
rank test. P values less than 0.05 were considered significant. Analysis of variance with 
Bonferroni test and Kaplan–Meier analysis with log-rank test were performed using 
GraphPad Prism 5 (GraphPad Software, Inc.).  
2.3 Results and Discussion 
2.3.1 Synthesis and characterization of PEG-b-PGlu-b-PPhe 
The synthesis of the amphiphilic hybrid polypeptide-based triblock copolymers PEG-











Figure 2.1. Scheme for the synthesis of PEG-b-PGlu-b-PPhe polymer via ring-opening 
NCA-based polymerization. 
 
The copolymers were synthesized via sequential ring-opening polymerization of BGlu-
NCA and Phe-NCA monomers using amino-terminated PEG (Mw = 5,000 g mol
-1
) as 




The length of PBGlu block was set constant by using feed molar ratio of mPEG-NH2 to 
BGlu-NCA at 1 : 100. The second step was polymerization of Phe-NCA initiated by 
PEG-b-PBGlu copolymer. The length of PPhe block was varied by adjusting the feed 
molar ratio of NCA monomers, BGlu-NCA : Phe-NCA (10:1 and 10:3). At the final step, 
the deprotection of the glutamate residues was carried out by alkali hydrolysis to obtain 
PEG-b-PGlu-b-PPhe. The chemical composition of two resulting triblock copolymers 
was determined by 
1
H-NMR analysis (Fig. 2.2) and further confirmed by Fourier 






H NMR spectra for A) BGlu-NCA,  B) Phe-NCA, C) PEG-PBGlu and D) 
PEG-PBGlu-PPhe 
Notes: peak assignments are as follows:  
A) BGlu-NCA.  
1
H-NMR (CDCl3): δ ppm= 2.22 (2H, m, -CH2-), 2.60 (2H, t, -CH2-), 
4.37 (1H, m, -CH-), 5.15 (2H, s, -CH2-), 7.33 (5H, m, C6H5), 9.10 (1H, s, -NH-), 
B) Phe-NCA. 
1
H-NMR (CDCl3): δ ppm= 3.01 (2H, s, -CH2-), 4.90 (1H, m, -CH2-); 7.20 
(5H, m, C6H5), 9.10 (1H, s, -NH-). 
C) PEG-PBGlu 
1
H-NMR (DMSO-d6): δ ppm= 1.95 (2H, broad s, -CH2-) 2.25 (2H, broad 
s, -CH2), 3.45 (4H, s, CH2CH2-), 5.06 (2H, m, -CH2-); 7.24 (5H, m, C6H5).  
D) PEG-PBGlu-PPhe 
1
H-NMR (DMSO-d6): δ ppm = 1.95 (2H, broad s, -CH2-) 2.25 (2H, 
broad s, -CH2-), 3.05 (2H, broad s, -CH2-), 3.45 (4H, s, CH2CH2-), 3.95 (1H, broad s, -
CH-), 5.06 (2H, m, -CH2-); 7.24 (10H, m, C6H5).  
 
The polymerization degrees of PGlu and PPhe blocks are summarized in Table 2.1. 
Table 2.1. Characteristics of the PEG-PGlu-PPhe triblock copolymer. 






 PEG   BGlu-NCA  Phe-NCA    PEG         PGlu         Phe  
 PEG-PGlu92-PPhe7 0.02            2              0.2    114          92             7 19,700 




Notably, PEG-b-PGlu-b-PPhe maintained the same degree of polymerization after 
complete removal of the benzyl protecting groups. These copolymers had a constant PEG 
block (114 repeating units), practically identical length of anionic PGlu block (about 90 
repeating units), and differed in the length of PPhe blocks (7 and 25 repeating units). 
They are further denoted as PEG-PGlu90-PPhe7 and PEG-PGlu90-PPhe25, respectively.  
2.3.2 Synthesis and characterization of NGs 
We anticipated that incorporation of hydrophobic PPhe block into triblock copolymer 
confers amphiphilic properties and facilitate the formation of micellar aggregates in 
aqueous medium. Indeed, formation of small (intensity-average diameter of 
approximately 90 nm) particles with relatively narrow particle size distribution (PDI = 
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0.16) and net negative charge (ξ-potential = -22 mV) was detected in aqueous solutions 
of PEG-PGlu90-PPhe25 copolymer. In contrast, formation of large aggregates with a broad 
size distribution was observed only in relatively concentrated PEG-PGlu90-PPhe7 
solutions. Differences in association behavior of PEG-PGlu-PPhe block copolymers were 
further confirmed by a fluorescence measurements using pyrene as a probe (Fig. 2.3). 
 
Figure 2.3. Plot of fluorescence intensity I1 (from pyrene emission spectra) as a function 
of PEG-PGlu90-PPhe25 (●) and PEG-PGlu90-PPhe7 (■) concentration. 
 
 Using this approach, we determined that the critical micelle concentration (cmc) for 
PEG-PGlu90-PPhe25 was low (62.5 mg/L). In contrast the onset of aggregation of PEG-
PGlu90-PPhe7 chains was detected at concentrations higher than 1000 mg/L. These data 
indicate that increase in the length of the hydrophobic PPhe block from 7 to 25 units is 
accompanied by an order of magnitude decrease in the cmc value. A similar trend in the 
dependency of cmc on the length of core-forming block was observed earlier for other 
amphiphilic block copolymers [19]. In dilute solution, hydrophobic and π-π stacking 
interactions of the phenylalanine residues play a major role in driving self-assembly of 
Phe-based peptides like amyloid β peptide [20] or synthetic polypeptides [21]. A red shift 
of the emission peak from the normal phenylalanine fluorescence maximum (around 280 
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nm) has been previously observed upon assembly in amyloid system [20]. In the present 
case, the fluorescence spectra obtained from 0.01% solutions of PEG-PGlu-PPhe 
copolymers displayed a peak at 320 nm that is attributable to π-π stacking interactions of 
phenyl units; though the intensity of the fluorescence was lower for PEG-PGlu90-PPhe7 
copolymer (Fig. 2.4).  
 
Figure 2.4. Emission spectra of A) PEG-PGlu90-PPhe25 (●) and B) PEG-PGlu90-PPhe7 
(■) in water (1mg/mL, λex=265 nm). 
 
Notably, the fluorescence spectrum for PEG-PGlu90-PPhe7 was recorded below the cmc. 
It is possible that some loose pre-micelle aggregates of copolymer chains with short PPhe 
blocks might exist below experimentally determined cmc and the observed fluorescence 
characteristics may reflect the local association of aromatic units in such pre-aggregates. 
Interestingly, it was previously reported that peptide-PEG amphiphiles containing the 
hydrophobic sequence of four Phe residues conjugated to PEG of molar mass 5,000 g 
mol
-1
 (PEG-PPhe4 using our nomenclature) exhibit self-assembly behavior despite its 
relatively short peptide sequence with cmc value of 950 mg/L in water. It seems that 
insertion of ionic PGlu block into PEG-b-PGlu-b-PPhe triblock copolymer provides for 
additional negative contribution to micellization and increasing cmc. This may be 
69 
 
explained, on the one hand, by stabilization of the single polymer chains in solution, and, 
on the other hand, by destabilization of multimolecular NGs due to the strong 
electrostatic repulsion of PGlu chains in the micelle corona. Overall, the optimal 
hydrophilic-lipophilic balance (HLB) in terms of numbers of Phe groups with respect to 
PEG and PGlu chains is essential for the formation of multilayer NGs with well-defined 
and distinct domains: hydrophobic PPhe core, the intermediate ionic PGlu layer, and 
hydrophilic nonionic PEG outer shell.  
The PEG-PGlu90-PPhe25 micelles were further utilized as ‘‘core–shell’’ templates for 
synthesis of NGs. The cross-linking was achieved via condensation reactions between the 
carboxylic groups of PGlu chains in intermediate layer and the amine groups of 
ethylenediamine in the presence of a water-soluble carbodiimide, EDC. The targeted 
extent of cross-linking (20%) was controlled by the molar ratio of cross-linker to 
carboxylic acid groups of the Glu residues. The NGs displayed an effective diameter of 
about 90 nm (ξ-potential = - 20 mV) and were uniform (monomodal, narrow size 
distribution) as determined by DLS. It is important to note that NGs had comparable sizes 
with the precursor PEG-PGlu90-PPhe25 micelles (90 ± 1.2 nm) indicating that the micelles 
retained their integrity and formation of cross-links was limited to intramicellar reactions. 
It is likely that the outer PEG shell of the micelles prevented the undesirable intermicellar 
reactions. The dimensions and morphology of NGs were further characterized by TEM 
and tapping-mode AFM in air. Based on AFM and TEM images PEG-PGlu90-PPhe25 
NGs had a spherical morphology. As expected the number-average particle height (Hav) 
and diameter (Dav) values of dehydrated NGs were reduced compared to the 
hydrodynamic diameters Deff determined by DLS (Table 2.2). Upon adsorption on mica 
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surface NGs exhibited a high diameter versus height aspect ratios (Dav/Hav) suggesting 
substantial flattering of the particles. This observation was in agreement with the 
expected flexible character of the PEG-PGlu shell of the NGs. The electrostatic 
interactions of the negatively charged NGs with the positively charged amino-modified 
mica surface may induce additional flattering of NGs.  








 Dav, nm Dav, nm Hav, nm Deff, nm 
NG 45 ± 3.3 47 ± 6.8 8.7 ± 3.7 90 ±1.2 
a
 Number-average diameter (Dav), n = 27. A drop of the sample solution was allowed to 
settle on a Formvar precoated copper grid and the sample was allowed to air-dry.  
b 
Number-average height (Hav) and diameter (Dav), n = 55. NGs were deposited from 




Deff) for DLS was determined at pH 7.4, n= 
5. 
Data are expressed as mean ± SD.  
Interestingly, the hybrid PEG-PGlu90-PPhe25 NGs were characterized by a significantly 
lower aspect ratio (ca. 6) compared to PEG-poly(methacrylic acid) (PEG-PMA) NGs 
containing entirely hydrophilic cross-linked PMA cores [22]. For example, PEG-PMA133 
and PEG-PMA75 NGs were characterized by dimension aspect ratios of 13.3 and 15.0, 
respectively. The observed topological differences can be explained by the presence of 
relatively rigid hydrophobic PPhe cores in the PEG-PGlu90-PPhe25 NGs that rendered 
them more stiff and deceased their deformation at the substrate surface.   
The pH-induced dimensional changes (nanogel-like behavior) of the NGs were 






                             A                                                                        B 
          
Figure 2.5. Swelling behavior (A) and stability (B) of NGs. (A) The effective diameter, 
Deff (●) and ζ-potential (■) of NGs as a function of pH. (B) Changes in Deff of NGs (●) 
and non-crosslinked NGs (■) upon treatment with different concentrations of 8M urea. 
 
Such behavior was indicative of ionization and swelling of the intermediate layer formed 
by the cross-linked PGlu chains in the shell of the NGs. The kinetic stability of NGs was 
further analyzed in the presence of urea (Fig. 2.5B). Urea, a small hydrophilic molecule, 
is widely used as protein denaturant due to its ability to form stronger attractive 
dispersion interactions with the protein side chains and backbone than does water. 
Therefore, it was expected that urea is able to destabilize PEG-PGlu90-PPhe25 NGs by 
weakening the hydrophobic interactions in PPhe core region as well as by disrupting 
hydrogen-bonding interactions between polypeptide chains. Indeed, for non-cross-linked 
NGs addition of 8 M urea led to significant increase in the size and PDI of the aggregates. 
In the meantime, only little changes in the average size of NGs were detected in the 
presence of urea (Fig. 2.4B). The observed limited swelling of PEG-PGlu90-PPhe25 NGs 
can be thus directly related to a restricted mobility of the PGlu chains in the shell and 
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provides additional evidence that the physical stability of NGs can be greatly enhanced 
via covalent crosslinking. Importantly, the cross-linking did not prevent the degradation 
of NGs by proteolytic enzymes. The enzymatic biodegradability of PEG-PGlu90-PPhe25 
NGs was determined by incubating the NGs with cathepsin B followed by analysis of the 
reaction mixture using size exclusion chromatography (SEC) (Fig. 2.6).  


























Figure 2.6. Degradation of NGs upon treatment with cathepsin B at 37
0
C wherein 
aliquots were removed at 0 h (●), 12 h (■) and 24 h (▲) followed by its analysis using 
FPLC.   
 
A gradual decrease in the UV absorption of the micelle peak was observed in SEC 
chromatograms over the incubation time, which almost disappeared after 24 hrs. 
Furthermore, decrease in light scattering intensity along with the drastic increase of PDI 
was detected by DLS of the NGs dispersions already after 12 hrs of incubation with 
cathepsin B suggesting structural disintegration of such NGs (Table 2.3).  
Table 2.3. Physicochemical characteristics of NGs after incubation with cathepsin B (10 
units/mL). 
Time (h)         NGs + cathepsin B
a
 
 Deff, nm  PDI 
0     125±1.5   0.223  
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12    181±2.2   0.424 
24    738±9.0   0.619 
a
 Effective diameter (Deff) and polydispersity index (PDI) were determined 
in water (pH 6.1). Data are expressed as mean ± SD (n=3).  
 
However, further studies will be necessary to characterize the degradation products and 
determine whether drug incorporation can alter the degradation pattern of the NGs. 
Overall, these results imply that the reinforcing cross-links within the shell of PEG-
PGlu90-PPhe25 NGs can permanently suppress their dissociation. Resulting NGs can 
withstand environmental challenges and sink conditions encountered after systemic 
administration and, consequently, provide means for temporal control over drug 
disposition. On the other hand, enzymatic degradation of the polypeptide-based building 
blocks of NGs reduces the risk of polymer accumulation inside cells and can also 
facilitate specific intracellular drug release.  
2.3.3 Drug loading and release from NGs. 
PEG-PGlu90-PPhe25 NGs have a well-defined structure with a central hydrophobic 
core formed by PPhe chains, swollen intermediate layer of a cross-linked PGlu network 
and external PEG shell surrounding the core and intermediate layer.  Each of these three 
nanodomains contributes to the utility of NGs as drug nanocarriers. A PPhe core can 
serve as a cargo for water-insoluble drugs. An ionic intermediate layer can incorporate 
hydrophilic drug molecules through electrostatic or covalent bonding while PEG shell in 
addition to stabilizing NGs in dispersion also allows minimizing interactions of the NGs 
with blood components. Therefore, such NGs would provide unique opportunity to 
simultaneously incorporate and deliver multiple chemotherapeutic drugs with very 
different physical properties and modes of action inside a single polymeric carrier in 
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order to achieve a synergistic effect and enhance the efficacy of treatment. In the present 
study NGs with binary drug combination of hydrophilic CDDP and hydrophobic PTX 
were prepared. At first, PTX was solubilized into the PPhe cores of the NGs using 
micelle extraction method.  According to this method, PTX dissolved in ethanol was 
added to the aqueous dispersion of NGs upon agitation followed by evaporation of 
organic solvent and removal of unbound PTX. Under these conditions PTX loading 
capacity (the net amount of drug loaded into a carrier) was about 9 w/w% weight as was 
quantified by HPLC. The size and ζ-potential of the PTX-loaded NGs were comparable 
to those of empty NGs indicating that the PTX incorporation into PPhe cores did not 
affect the macroscopic characteristics of the pre-formed NGs. As the next step, CDDP 
was incubated with the aqueous dispersions of PTX-loaded NGs for 48 h at pH 9.0 [7]. 
Such conditions were chosen to maximize the swelling of PGlu cross-linked layer (Fig. 
2.4A) and increase the accessibility of the bulk of the carboxylate groups to CDDP. As 
expected, the net negative charge and particle size of NGs decreased upon CDDP loading 
consistent with neutralization and condensation of PGlu segments by CDDP (Table 2.4).  
Table 2.4. Physicochemical characteristics of NGs before and after drug loading. 
Sample Deff (nm) PDI ζ-potential (mV) LC (w/w%)
b
 
NGs 90 ± 1.2 0.14 -20.0 ± 1.2 - 
PTX/NG 105 ± 2.8 0.23 -19.1 ± 1.5 8.4 
CDDP/NG 71 ± 3.3 0.19 -3.7 ± 1.0 22.4 




 Effective diameter (Deff), polydispersity index (PDI) and ζ-potential were determined in 




 Pt and PTX content were deternined by ICP-MS and HPLC, respectively.  Loading 
capacity (LC) is expressed as mass of incorporated drug per mass of drug loaded NGs 
(w/w). 
C 
Total LC for combination of CDDP (15.4%) and PTX (9.4%). 
Data are expressed as mean ± SD (n = 3).  
 
15 w/w% loading was achieved with respect to CDDP while total loading values for 
binary drug combination was about 25% and corresponded to 10 : 1 molar ratio (CDDP : 
PTX) of drugs in the NGs. (CDDP+PTX)/NG maintained their spherical morphology as 
was confirmed by TEM (Fig. 2.7).   
 
Figure 2.7. TEM image of (CDDP+PTX)/NG. Bar equals 100nm 
 
Notably, (CDDP+PTX)-loaded NGs were stable in aqueous dispersions, exhibiting no 
aggregation or precipitation with loading capacity preserved for as long as month (Table 
2.5).  
 
Table 2.5. Physicochemical characteristics of empty and drug-loaded NGs after one 
month of storage in aqueous dispersion at 4
o
C. 
Sample Deff (nm) PDI ζ-potential (mV) LC (w/w%)
b
 
NG 95 ± 0.8 0.16 -24.6 ± 3.2 - 




 Effective diameter (Deff), polydispersity index (PDI) and ζ-potential were determined in 
water (pH 6.5). 
b
 Pt and PTX content were deternined by ICP-MS and HPLC, respectively. 
C 
Total LC for combination of CDDP (13.8%) and PTX (7.4%). 
 
Interestingly, the loading capacity of NGs with respect to CDDP was decreased after 
loading of PTX as compared to single CDDP/NG formulation (15% vs. 23%). This 
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apparent difference in drug loading is not yet understood and needs to be investigated 
further. We hypothesize that the presence of hydrophobic solute in the core of the micelle 
affects the conformation of the polypeptide chains at the PPhe core - PGlu shell interface. 
Specifically, in more hydrophobic environment PGlu chains can transition from random 
coil to α-helical conformation leading to structural condensation in this region which may 
restrict space for the loading CDDP molecules. Validation of this hypothesis is of 
considerable interest and is ongoing in our laboratory. 
 The release of the drugs from NGs was studied by equilibrium dialysis at 37 °C at 
either pH 7.4 (PBS) or pH 5.5 (ABS), which reflect conditions encountered in plasma and 
in intracellular compartments (lysosomes), respectively. The kinetic profiles of drug 
release from (CDDP+PTX)/NGs are presented in Fig. 2.8. As seen from these data 
sustained but temporally distinct release of Pt(II) species and PTX was observed. 
Notably, PTX release was much faster than that of Pt(II), which is expected since PTX is 
physically entrapped into the PPhe core. In contrast, CDDP binds with PGlu chains 
through electrostatic and coordination interactions and its release usually proceeds via 
ligand exchange reactions with chloride or other biologically abundant anions, thus 
delaying its liberation from the NGs. Pt(II) release from the NGs was also a pH-
dependent process. Indeed, Pt(II) species were liberated from the NGs faster at pH 5.5 
than at pH 7.4 (Fig. 2.8B), probably, due to protonation of carboxylic groups of PGlu, 
which weakens the drug and micelle electrostatic coupling. For example, during 24 hrs 
(CDDP+PTX)/NGs released 16.7 ± 5.5% of loaded Pt(II) at pH 5.5 and only 8.8 ± 3.6% 
at pH 7.4, respectively.  
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                       A                                             B                                            C
 
Figure 2.8. In vitro drug release profiles for Pt (●) and PTX (■) from NGs in  (A) PBS, 
pH 7.4; (B) ABS, pH 5.5; and (C) ABS in presence of cathepsin B (10 units/mL) at 37
o
C. 
Data are expressed as mean ± SD (n=3). 
 
Notably, pH changes practically did not affect the release of PTX. Also, noteworthy that 
Pt (II) release from (CDDP+PTX)/NG at the acidic pH was further accelerated in 
presence of cathepsin B in the media (Fig. 2.8C). Cathepsin B is a lysosomal thiol-
dependent protease [23] and is also extracellularly present in pathological tissues such as 
tumors and sites of inflammation [24, 25]. These results indicate that degradation of NGs 
can further facilitate the drug release once located within targeted tissue and cells.  
2.3.4 In vitro cytotoxicity of the drug-loaded NGs 
The cytotoxicity of drug combination loaded into NGs was determined in human 
ovarian carcinoma A2780 cells using MTT assay. Calculated IC50 values are summarized 
in Table 2.6.  
Table 2.6. Comparison of IC50 values for various drug-loaded NGs and free CDDP 
against A2780 cells as determined by the MTT assay. 
 
 IC50 (µM) 




CDDP/NG + PTX/NG 6.3* 




Importantly, NGs alone were nontoxic to the cells up to the concentration of 5 mg/mL. 
CDDP/NG displayed lower cytotoxic activity than free CDDP. Since unloaded NGs did 
not affect the cell survival in the entire range of concentrations the cytotoxic activity of 
CDDP/NG was mediated by the Pt(II) species slowly released from the NGs. However, 
we found that (CDDP+PTX)/NG were significantly more effective in killing A2780 
ovarian cancer cells than CDDP/NG. The dose of CDDP in NGs was indeed reduced 
nearly by 30-fold when used in combination with PTX (at 10 : 1 CDDP/PTX molar ratio) 
to achieve the same cytotoxic effect produced by the CDDP loaded NGs. The CI value at 
IC50 for this (CDDP+PTX)/NG combination was 0.078, indicating strong synergistic 
cytotoxicity against A2780 ovarian cancer cells. Notably, the combination of two 
separate micellar formulations (CDDP/NG +PTX/NG) applied at the same drug ratio 
elicited cytotoxicity comparable to that of the CDDP/NG formulation (Table 4) and 
displayed antagonistic CI value of 1.2 at IC50. These data suggest that synchronized 
delivery of this drug combination in the same cl-micelle formulation may play an 
essential role in the cytotoxic activity. 
2.3.5 Antitumor activity   
Motivated by the enhanced in vitro efficacy of (CDDP+PTX)/NG formulation, we 
evaluated its antitumor efficacy in vivo in mice bearing A2780 human ovarian cancer 
xenografts. Free CDDP and CDDP/NG were injected 4 times at 4-day intervals at an 
equivalent dose of 4 mg-CDDP/kg determined as the maximum tolerated dose upon this 
treatment schedule [18]. Animals injected with (CDDP+PTX)/NG received 4mg/kg 
CDDP and 1 mg/kg PTX equivalents per dose. The changes in the relative tumor volume, 
body weight and animal lifespan are shown in Fig. 2.9.  
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            A                                           B                                          C 
  
Figure 2.9. In vivo antitumor efficacy of (CDDP+PTX)/NG in A2780 human ovarian 
cancer xenograft-bearing female nude mice. Relative changes in (A) tumor volume and 
(B) body weight were measured following intravenous administration of 
(CDDP+PTX)/NG (●) or CDDP/NG (■) or PTX/NG (▲) or free CDDP (▼) or 5% 
dextrose (♦). Drug formulations were injected in100 μL at a dose of 4 mg CDDP or 1mg 
PTX equivalents/kg body weight 4 times at 4-day intervals as indicated by the arrows. 
Values indicated are means ± SEM (n = 8). (C) Kaplan–Meier analysis of overall 
survival in (CDDP+PTX)/NG group (1) or CDDP/cl-micelles group (2) or PTX/NG 
group (4) or free CDDP group (3) or control group (5). Tumor volume and body weight 
are normalized with respect to tumor volume or body weight at day 0. * P<0.05. 
Tumor burden was significantly decreased by both free CDDP (P<0.05) and CDDP/NG 
(P<0.05) treatments compared to control (Fig. 2.9A). However, tumors in the animals 
treated with CDDP/NG remained relatively smaller than in animals treated with free 
CDDP between days 0 and 18. As a result, increased survival of the animals was 
observed in mice treated with CDDP/NG compared to CDDP alone (Fig. 2.9C). Notably, 
treatment with PTX-loaded NG did not have any substantial effect on the tumor growth 
and only minor increase in survival was observed over controls. In contrast, nearly 
complete inhibition of tumor growth was observed for the mice treated with 
(CDDP+PTX)/NG from day 0 to 14, which translated into significantly increased overall 
survival of the animals treated with (CDDP+PTX)/NG compared to either CDDP/NG 
(P<0.05) or CDDP alone (P<0.05)  (Fig. 2.9A and C). On the second day post treatment 
animals injected with either  (CDDP+PTX)/NG or CDDP/NG displayed significantly 
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higher levels of Pt in tumors compared to free CDDP treatment group (P<0.05) which 
may be attributed to the enhanced permeability and retention (EPR) effect (Fig. 2.10A) 
[26].  
                              A                                                                           B     
                     
Figure 2.10. Tissue distribution of platinum in different treatment groups as determined 
ICP- MS. (A) Mice were sacrificed at day 14 of the treatment with (CDDP+PTX)/NG or 
CDDP/NG or free CDDP. (B) Significant reduction in the Pt levels in various organs of 
mice treated with (CDDP+PTX)/NG was confirmed by comparing Pt levels at day 14 and 
day 45. Values indicated are means ± SEM (n = 3),   * P<0.05. 
To elucidate the mechanism underlying the enhanced antitumor activity of 
(CDDP+PTX)/NG, the tumors were excised post-treatment (on 2
nd
 day after last 
injection) and processed for Ki-67-Caspase-3 assay to examine the effect of each 




Figure 2.11. Ki-67-caspase-3 apoptosis assay. Quantification of caspase-3 positive cells 
in tumor tissue from mice from various groups. Data are presented as mean ± SD (n = 5 
random microscopic fields for each tumor slice).  
The number of caspase-3 positive cells were significantly higher in tumors from mice 
that received (CDDP+PTX)/NG compared to tumors in CDDP/NG (P<0.05) or PTX/NG 
(P<0.05) or free CDDP (P<0.05) (Fig. 2.11). This assay further corroborates the superior 
antitumor efficacy of binary drug combination NG formulation over single drug-loaded 
NGs or CDDP alone. Since the levels of Pt accumulation in tumors were comparable for 
the treatments with both single and binary drug formulations, we rationalize that an 
increase in therapeutic efficacy of (CDDP+PTX)/NG can be related to highly synergistic 
interactions between CDDP and PTX simultaneously delivered to the tumors. Indeed, the 
average weight ratio of the CDDP and PTX in the tumors of the animals treated with 
(CDDP+PTX)/NG was determined to be 4 : 1, the same as the drug loading ratio in NG, 
indicating the spatial-temporal synchronization of drug exposure. CDDP and PTX are 
highly suited for combination chemotherapy because they have distinct mechanisms of 
action. CDDP binds to DNA base pairs creating adducts, cross-links, and strand breaks 
that inhibit DNA replication. Unrepairable DNA damage often results in activation of the 
apoptotic pathway. Paclitaxel acts by binding to intracellular β-tubulin, which leads to 
microtubule stabilization, G2–M arrest and apoptosis [27]. CDDP is thought to be 
relatively non-cell cycle specific in terms of its cell-killing effects and tends to synergize 
or have additive cytotoxicity with agents that alter mitosis (PTX) [28, 29]. Apart from the 
mechanism basis, synergistic effect greatly depends on drug dosages, combination ratios, 
cell lines and intervention schedules. Indeed, synergy between CDDP and PTX was 
reported to be highly schedule dependent [30, 31]. Profound synergistic effects were 
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observed when PTX was administered prior to CDDP [28, 30] while the sequence of 
CDDP before PTX had less antitumor activity in vitro [31], and induced more profound 
neutropenia in vivo [32]. One can speculate that the ability of (CDDP+PTX)/NG to 
supply drugs in a temporally controlled fashion by releasing PTX significantly faster than 
CDDP may contribute into observed improvement of antitumor efficacy of drug 
combination. 
It should be emphasized that PTX and CDDP may also interact synergistically with 
respect to toxicity to the normal tissues as well. However, this was not the case in our 
studies. Fig. 2.9B shows that either single or binary drug loaded NG did not induce body 
weight loss while the same dose of the free CDDP produced a considerable body weight 
loss (P < 0.05), which indicated systemic toxicity of free CDDP.  In the kidney, the 
primary target organ of CDDP toxicity [33, 34], single or binary drug loaded NGs 
showed significantly lower Pt levels than the free CDDP (Fig. 2.12A). Reduced Pt 
accumulation in kidney after (CDDP+PTX)/NG or CDDP/NG treatment ameliorated 




Figure 2.12. Light microscopy images (original magnification 100×) of hematoxylin and 
eosin-stained kidney sections of mice. Tissue samples were collected at day 14.  
Light microscopic examination of H&E stained kidney sections from sacrificed animals 
indicated focal tubular basophilia with regeneration in kidneys from all animals treated 
with free CDDP, while no histopathological changes were observed in kidney from 
animals in the (CDDP+PTX)/NG-treated or CDDP/NG-treated groups compared with the 
control (Fig. 2.12). Reduced nephrotoxicity of (CDDP+PTX)/NG or CDDP/NG is likely 
due to its macromolecular size coupled with slow release of the drug, which leads to a 
lower renal tubular drug exposure. This is a significant result considering renal toxicity is 
the most severe, dose-limiting toxicity with CDDP treatment [35]. (CDDP+PTX)/NG 
showed very high Pt accumulation in spleen and liver (Fig. 2.10A), but this amount 
reduced significantly (P<0.01) with time (Fig. 2.10B). Despite much higher exposure of 
liver and spleen to CDDP in the (CDDP+PTX)/NG or CDDP/NG treatment, there was no 
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significant change in hepatic toxicity markers of blood chemistry (Table 2.7), indicating 
no obvious toxicity to the liver.  
Table 2.7. Clinical chemistry parameters at day 14 of the treatment. 
 ALP             ALT 
Control <5              43 ± 8 
Free CDDP <5               58 ± 2 
CDDP/NG <5               45 ± 9 
PTX/NG <5               66 ± 17 
(CDDP+PTX)/NG <5               41 ± 9 
Data were expressed as mean ± SD (n=3) 
Values of ALP and ALT are expressed as U/L 
Abbreviations: Alkaline phosphatase; ALP, alanine aminotransferase; ALT. 
There was no evidence of liver or splenic toxicity by histopathology (data not shown). In 
spleen, the NGs (either free or localized inside macrophages) were detected 
predominantly in the red pulp with little to no staining in the lymphoid region (Fig. 2.13).  
Free CDDP treatment has previously been reported to have a remarkable effect on 
immunological function due to its ability to reduce lymphocytes in the thymus and the 






Figure 2.13. Confocal image of spleen section stained for NGs (green) and macrophages 
(red). Spleen shows accumulation of NGs only in the red pulp region.   
 
Absence of (CDDP+PTX)/NG in lymphoid regions of white pulp may thus limit free-
drug exposure to these follicles. Collectively, these results demonstrate that 
biodegradable PEG-polypeptide hybrid NGs carrying CDDP and PTX drug combination 
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exerted superior antitumor efficacy, both in terms of tumor inhibition and survival, which 
could be attributed to the preferential simultaneous accumulation, and increased potency. 
2.4 Conclusions   
In the present investigation, NGs based on biodegradable and biocompatible 
amphiphilic PEG-b-PGlu-b-PPhe triblock copolymers were evaluated as potential carriers 
for co-delivery of chemotherapeutic drugs with various physicochemical properties and 
modes of action. These nanostructures were designed to have multicompartment 
morphology for drug loading and were cross-linked at an intermediate layer within the 
polymeric NGs to ensure their prolong stability upon systemic administration. 
Hydrophilic CDDP and hydrophobic PTX were loaded in such NGs with high efficiency, 
exhibited differential release profiles and synergistic cytotoxic effect against ovarian 
cancer cells. The binary drug combination simultaneously delivered using NGs exhibited 
superior antitumor efficacy over single drug cl-micelle analogues in vivo in synergistic 
manner. Altogether, this study demonstrates a fundamental possibility for simultaneous 
delivery of chemotherapeutics and molecular targeting agents via single well-defined and 
structurally tunable polymeric nanocarrier.  
Acknowledgments 
We acknowledge the assistance of NMR, Electron Microscopy and Nanoimaging Cores 
(University of Nebraska Medical Center). The authors are grateful to Dr. Larisa 
Poluektova for assistance with IHC studies and Dr. Hardeep Oberoi for help with animal 
studies. We acknowledge assistance of Dr. Jinjin Zhang and Dr. Zhengyuan Zhou for the 





[1] R.C. Bast, B. Hennessy, G.B. Mills, The biology of ovarian cancer: new opportunities 
for translation, Nat. Rev. Cancer, 9 (2009) 415-428. 
[2] A. Kim, Y. Ueda, T. Naka, T. Enomoto, Therapeutic strategies in epithelial ovarian 
cancer, J. Exp.  Clin. Cancer Res.: CR, 31 (2012) 14. 
[3] B. Lippert, Cisplatin: chemistry and biochemistry of a leading anticancer drug, Wiley-
VCH, 1999. 
[4] R.S. Go, A.A. Adjei, Review of the comparative pharmacology and clinical activity 
of cisplatin and carboplatin, J. Clin. Oncol., 17 (1999) 409-409. 
[5] N.J. Wheate, S. Walker, G.E. Craig, R. Oun, The status of platinum anticancer drugs 
in the clinic and in clinical trials, Dalton Trans., 39 (2010) 8113-8127. 
[6] Y. Matsumura, K. Kataoka, Preclinical and clinical studies of anticancer 
agent‐incorporating polymer micelles, Cancer Sci., 100 (2009) 572-579. 
[7] H.S. Oberoi, F.C. Laquer, L.A. Marky, A.V. Kabanov, T.K. Bronich, Core cross-
linked block ionomer micelles as pH-responsive carriers for cis-
diamminedichloroplatinum (II), J. Control. Release, 153 (2011) 64-72. 
[8] N.V. Nukolova, H.S. Oberoi, S.M. Cohen, A.V. Kabanov, T.K. Bronich, Folate-
decorated nanogels for targeted therapy of ovarian cancer, Biomaterials, 32 (2011) 5417-
5426. 
[9] Y. Han, Z. He, A. Schulz, T.K. Bronich, R. Jordan, R. Luxenhofer, A.V. Kabanov, 
Synergistic combinations of multiple chemotherapeutic agents in high capacity poly (2-
oxazoline) micelles, Mol. Pharm., 9 (2012) 2302-2313. 
[10] J. Sandercock, M. Parmar, V. Torri, W. Qian, First-line treatment for advanced 
ovarian cancer: paclitaxel, platinum and the evidence, Br. J. Cancer, 87 (2002) 815-824. 
[11] G. Batist, K.A. Gelmon, K.N. Chi, W.H. Miller, S.K. Chia, L.D. Mayer, C.E. 
Swenson, A.S. Janoff, A.C. Louie, Safety, pharmacokinetics, and efficacy of CPX-1 
liposome injection in patients with advanced solid tumors, Clin. Cancer Res., 15 (2009) 
692-700. 
[12] H.-C. Shin, A.W. Alani, H. Cho, Y. Bae, J.M. Kolesar, G.S. Kwon, A 3-in-1 
polymeric micelle nanocontainer for poorly water-soluble drugs, Mol. Pharm., 8 (2011) 
1257-1265. 
[13] N. Kolishetti, S. Dhar, P.M. Valencia, L.Q. Lin, R. Karnik, S.J. Lippard, R. Langer, 
O.C. Farokhzad, Engineering of self-assembled nanoparticle platform for precisely 
controlled combination drug therapy, Proc. Natl. Acad. Sci., 107 (2010) 17939-17944. 
[14] K. Ananthapadmanabhan, E. Goddard, N. Turro, P. Kuo, Fluorescence probes for 
critical micelle concentration, Langmuir, 1 (1985) 352-355. 
[15] D. Yang, S. Van, X. Jiang, L. Yu, Novel free paclitaxel-loaded poly(L-gamma-
glutamylglutamine)-paclitaxel nanoparticles, Int. J. Nanomedicine, 6 (2011) 85-91. 
[16] M. Ferrari, M.C. Fornasiero, A.M. Isetta, MTT colorimetric assay for testing 
macrophage cytotoxic activity in vitro, J Immunol. Methods, 131 (1990) 165-172. 
[17] T.C. Chou, Drug combination studies and their synergy quantification using the 
Chou-Talalay method, Cancer Res., 70 (2010) 440-446. 
[18] H.S. Oberoi, N.V. Nukolova, F.C. Laquer, L.Y. Poluektova, J. Huang, Y. Alnouti, 
M. Yokohira, L.L. Arnold, A.V. Kabanov, S.M. Cohen, Cisplatin-loaded core cross-
linked micelles: comparative pharmacokinetics, antitumor activity, and toxicity in mice, 
Int. J. Nanomedicine, 7 (2012) 2557. 
87 
 
[19] I. Astafieva, K. Khougaz, A. Eisenberg, Micellization in block polyelectrolyte 
solutions. 2. fluorescence study of the critical micelle concentration as a function of 
soluble block length and salt concentration, Macromolecules, 28 (1995) 7127-7134. 
[20] M.J. Krysmann, V. Castelletto, A. Kelarakis, I.W. Hamley, R.A. Hule, D.J. Pochan, 
Self-assembly and hydrogelation of an amyloid peptide fragment, Biochemistry, 47 
(2008) 4597-4605. 
[21] J. Sun, X. Chen, C. Deng, H. Yu, Z. Xie, X. Jing, Direct formation of giant vesicles 
from synthetic polypeptides, Langmuir, 23 (2007) 8308-8315. 
[22] N.V. Nukolova, Z. Yang, J.O. Kim, A.V. Kabanov, T.K. Bronich, Polyelectrolyte 
nanogels decorated with monoclonal antibody for targeted drug delivery, React. Funct. 
Polym., 71 (2011) 315-323. 
[23] H.H. Otto, T. Schirmeister, Cysteine proteases and their inhibitors, Chem. Rev., 97 
(1997) 133-172. 
[24] J.E. Koblinski, M. Ahram, B.F. Sloane, Unraveling the role of proteases in cancer, 
Clin. Chim. Acta., 291 (2000) 113-135. 
[25] Y. Hashimoto, H. Kakegawa, Y. Narita, Y. Hachiya, T. Hayakawa, J. Kos, V. Turk, 
N. Katunuma, Significance of cathepsin B accumulation in synovial fluid of rheumatoid 
arthritis, Biochem. Biophys. Res. Commun., 283 (2001) 334-339. 
[26] H. Maeda, J. Wu, T. Sawa, Y. Matsumura, K. Hori, Tumor vascular permeability 
and the EPR effect in macromolecular therapeutics: a review, J. Control. Release, 65 
(2000) 271-284. 
[27] R. Agarwal, S.B. Kaye, Ovarian cancer: strategies for overcoming resistance to 
chemotherapy, Nat. Rev. Cancer, 3 (2003) 502-516. 
[28] A. Jekunen, R. Christen, D. Shalinsky, S. Howell, Synergistic interaction between 
cisplatin and taxol in human ovarian carcinoma cells in vitro, Br. J. Cancer, 69 (1994) 
299. 
[29] P. Engblom, V. Rantanen, J. Kulmala, H. Helenius, S. Grenman, Additive and supra-
additive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines, Br. 
J. Cancer, 79 (1999) 286. 
[30] C.G. Milross, L.J. Peters, N.R. Hunter, K.A. Mason, L. Milas, Sequence‐dependent 
antitumor activity of paclitaxel (taxol) and cisplatin in vivo, Int. J. Cancer, 62 (1995) 599-
604. 
[31] U. Vanhoefer, A. Harstrick, H. Wilke, N. Schleucher, H. Walles, J. Schröder, S. 
Seeber, Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and 
ovarian carcinoma cell Lines in vitro, Eur. J. Cancer, 31 (1995) 92-97. 
[32] E.K. Rowinsky, M. Gilbert, W. McGuire, D. Noe, L. Grochow, A. Forastiere, D. 
Ettinger, B. Lubejko, B. Clark, S. Sartorius, Sequences of taxol and cisplatin: a phase I 
and pharmacologic study, J. Clin. Oncol., 9 (1991) 1692-1703. 
[33] H. Uchino, Y. Matsumura, T. Negishi, F. Koizumi, T. Hayashi, T. Honda, N. 
Nishiyama, K. Kataoka, S. Naito, T. Kakizoe, Cisplatin-incorporating polymeric micelles 
(NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats, Br. J. Cancer, 
93 (2005) 678-687. 
[34] Y. Mizumura, Y. Matsumura, T. Hamaguchi, N. Nishiyama, K. Kataoka, T. 
Kawaguchi, W.J.M. Hrushesky, F. Moriyasu, T. Kakizoe, Cisplatin‐incorporated 
polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity, 
Cancer Sci., 92 (2001) 328-336. 
88 
 
[35] I. Arany, R.L. Safirstein, Cisplatin nephrotoxicity, in:  Semin. Nephrol., 2003, pp. 
460. 
[36] Ž. Milićević, V. Slepčević, D. Nikolić, V. Živanović, N. Milićević, Effects of cis-
Diamminedichloroplatinum II (Cisplatin) on the Splenic Tissue of Rats: A 




























TARGETED DELIVERY OF PLATINUM-TAXANE COMBINATION THERAPY 
IN OVARIAN CANCER 
3.1. Introduction  
Combination chemotherapy is preferred over treatment with single agents to combat most 
cancers as it targets multiple cell-survival pathways at the same time and delays the onset 
of resistance. This helps in achieving long-term tumor remission and increases median 
survival [1]. Cisplatin (CDDP)-based therapy has been the standard treatment for ovarian 
cancer since its discovery. After paclitaxel (PTX) was shown to be effective in ovarian 
cancer, multiple clinical trials studied the overall efficacy of CDDP and PTX and found 
significant benefit over the pre-existing treatments. Since then, this combination has been 
the treatment of choice for both early stage as well as advanced cases of ovarian cancer 
[2, 3]. However, administration of two different agents comes with the inconvenience of 
repeated or extended duration of drug infusion in patients. Moreover, the most 
extensively used conventional formulation of paclitaxel, Taxol
®
, utilizes Cremophor EL 
(polyethoxylated castor oil) that has been linked to significant toxicities including 
allergic, hypersensitivity and anaphylactic reactions during infusion that require 
premedication and prolonged peripheral neuropathy. Combining such drugs in one 
delivery carrier is therefore a well-suited and convenient strategy for controlling the 
pharmacokinetics and co-delivery of the desired drug ratio in vivo, to maximize the 
therapeutic potency and minimize drug-associated toxicities.  
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      Cross-linked nanogels have been found to be promising drug carriers to achieve this 
goal. Being mostly hydrophilic in nature, nanogels are highly biocompatible with a high 
loading capacity for guest molecules [4]. The nanogel structure can be readily adjusted to 
integrate features of different materials and, thus, offer advantages for combinatorial 
encapsulation of drugs with varying physicochemical properties. One of the widespread 
synthetic techniques for the synthesis of nanogels is the crosslinking of preformed core-
shell self-assemblies such as polymer micelles that allows introducing a high degree of 
spatial organization into the nanogels [4, 5]. Cross-linking is known to impart control 
over the swelling behavior of the nanogels and thus helps in achieving controlled release 
of the incorporated cargo, which is an added advantage over the structural integrity 
imparted to the carrier system upon in vivo administration [4, 6]. The enhanced stability 
also makes the prolonged circulation of the nanogels possible, which in turn allows for 
increased drug accumulation at the target site [5-9]. 
      We have previously described a biodegradable hybrid nanogel carrier system (NG) 
for the combination of CDDP and PTX for ovarian cancer therapy, which not only 
mitigated the toxicities associated with the use of free drugs but also improved treatment 
outcome [10]. However, our system relied solely on the enhanced permeation and 
retention (EPR) effect to facilitate the delivery of the drug combination to the tumor site 
[11].  Regardless of the importance and popularity of EPR effect-based drug delivery, 
this strategy has some limitations related to the inter- and intra-tumor heterogeneity, 
variations in the density as well as permeability of the tumor vasculature that can affect 
the accumulation of nanocarriers. One of the popular approaches to circumvent these 
problems is by surface-functionalization of the drug carrier with ligands that can target 
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receptors with differential expression on the cancer cell surface, which helps in 
increasing the mean residence time of the delivery system at the tumor site and improving 
target cell uptake [12-15]. One such receptor of interest is the folate receptor (FR). 
Malignant cells, due to their high rate of cell division, have an increased requirement of 
folic acid (FA), since it is essential component of cell metabolism and DNA synthesis 
and repair. To fulfill this higher need of FA, FR is known to be over-expressed in a large 
number of malignant tissues, including ovarian cancer, compared to normal tissues with 
the exception of the kidney and choroid plexus [16, 17]. Furthermore, this receptor 
becomes accessible via the plasma compartment only after the cells lose their polarity 
owing to malignant transformation which makes it a differential target for cancer tissue 
that is easily accessible for intravenously administered FA conjugated systems. Its natural 
ligand, FA, comes with the advantages of high binding affinity, stability and a simple 
chemical structure together with ease of availability, making it a suitable targeting ligand 
for ovarian cancer therapy. FA can thus be successfully conjugated to macromolecular 
systems without loss of binding affinity to its receptor [18]. Many different agents 
targeting the folate pathway are currently in clinical development [19]. To date, FA-
targeted agents showed significant promise in phase II clinical trials but it has not been 
confirmed in phase III studies [20-22]. Accordingly, there is a need for further 
identification of new therapeutic combinations and refinement of patient selection. To 
this end, FA-conjugated imaging agents could be used for pre-selection of patients based 
on the expression of FR [23] and several methods have been already developed for this 
purpose [24, 25].  
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      Our group has previously demonstrated a tumor-specific delivery and improved anti-
cancer effect in vivo of CDDP-loaded NGs decorated with FA targeting groups [26]. In 
the current study, we designed FA-linked NGs incorporating platinum-taxane 
combination, and examined whether FR-targeted concurrent delivery of synergistic 
combination of CDDP and PTX can lead to enhanced therapeutic efficacy compared to 
nontargeted NG system.  
3.2. Materials and Methods 
3.2.1. Materials  
α-Amino-ω-methoxy poly(ethylene glycol) (mPEG-NH2, Mw = 5000 g mol
−1
 , Mw/Mn = 
1.05) was purchased from Creative PEGWorks Inc., (NC, USA). Fmoc-NH-PEG-NH2 
(Mw = 7500 g mol
-1
, Mw/Mn = 1.04) was purchased from JenKem technology (TX, 
USA). CDDP was purchased from Acros Organics (NJ, USA). L-Glutamic acid γ-benzyl 
ester (BGlu), L-phenylalanine (Phe), 1,2-ethylenediamine (ED), 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), paclitaxel, folic acid 
and other chemicals were purchased from Sigma-Aldrich (MO, USA) and were used 
without further purification. Fetal bovine serum (FBS), RPMI 1640 medium, penicillin, 
streptomycin, Trypsin–ethylenediaminetetraacetic acid (EDTA) (0.5% trypsin, 5.3 mM 
EDTA tetra-sodium) and other chemicals were purchased from Invitrogen (CA, USA). 
3.2.2. Preparation of polymeric NGs 
Poly(ethylene glycol)-b-poly(L-glutamic acid)-b-poly(L-phenylalanine) block copolymer 
with 90:25 ratio of glutamic acid and phenylalanine units (PEG-PGlu90-PPhe25) was 
synthesized as previously described [10]. Details of the procedures used for polymer 
synthesis and characterization are described in the Chapter 2. NGs were prepared by 
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using previously described method [10] using PEG-PGlu90-PPhe25 micelles  as templates 
for further cross-linking by ED and EDC ([EDC]/[ED] = 2; [COOH]/[EDC] = 5) at r.t., 
overnight. Byproducts of the cross-linking reaction were removed by exhaustive dialysis 
of the reaction mixtures against distilled water. To synthesize fluorescence (Alexa 594)-
labeled NGs, solution of Alexa  luor 594 hydrazide (0.25 μmol, equivalent to 1% of 
carboxylate groups in NGs) in DMF was added to aqueous dispersion of NGs and the 
mixture was incubated for 2 h in dark. Unbound dye was removed by filtration on 
Ultracon filter units (MWCO 10,000 Da, Millipore) at 3000 rpm for 15 min (3 washes) 
and then additionally purified using NAP-10 column (GE healthcare). Notably, the same 
stock of Alexa 594-labeled NGs was used to prepare FA-decorated NGs. 
3.2.3. Synthesis of FA-decorated NGs and drug loading  
FA targeting moieties were conjugated to drug-loaded NGs via PEG spacer having Fmoc 
protection group (Fmoc-NH-PEG-NH2). Firstly, Fmoc-NH-PEG-NH2 (0.013 mmol, 0.05 
eq with respect to the amount of carboxylate groups and 1.5 eq with respect to required 
FA) was conjugated to the free carboxyl groups (0.25 mmol) of NGs via EDC (0.023 
mmol) chemistry. Fmoc group was then removed by adding 5 µL of 30% 
piperidine/DMF (1.1 eq piperidine, 0.014 mmol) and incubating the reaction mixture for 
10 min. Resulting constructs were purified using repeated ultrafiltration (MWCO 30,000, 
Millipore) at 3000 rpm for 15 min (3 washes). Size exclusion chromatography ( KTA 
Fast Protein Liquid Chromatography system) was used to determine the presence of 
residual PEG. PEG-NGs conjugates were analyzed by proton nuclear magnetic resonance 
spectroscopy (
1
H NMR) using Varian INOVA 500 NMR spectrometer (Varian, Palo 
Alto, CA) operating at 500 MHz (1 mg/mL, D2O, pH 7.0, 25 °C). The dispersion of PEG-
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conjugated NGs was mixed with an aqueous solution of CDDP (1mg/mL) at pH 9.0 at a 
0.5 molar ratio of CDDP (0.12 mmol) to carboxylate groups (0.24 mmol) of the NGs 
followed by incubation at 37 °C for 48 h. Unbound CDDP was removed by Ultracon 
filter units (MWCO 10,000 Da, Millipore) at 3000 rpm for 15 min. FA (0.025 mmol) 
dissolved in water was subsequently reacted with 1.5 eq EDC (0.037 mmol) at pH 7 for 2 
h. This EDC-activated FA was then conjugated to amine terminus of the PEG linker. 
Amount of FA was selected based on the previously reported optimal density of FA on 
NGs (0.1-0.2 µmol/mg of polymer) to maintain good loading, stability and cell uptake 





) using non-modified PEG-conjugated NGs reference. Finally, PTX (0.01 mmol) 
was solubilized into the hydrophobic PPhe core of CDDP-loaded FA-modified NGs 
using an extraction method [27]. According to this method, a thin film of PTX (prepared 
by evaporation of a methanol solution of PTX) was incubated with aqueous dispersion of 
NGs (24 h, r.t.). Unincorporated PTX was removed by filtration with 0.8 µm syringe 
filters (Thermo Scientific). Similar procedures were used to prepare single drug NGs 
formulations. Pt content in NGs (Pt194/Pt195) was measured by the inductively coupled 
plasma-mass spectrometer (ICP-MS, NexION 300Q, ICP-MS spectrometer, 
PerkinElmer) calibrated with Pt (2-100 ng/ml) and Holmium as the internal standard. 
Samples were diluted in 1% HNO3. PTX levels were determined by HPLC analysis under 
isocratic conditions using an Agilent 1200 HPLC system with a diode array detector set 
at 227 nm. As stationary phase a Nucleosil C18 column was used (250 mm × 4.6 mm), a 




3.2.4. Physicochemical characterization of the NGs and drug release study 
Intensity-mean Z-averaged particle diameter (Deff) and ζ-potential of NGs were 
determined using a Zetasizer NanoZS (Malvern Instruments Ltd.). All measurements 
were performed in automatic mode at 25
0
C. Software provided by the manufacturer was 
used to calculate size, polydispersity indices and ζ-potential of NGs. All measurements 
were performed at least in triplicate to calculate the mean values ± SD. Drug release from 
NGs was examined in PBS (pH 7.4, 0.14M NaCl) by dialysis method using a membrane 
with 3500 Da cutoff. The concentrations of Pt and PTX released were determined by 
ICP-MS and HPLC, respectively, and expressed as a percentage of the total Pt or PTX 
available vs. time. 
3.2.5. Cell culture 
A2780 human ovarian carcinoma cells were provided by Dr. P. Rogers (Institute of 
Cancer Research, University of Bristol, UK). A2780 cells were transfected using F-Luc-
G P Lentivirus (Capital Biosciences, Rockville, MD) according to manufacturer’s 
protocol to obtain A2780/Luc cell line. Cells were cultured in folate-depleted RPMI 1640 
medium (FD-RPMI) with 2 mM glutamine, 10% (v/v) FBS, 100 U/ml penicillin and 0.1 
mg/mL streptomycin at 37
0
C, 5% CO2. This medium contains nearly physiological level 
of FA. 
3.2.6. Flow cytometry  
Cells (50,000 cells/well) grown in FD-RPMI media in 24-well plates for 2 days were 
exposed to Alexa 594-labeled NGs or FA-NG (0.20 µmol FA/mg of polymer) at 37
0
C for 
up to 2 h, washed three times with PBS, trypsinized, centrifuged (1500 rpm, 5 min) and 
re-suspended in PBS (pH 7.4). The % gated cells were analyzed using Becton Dickinson 
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FACStarPlus flow cytometer and FACSDiva software (Version 8.0, Becton Dickinson, 
San Jose, CA). At least 5,000 events were acquired in linear mode, gated to exclude 
debris and dead cells, and visualized in logarithmic mode. For the competition assay, 
cells were co-incubated with Alexa 594-labeled FA-NGs in presence of free FA (25mM), 
and the experiment was carried out as described above. 
3.2.7. In vitro cytotoxicity 
A2780 cells seeded in 96-well plates (10,000 cells/well) 24 h before the experiment were 
exposed to various doses (0 -10 µg/ml on CDDP basis) of (CDDP+PTX)/NG or FA-
(CDDP+PTX)/NG for 24 or 48 h in FD-RPMI at 37
0
C followed by washing with PBS, 
and maintaining in FD-RPMI medium with 10% FBS for additional 24 h. Cytotoxicity 
was determined by standard colorimetric MTT assay [28] and the IC50 values were 
calculated using GraphPad Prism Software. Ratio of CDDP to PTX was c.a. 10:1 
(mol/mol).  
3.2.8. Animals and bioluminescence imaging procedure 
Female six-week old nude mice (athymic nude-nu) were obtained from Charles River 
Laboratories and housed in AAALAC accredited facility. Food and reverse osmosis 
water were available ad libitum throughout the study. Animals were quarantined for 7 
days prior to study initiation. All animal studies were conducted in accordance with the 
protocol approved by the University of Nebraska Medical Center Institutional Animal 
Care and Use Committee. Imaging was conducted with the in vivo imaging system IVIS-
200 (Xenogen Corporation, Alameda, CA) composed of a cooled charge-coupled device 
camera connected to a light-tight black chamber. Animals were maintained on a FA 
deficient diet (Harlan diet TD.00434) for a week before tumor inoculation and during the 
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period of studies to achieve plasma folate levels in the physiologic range normally seen 
for humans [29]. Before in vivo imaging, animals were anesthetized with isoflurane 
(Henry Schein, Dublin, OH) and injected IP with D-luciferin (Perkin-Elmer, Waltham, 
MA) at the dose of 150 mg/kg (reconstituted in sterile PBS). Whole-body Imaging was 
performed 5 min after injection.  Total bioluminescence signal in the regions of interest 
(ROIs) drawn around the whole abdomen region was quantified using Living Image 
software (version 2.50; Xenogen) and expressed as photons/s/cm
2
/sr.  
3.2.9. Animal studies  
Peritoneal carcinomatosis was generated by IP injection of A2780/Luc cells (~1.75 × 10
6
 
cells). After development of tumors (3 days after injection) animals were randomized (8 
treatment groups, n = 8) and treated with 5% dextrose (control) or free CDDP or 
(CDDP+PTX)/NG or combination of CDDP/NG and PTX/NG at the same drug ratio or 
FA-(CDDP)/NG or combination of FA-(CDDP)/NG and FA-(PTX)/NG or FA-
(CDDP+PTX)/NG or  FA + FA-(CDDP+PTX)/NG at an equivalent dose of 4 mg/kg 
CDDP, or (4 mg/kg CDDP + 1 mg/kg PTX). Treatments were administered via tail vein 
injections at 4-day intervals. We used one additional group which received IP injection of 
FA-(CDDP+PTX)/NG. The treatment groups and the doses of each drug are presented in 
Table 3.1. 












Control IV - - - 
Free CDDP IV 4 - - 
(CDDP+PTX)/NG IV 4 1 - 
FA-(CDDP)/NG IV 4 - - 
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FA-(CDDP)/NG + FA-(PTX)/NG IV 4 1 - 
FA-(CDDP+PTX)/NG IV 4 1 - 
FA + FA-(CDDP+PTX)/NG  IV 4 1 1 
FA-(CDDP+PTX)/NG IP 4 1 - 
 
Animal body weight and tumor progression, as assessed by BLI, were monitored every 
fourth day. All images were acquired using identical BLI system settings. Tumors were 
allowed to grow until ascites developed or the mice showed signs of pain and/or distress, 
then the mice were euthanized via CO2 asphyxiation. At necropsy, the abdominal cavity 
was carefully checked and the extent of tumor was determined.           
3.2.10. Sample preparation and CDDP measurement in tissue 
Known weights of thawed tissues (tumor, kidney, spleen, liver and lung), collected from 
the animals sacrificed at day 14 (2-3 mice per group) during treatment, were decomposed 
by wet-ashing in screw-capped vials with six volumes of concentrated nitric acid, 
overnight heating, and stirring at 65
0
C. An iridium internal standard was added prior to 
digestion. Total platinum concentrations were determined by ICP-MS using iridium 
correction. Calibration range for the assay was platinum 2–100 ng/mL with extrapolation 
to platinum 1000 ng/mL. Necessary dilutions were made when the platinum 
concentration exceeded the calibration range. Assay sensitivity was 0.8 ng of Pt/mL, with 
inter- and intraday assay variability not exceeding 5%.  
3.2.11. Cancer antigen (CA)-125 assay and histopathology 
Serum from the blood of sacrificed animals was collected and analyzed for CA-125 
levels using CA-125 ELISA kit (Abcam, MA) according to the manufacturer’s 
instructions. Formalin-fixed tissues were processed, sectioned, inserted into tissue 
cassettes, dehydrated in 70% ethanol overnight, and paraffin embedded (UNMC Tissue 
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Sciences  acility, Omaha, NE). Serial 5 μm sections were stained with hematoxylin and 
eosin (H&E). For histopathological diagnosis, H&E-stained slides were examined by 
light microscopy and photomicrographs were taken using a Nikon camera mounted on a 
Nikon Eclipse 600 microscope (both Nikon Instruments, Melville, NY) with Adobe 
Elements 3.0 software (Adobe Systems, San Jose, CA).  
3.2.12. Statistical analysis 
Statistical comparisons for in vitro studies were carried out using Students t-test. In 
animal studies, group means BL signal intensity and body weights were analyzed using 
one-way analysis of variance [30]. Survival was estimated using Kaplan–Meier analysis 
and compared using log-rank test. P values less than 0.05 were considered significant. 
Analysis of variance and Kaplan–Meier analysis tests were performed using GraphPad 
Prism 5 (GraphPad Software, Inc.).  
3.3. Results and Discussion 
3.3.1. Preparation and characterization of folate-targeted NGs 
Triblock copolymer PEG-PGlu90-PPhe25 was utilized for the synthesis of multi-
compartment biodegradable NG. We have previously demonstrated that the incorporation 
of Phe moieties into PEG-PGlu block copolymers facilitated self-assembly of block 
copolymers in an aqueous medium, which was ascribed to hydrophobic and π-π stacking 
interactions of the phenylalanine units, and was essential for solubilization of various 
hydrophobic compounds [10, 27]. As it was reported, the incorporation of aromatic units 
in the polymer chains forming the hydrophobic micellar core can considerably improve 
the stability, loading capacity and drug retention of taxane-loaded polymeric micelles 
[31-34]. These favorable properties were attributed to π-π stacking and hydrophobic 
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interactions between aromatic groups in the micelle’s core, and those of the drug. 
Therefore, we believe that PPhe domains in our NG system may provide a suitable 
environment for encapsulation of PTX. NGs were prepared as previously described by 
template-assisted method involving self-assembly of these amphiphilic block copolymers 
into micelles, followed by chemical cross-linking of the polyion chains [10]. The cross-
linking was achieved via condensation reactions between the carboxylic groups of PGlu 
segments and the amine groups of ethylenediamine in the presence of a water-soluble 
carbodiimide. The resulting NGs displayed an average diameter of about 90 nm (ζ-
potential = −20 mV) and were uniform (monomodal, narrow size distribution) as 
determined by dynamic light scattering (DLS). Such NGs have 1) a hydrophobic core 
formed by PPhe chains, which serves as a reservoir for PTX solubilization, 2) an anionic 
intermediate layer, which can incorporates CDDP through coordination with the 
carboxylic groups of PGlu, and 3) an outer PEG shell, which stabilizes NGs in aqueous 
dispersion. The crosslinks incorporated into PGlu block layer ensure that NGs remain 
stable until they encounter proteases, which degrade them by cleaving the polypeptide 
chains of the block copolymers [10]. NGs were further modified by FA via a PEG linker 
for delivering drug combination to FR-positive ovarian tumors.  Scheme for the 




Figure 3.1. Scheme for the preparation of FA-decorated NGs. 
To this end, EDC activated NGs were first reacted with Fmoc-NH-PEG-NH2 (we chose 
PEG with a longer chain length, Mw = 7.5 kDa, to reduce steric interference with 
receptor binding) followed by deprotection of Fmoc groups. The deprotection was 
confirmed by disappearance of Fmoc signals in PEG-NGs 
1
H NMR spectrum (Fig. 3.2). 
 





The hydrodynamic diameter of PEGylated NGs was 94 ± 3 nm, which is only slightly 
larger than that of precursor NGs (88 ± 2 nm). However, the ζ-potential of the PEG-
modified NGs significantly increased to -11.1 ± 2.5 mV compared to -20.0 ± 1.2 mV for 
the unmodified NGs (Table 3.2), which can be indicative of consumption of the PGlu 
carboxylate groups that reacted with the PEG linkers as well as additional shielding of 
surface charge by tethered PEG chains. Finally, EDC-activated FA was reacted to amino 
groups on NG-attached PEG linkers. Conjugation using carbodiimide chemistry is known 
to produce inactive α- and active γ-isomers of folate. However, since multiple folate 
residues were linked to each nanogel, the resulting FA-NGs contained sufficient amounts 
of the active γ-derivative as shown in the cell association studies described below. After 
thorough purification, little to no residual PEG or FA was present in the final FA-NGs as 
was confirmed by size exclusion chromatography (Fig. 3.3). 
 
Figure 3.3. Estimation of residual content in FA-NG after its purification using FPLC.  
 
The particle size and ζ-potential of FA-NGs remained practically the same as those of the 




Table 3.2. Physicochemical characteristics of empty NGs. 
 







NG 88 ± 2 0.14 -20.0 ± 1.2 
PEG-NG 
FA-NG 
94 ± 3 
98 ± 4 
0.19 
0.20 
-11.5 ± 2.5 
-10.9 ± 1.3  
 
a
 Effective diameter (Deff), polydispersity index (PDI) and ζ-potential were determined in 
water (pH 6.5). Data are expressed as mean ± SD (n = 3).  
 
      We have previously shown that the attachment of the FA groups should be carried out 
after NGs loading with CDDP to avoid inactivation of folate through CDDP binding with 
its carboxylic groups [26]. Therefore, in this study to prepare targeted NGs with binary 
drug combination (further abbreviated as FA-(CDDP+PTX)/NGs), CDDP was first 
loaded into PEGylated NGs followed by conjugation of FA ligands to PEG linkers. At 
the next step, PTX was solubilized into targeted CDDP/NGs using an extraction method. 
FA-(CDDP+PTX)/NG were small particles (Deff of approximately 95 nm) with unimodal 
particle size distribution (PDI = 0.24) and contained 0.2 μmol  A per mg of polymer. As 
expected, the net negative charge of drug-loaded NGs was further decreased (ζ-potential 
= −5 mV) as a result of neutralization of PGlu segments upon CDDP binding. The 
average weight ratio of the CDDP and PTX incorporated into NGs was about 4 : 1, which 
has been previously shown to provide strong synergistic cytotoxic effects [10]. A similar 
procedure was used to prepare nontargeted (CDDP+PTX)/NGs from PEGylated NG 
precursors. Notably, the drug content and physicochemical characteristics of targeted FA-
(CDDP+PTX)/NGs were quite similar to nontargeted NGs (Table 3.3). Moreover, FA-
(CDDP+PTX)/NG were stable in aqueous dispersions, exhibiting no aggregation or 
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precipitation for a prolonged period of time (weeks) (Table 3.3). We have previously 
showed that such NG system can retain drug cargo for longer period of time (weeks) [10] 
Table 3.3. Physicochemical characteristics of drug-loaded NGs. 






 CDDP:PTX (wt/wt) 
 (CDDP+PTX)/NG 86 ± 2 0.26 -7.0 ± 0.7 3.84:1 
FA-(CDDP+PTX)/NG 95 ± 3 0.24 -5.5 ± 1.0 3.78:1 
FA-(CDDP+PTX)/NG 
b
 96 ± 4 0.25  -5.7 ± 2.7 - 
a
 Effective diameter (Deff), polydispersity index (PDI) and ζ-potential were determined in 
water (pH 6.5). Data are expressed as mean ± SD (n = 3).  
b 
Effective diameter, polydispersity index and ζ-potential after one month of storage in 




For both drugs there was very little difference in the release profiles between targeted 
FA-(CDDP+PTX)/NG and nontargted (CDDP+PTX)/NG, which indicates that the 
modification of nanogels with targeting groups had no influence on drug retention (Fig. 
3.4). As it seen in Fig. 4, sustained but temporally distinct release of Pt [35] species and 
PTX was observed. Notably, PTX release was much faster than that of Pt [35], which is 
expected since PTX is physically entrapped into the PPhe core.  
 
Figure 3.4. Drug release profiles from FA-(CDDP+PTX)/NG (solid line) and 
(CDDP+PTX)/NG (dotted line) for Pt (●) and PTX (■) in PBS buffer, pH 7.4. The data 




3.3.2. Cellular association and in vitro cytotoxicity of FA-NGs 
To demonstrate effect of attachment of FA on cellular association of NGs, we used FR+
 
human ovarian carcinoma A2780 cells and FR- A549 lung carcinoma cells [26]. Cultured 
cells were treated with fluorescence Alexa 594-labeled FA-NGs or NGs for 30 min at 
37°C. Particle association with cells was determined by flow cytometry. As expected, the 
cellular association of FA-NGs with FR+ cells significantly (P < 0.01) exceeded that of 
the nontargeted NG (Fig. 3.5). On the other hand, no difference in association of targeted 
and nontargeted NGs was observed with A549 cells (Fig. 3.5).  
 
Figure 3.5. A) Cellular association of Alexa fluor 594-labeled NG, FA-NG and FA-NG 
in presence of free FA in FR+ A2780 and FR- A549 cell lines at 30 min. B) Inhibitory 
effect of free FA on the cellular association of FA-NG in FR+ A2780 as analyzed by flow 
cytometry. FA-NG = 0.5 mg/mL and 0.2 μmol  A/mg polymer. [ A-NG] = 0.5 mg/mL 
and 0.2 μmol folate/mg polymer. ** indicate significantly higher uptake of FA-NG vs. 
NG and FA-NG in presence of free FA. ** P < 0.01 and NS - not significant. Data are 
mean ± SD (n = 3). 
 
To further elucidate whether the enhanced cellular association of FA-NGs depends on 
specific binding to FR on the cell surface, A2780 cells were treated with FA-NGs in the 
presence of excess free FA (25 mM). Flow cytometry analysis revealed that the cellular 
association of FA-NGs was suppressed to the level of the nontargeted NGs (Fig. 3.5). 
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This inhibition was also significant (P < 0.05) after 1 h of treatment in the FR+ A2780 
cells (Fig. 3.6). These results validate that the conjugation of FA to the surface of NGs 
resulted in efficient and specific association with FR+ cells.  
 
Figure 3.6. Cellular association of Alexa 594-labeled NG, FA-NG and FA-NG in 
presence of free FA with A) FR-positive A2780 and B) FR-negative A549 cell lines at 
different time points. [FA-NG] = 0.5 mg/mL and 0.2 μmol  A/mg polymer. * and ** 
indicate significantly higher cellular association of FA-NG vs. NG and FA-NG in 
presence of free FA. ** P < 0.01 and ** P < 0.05. Data are mean ± SD (n = 3). 
 
It is worth noting that after two hours of treatment there was no significance between FR-
targeted and nontargeted NGs uptake, which internalized efficiently (approx. 90% gated 
cells) in both cell types (Fig. 6), indicating that a long incubation time could enhance 
non-specific uptake of NGs. These differences in cellular association translated into 
cytotoxicity (Table 3.4). The cytotoxicity of FA-(CDDP+PTX)/NG against FR+ A2780 
cells was increased by two fold compared to (CDDP+PTX)/NG (IC50 expressed in CDDP 
equivalents: 1.4 ± 0.75 μM vs 3 ± 1.3 μM) at 24 h. Notably, the difference between 
targeted and nontargeted formulations was only apparent at lower time point and it 
becomes negligible at 48 h.  
 
Table 3.4. Comparison of IC50 values for targeted and nontargeted drug-loaded NGs 






 24 h 48 h 
(CDDP+PTX)/NG   3.0 ±1.3 0.4 ± 0.1 
FA-[(CDDP+PTX)/NG]   1.4 ± 0.7 0.3 ± 0.1 
                            a
Calculated with respect to CDDP. 
3.3.3. Antitumor activity in intrapertoneal xenograft model 
Our previous studies have shown effective tumor inhibition by platinum-taxane-loaded 
NG system in subcutaneously growing ovarian tumor model. Herein, we tested the 
efficacy and the toxicity of FR-targeted combination therapy in peritoneal xenograft 
model that mimics the clinical manifestations in the advanced stage of the human ovarian 
carcinomatosis. The A2780/luc cells, injected into the peritoneum of female nude mice, 
grew rapidly in vivo and were able to trigger formation of tumor nodules throughout the 
abdominal peritoneum that were detectable by BLI as early as 3 days post inoculation. If 
mice were left untreated, the bioluminescene signal rapidly increased and mice ultimately 
developed ascites in 2-3 weeks. Treatments were initiated on 4
th
 day post A2780/luc 
inoculation. IV administrations of each formulation were given 4 times at 4-day intervals 
at 4mg/kg CDDP and 1 mg/kg PTX equivalents per dose. CDDP (4 mg/kg) was also used 
as a control-free drug with the same dosing schedule. As shown in Fig. 4, all treatments 
were effective in delaying tumor progression in comparison with control group. Tumor 
growth inhibition ratio between treated versus control groups (T/C value) was calculated 
on day 16 after treatment initiation according to the formula: T/C = (Rt - Ro) treated tumor/ (Rt 
- Ro) control tumor, where Rt and Ro represent the mean bioluminescence intensity on the 
evaluation day and at the start of the treatment, respectively (Table 3.5). Consistent with 
our previous observations [10], platinum-taxane combination administered as single NG 
formulation, (CDDP+PTX)/NG, was found to be significantly more effective (T/C= 0.26) 
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than CDDP alone (T/C = 0.56, P < 0.05, Fig. 3.7). In contrast, the mice treated with a 
cocktail of single drug NG formulations (CDDP/NG + PTX/NG) at the same drug ratio 
had a similar impact on the tumor progression as free CDDP (Fig. 3.7). These data 
reinforce our hypothesis that synchronized delivery of platinum-taxane combination 
chemotherapy using NGs plays an essential role in its cytotoxic activity.  
Table 3.5. In vivo antitumor efficacy of various formulations in ovarian cancer xenograft-
bearing female nude mice. 
 
Treatment group T/C 
  Median survival 
(days) 
Control - 19 
Free CDDP 0.56 23 
(CDDP+PTX)/NG 0.26 31 
FA-(CDDP)/NG + FA-(PTX)/NG 0.31 30 
FA-(CDDP+PTX)/NG 0.09 41 
FA-(CDDP+PTX)/NG IP 0.05 43 
FA + FA-(CDDP+PTX)/NG 0.29 27 
Note: T/C = (Rt - Ro) treated tumor/ (Rt - Ro) control tumor, where Rt and Ro represent 
the mean bioluminescence intensity on the evaluation day and at the start of the 
treatment, respectively. 
 Figure 3.7. In vivo antitumor efficacy of (CDDP+PTX)/NG] vs. CDDP/NG + PTX/NG 
in A2780/Luc human ovarian cancer xenograft-bearing female nude mice. (A) 
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Bioluminescence images of each 3 mice representative for 8 mice per experimental arm 
at the end of treatment (day 16). The colored scale bar indicates the intensities of 
bioluminescence in photons/s/cm
2
/sr. (B) Comparison of tumor growth inhibition 
following IV administration of (CDDP+PTX)/NG (▲) or CDDP/NG + PTX/NG (Ж) or 
free CDDP (■) or control (●). Drug formulations were injected in100 μL at a dose of 4 
mg CDDP or 1mg PTX equivalents/kg body weight 4 times at 4-day intervals as 
indicated by the arrows. Data presented in terms of relative bioluminescence units (Rt/Ro) 
to the day when treatment was initiated for individual animal. Values indicated are means 
± SD    (n = 8), *P < 0.05.   (C) Kaplan–Meier analysis of overall survival in 
(CDDP+PTX)/NG (1) or CDDP/NG + PTX/NG group (2) or free CDDP (3) or control 
group (4). * P<0.05. 
 
Tumor growth in the mice treated with (CDDP+PTX)/NG was further suppressed 
when the same drug combination was administered in FA-decorated NGs. FA-
(CDDP+PTX)/NG showed  significant tumor reduction as measured by BLI (T/C = 0.09) 
compared to nontargeted (CDDP+PTX)/NG group (T/C = 0.26, P < 0.05) (Fig 3.8A and 
3.8B). As a result, combination therapy with FA-(CDDP+PTX)/NG significantly 
increased the probability of survival compared to its nontargeted counterpart (Fig. 3.8C). 
The median survival times (post-tumor inoculation) for the FA-(CDDP+PTX)/NG and 
(CDDP+PTX)/NG groups were 41 and 31 days, respectively (P < 0.01) (Table 3.5). 
Notably, the enhanced antitumor effect of FA-(CDDP+PTX)/NG was inhibited when it 
was administered with free FA (Fig 3.8A and 3.8B) suggesting that FA-decorated 
(CDDP+PTX)/NG display folate specificity and exhibit elevated activity through a 
mechanism involving in vivo FR. The peritoneal cavity is the principal site of disease in 
ovarian cancer. The concept of direct IP administration of chemotherapy, especially to 
treat microscopic residual disease after debulking surgery, has been evaluated in many 
clinical trials and has demonstrated an improvement in overall and disease-free survival 
[2, 36, 37]. A randomized phase III clinical trial showed IP administration of CDDP and 
PTX plus IV PTX improves survival when compared to standard of care with IV 
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combination of CDDP and PTX [2]. However, IP chemotherapy also led to significantly 
higher toxicities due to exposure of both cancer and healthy tissues to high concentrations 
of drugs. We, therefore, utilized our FA-(CDDP+PTX)/NG formulation to determine 
whether there are therapeutic advantages in providing targeted IP chemotherapy in 
ovarian cancer. As seen in Fig. 8B the BLI data shows a trend towards enhanced 
therapeutic efficacy of FA-(CDDP+PTX)/NG when administered IP (T/C = 0.05) 
compared to IV regimen (T/C = 0.09). Kaplan-Mayer survival analysis also demonstrated 
that mice given IP FA-(CDDP+PTX)/NG appear to have the best outcomes. However, 
the differences between groups were not statistically significant. 
 
Figure 3.8. In vivo antitumor efficacy of FA-(CDDP+PTX)/NG in A2780/Luc human 
ovarian cancer xenograft-bearing female nude mice. (A) Bioluminescence images of each 
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3 mice representative for 8 mice per experimental arm after treatment (day 16). The 
colored scale bar indicates the intensities of bioluminescence in photons/s/cm
2
/sr.  (B) 
Comparison of tumor growth inhibition following IV administration of FA-
(CDDP+PTX)/NG (♦) or (CDDP+PTX)/NG (▲) or mixture of 1 mg/kg FA  and  FA-
(CDDP+PTX)/NG (ϕ) or free CDDP (■) or 5% dextrose (control) (●). We used one 
additional group which received IP injection of FA-(CDDP+PTX)/NG (▼). Drug 
formulations were injected in100 μL at a dose of 4 mg CDDP or 1mg PTX 
equivalents/kg body weight 4 times at 4-day intervals as indicated by the arrows. Data 
presented in terms of relative bioluminescence units (Rt/Ro) to the day when treatment 
was initiated for individual animal. Values indicated are means ± SD (n = 8), *P < 0.05.  
(C) Kaplan–Meier analysis of overall survival in FA-(CDDP+PTX)/NG IP group (1) or 
FA-(CDDP+PTX)/NG IV group (2) or (CDDP+PTX)/NG (3) or FA + FA-
(CDDP+PTX)/NG (4) or free CDDP (5) or control group (6). Log-rank test was used to 
determine statistical difference between (CDDP+PTX)/NG and free CDDP groups, *P < 
0.05, and between FA-(CDDP+PTX)/NG and (CDDP+PTX)/NG groups, **P < 0.01. 
 
     CA-125 also known as MUC16 is a protein that in humans is encoded by the MUC16 
gene [38]. Around 90% of women with advanced ovarian cancer have elevated levels of 
CA-125 in their blood serum, making CA-125 a useful tool for detecting ovarian cancer 
after the onset of symptoms [39]. Monitoring CA-125 blood serum levels is also useful 
for determining how ovarian cancer is responding to treatment and for predicting a 
patient’s prognosis after treatment [40]. It has frequently been used as an indicator of 
tumor progression in various ovarian cancer mouse xenograft models [41-43]. To further 
characterize tumor response to the treatments, we analyzed the serum CA-125 levels in 
mice on day 14 (second day after last injection). As shown in Fig. 3.9, levels of CA-125 
were significantly low in the mice that received (CDDP+PTX)/NG compared to either 
control group (P < 0.01) or free CDDP group (P < 0.05). CA-125 levels were lowest in 
the mice that received FA-(CDDP+PTX)/NG either IV or IP. Notably, compared to 
nontargeted (CDDP+PTX)/NG group, IP treatment with FA-(CDDP+PTX)/NG resulted 





Figure 3.9. CA-125 ELISA assay. Quantification of serum CA-125 levels in mice from 
various treatment groups. Data are presented as mean ± SD (n = 3). 
 
To compare the ability of the NGs-based carriers to deliver a cytotoxic payload to the 
tumor sites, we sacrificed 2-3 mice on day 14 and excised the tumors for CDDP content 
estimation. Both targeted and nontargeted drug-loaded NGs displayed enhanced tumor 
accumulation relative to administration of free drug supporting the well-known 
characteristic of nanoparticles to improve tumor drug delivery by the EPR effect (Fig. 
3.10). However, FA-(CDDP+PTX)/NG induced a significantly higher Pt accumulation in 
the target site compared to nontargeted (CDDP+PTX)/NG (P < 0.05). This increase 
appeared to be due to FR-specific interaction of folated NGs with cancer cells because it 
was completely reversed by co-administration of free folate. We have previously showed 
that the average weight ratio of the CDDP and PTX in the tumors of the animals was 
same as the drug loading ratio in (CDDP+PTX)/NG, indicating the spatial–temporal 
synchronization of drug exposure. We expect the similar synchronized delivery of CDDP 
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and PTX is occurred using our current NG systems as well. Notably, while all drug-
loaded NGs displayed considerable accumulation of Pt in the highly perfused organs such 
as liver and spleen, tumor was the only tissue where Pt content was significantly higher 
for FA-(CDDP+PTX)/NG (Fig. 3.10). FA-(CDDP+PTX)/NG treatment which was 
administered IP led to the maximum Pt retention in the tumors which may be a result of 
regional exposure to high drug concentrations at the tumor sites. This might be the reason 
for the observed enhanced tumor responsiveness with IP FA-(CDDP+PTX)/NG 
treatment.  The binding of FA-(CDDP+PTX)/NG  to and/or their uptake by FR+
 
cancer 
cells can retain them within the tumor for a longer period of time, prevent their rapid re-
entering into systemic circulation and, thus, provide some benefits over passively 
targeted formulations. The introduction of FA moieties can also have an effect on 
pharmacokinetics and biodistribution of NGs and influence tumor uptake. Further 
detailed pharmacokinetic study may help to elucidate the relationship between the 





Figure 3.10. Tissue distribution of platinum in different treatment groups as determined 
by ICP-MS. Mice were sacrificed at day 14 of the treatment with FA-(CDDP+PTX)/NG 
IP or FA-(CDDP+PTX)/NG or FA+ FA-(CDDP+PTX)/NG or (CDDP+PTX)/NG or free 
CDDP. Data are presented as mean ± SD (n = 3). * P < 0.05. 
 
To further determine whether concurrent targeted delivery of drug combination will have 
therapeutic benefits, we also compared the inhibition of tumor progression and survival 
between FA-(CDDP+PTX)/NG and a combination of targeted single drug formulations 
(FA-(CDDP)/NG + FA-(PTX)/NG) administered at the same drug ratio (Fig. 3.11 and 
3.12). Our data showed significantly better tumor growth inhibition and survival for FA-
(CDDP+PTX)/NG than FA-(CDDP)/NG + FA-(PTX)/NG. This confirms an advantage 
of delivering a platinum-taxane drug combination via single carrier to the same targeted 
cells simultaneously. We have not tested this strategy with other drug combinations. So at 





Figure 3.11. Bioluminescence images of each 3 mice representative for 8 mice per 
experimental arm at the end of treatment (day 16). The colored scale bar indicates the 





Figure 3.12. In vivo antitumor efficacy of FA-(CDDP+PTX)/NG vs. FA-(CDDP)/NG + 
FA-(PTX)/NG co-administration against A2780/Luc human ovarian cancer xenografts. 
(A) Comparison of tumor growth inhibition as indicated by relative radiance units over 
time following IV administration of FA-(CDDP+PTX)/NG (♦) or FA-CDDP/NG + FA-
PTX/NG or FA-(CDDP)/NG (Ж) or control (●). Drug formulations were injected in 100 
μL at a dose of 4 mg CDDP or 1 mg PTX equivalents/kg body weight 4 times at 4-day 
intervals as indicated by the arrows. Values indicated are means ± SD (n=8). (C) Kaplan–
Meier analysis of overall survival in FA-(CDDP+PTX)/NG (1) or FA-(CDDP)/NG + FA-
(PTX)/NG group (2) or FA-(CDDP)/NG (3) or control group (4). * P < 0.05. Log-rank 
test was used to determine statistical difference between FA-(CDDP+PTX)/NG and FA-
(CDDP)/NG + FA-(PTX)/NG groups, *P < 0.05. 
 
      Importantly, the introduction of targeting FA moieties on the surface of NGs did not 
alter the favorable toxicity profile of (CDDP+PTX)/NG formulation. Neither targeted nor 
nontargeted NG-based binary drug combination caused a significant change in body 
weight, indicating that the treatments were well tolerated (Fig. 3.13). In contrast, the 
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same dose of free CDDP produced a considerable body weight loss (> 15%, P < 0.05), 
which indicated systemic toxicity of free CDDP (Fig. 3.13).   
 
Figure 3.13. Relative changes in body weight were measured following intravenous 
administration of FA-(CDDP+PTX)/NG (♦) or (CDDP+PTX)/NG (▲) or  A + FA-
(CDDP+PTX)/NG (ϕ) or free CDDP (■) or control (●).Values indicated are means ± SD 
(n=3). * P<0.05. Values indicated are means ± SD. * P<0.05. 
 
In the kidney, the primary target organ of CDDP toxicity [44, 45], both targeted or 
nontargeted drug-loaded NGs showed significantly lower Pt levels than free CDDP (Fig. 
10) which ameliorated CDDP-induced nephrotoxicity as confirmed by tissue 
histopathology analysis. Light microscopic examination of H&E stained kidney sections 
from sacrificed animals indicated focal tubular degeneration and regeneration in kidneys 
from all animals treated with free CDDP, while no histopathological changes were 
observed in kidney from animals in the FA-(CDDP+PTX)/NG-treated or 
(CDDP+PTX)/NG-treated groups compared with the control (Fig. 14). This is a 
significant result since a higher expression of FR in this organ may raise a concern of 
toxicity to this tissue [46]. We also observed focal acute inflammation in the lungs of 
animals treated with free CDDP while no such changes were detected in any of the NGs 
formulation (Fig. 3.14). Despite relatively higher exposure of liver and spleen to CDDP 
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in the FA-(CDDP+PTX)/NG or (CDDP+PTX)/NG treatment, there was no evidence of 
liver or splenic toxicity by histopathology (Fig. 3.15).  
 
Figure 3.14. Light microscopy images (20X) of hematoxylin and eosin-stained kidney 
and lung sections of mice. Tissue samples were collected at day 14. 
 
 
Figure 3.15. Light microscopy images (20X) of hematoxylin and eosin-stained kidney 





Mice which received FA-(CDDP+PTX)/NG IP also did not show any evidence of 
toxicity in any of the investigated organs. Indeed, the local delivery of FA-
(CDDP+PTX)/NG into intraperitoneal cavity reduced nonspecific drug accumulation in 
normal tissues (spleen, liver, and kidney) (Fig. 3.10). Blood cell counting analysis on day 
14 was conducted and normal cell counts were observed for red blood cells and platelets 
for all groups (Table 3.6) while there was significant reduction in the count of white 
blood cells (below normal range) in the mice which were treated with free CDDP.  
 






/L)   
Control 6.03 ± 0.23 312 ± 32 
Free CDDP 4.66 ± 0.10 368 ± 26 
(CDDP+PTX)/NG 4.13 ± 0.31 273 ± 19 
FA-(CDDP+PTX)/NG 4.01 ± 0.19 350 ± 42 









Figure 3.16. Blood cell counting analysis for WBC at day 14. 
 
In contrast, mice treated with drugs loaded in NGs did not have any changes in white 
blood cells compared to control (Fig. 3.16).  
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      Collectively, these in vivo data support the efficacy of this targeted platinum-taxane 
combination therapy in FR-expressing ovarian cancer model without toxicity-related 
consequences. 
3.4. Conclusion  
In this study, we demonstrated that folate-decorated NGs carrying CDDP and PTX 
drug combination exerted enhanced antitumor efficacy, both in terms of tumor growth 
inhibition and survival, compared to its nontargeted counterpart in rapidly growing 
murine model of FR-positive ovarian cancer.  This better efficacy was only observed 
when CDDP and PTX are concurrently delivered to the tumor sites. Our data also 
indicate that IP administration of FA-(CDDP+PTX)/NG can be more effective in the 
context of targeted combination therapy without extending its cytotoxicity to the normal 
tissues. Localized chemotherapy has demonstrated survival advantages in advanced 
ovarian cancer patients and our NG-based drug delivery system can be a suitable 
candidate for further optimization and pre-clinical evaluation of intraperitoneal 
chemotherapy for ovarian cancer.  
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HSP90-INHIBITION ENHANCES THE LYSOSOMAL TARGETING AND 
EFFICACY OF ErbB2-TARGETED DRUG DELIVERY 
4.1. Introduction 
Overexpression of surface receptors on cancer cells presents opportunities to achieve 
targeted delivery of cytotoxic agents linked directly to targeting ligands/antibodies or 
encapsulated within nanometer-sized drug delivery vehicles decorated with targeting 
ligands/antibodies [1]. The receptor tyrosine kinase family members, EGFR and ErbB2 
are overexpressed in many types of cancers and have served as popular models for the 
development of targeted drug delivery modalities, including Antibody-Drug-Conjugates 
(ADCs) and nanoparticulate drug delivery systems. Trastuzumab-DM1 (Kadcyla, 
Genentech, San Francisco) is an example of an ADC developed against ErbB2-
overexpressing cancers in which the cytotoxic drug (Emtansine) is chemically conjugated 
to Trastuzumab (the humanized anti-ErbB2 monoclonal antibody) [2]. The success of 
these strategies is predictably dependent on robust endocytosis of the receptor-bound 
cargo and trafficking from early endosomes to the lysosomes, where the conjugate 
undergoes disintegration, resulting in the release of the cytotoxic drug into the cytosol. In 
normal cells, endocytosis and receptor trafficking is a highly regulated process mediated 
by several cellular factors. Receptors may be endocytosed via clathrin- or caveolin-
mediated pathways, or via macropinocytosis. Following endocytosis, the receptors are 
either routed to the lysosomes or recycled back to the cell-surface, process regulated 
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among other factors by receptor ubiquitination (mediated by E3 ubiquitin ligases such as 
Cbl) or de-ubiquitination (mediated by AMSH or USP8) [3-8]. Ubiquitin-dependent 
sorting proteins, known as ESCRT (Endosomal Sorting Complex Required for Transport) 
proteins recognize the ubiquitinated receptor cargo and help sort them into inner vesicles 
of multivesicular bodies for transport to lysosomes [4, 5, 9, 10]. Various Rab-family 
GTPases, functioning at distinct vesicular trafficking stages, also play a critical role in 
directing the sorting of endocytosed cargo between recycling and lysosomal pathways. 
Cancer cell-specific alterations (mutations, overexpression) in receptors themselves or in 
the trafficking regulators can alter the balance between receptor-recycling and lysosomal 
trafficking [3, 11]. While the focus has been more in designing receptor-targeted drug 
delivery systems, the consequence of alterations in regulatory factors that affect the 
recycling vs. lysosomal trafficking behavior of targeted receptors and consequently the 
efficiency of drug delivery have received little attention. In this study, we illustrate the 
importance of receptor dynamics on targeted drug delivery, using ErbB2-overexpressing 
breast tumor targeting through anti-ErbB2 humanized monoclonal antibody Trastuzumab 
as a model. 
The oncogenic receptor tyrosine kinase ErbB2, overexpressed in over 20% of 
breast cancers, has served as a major target for the development of targeted drug delivery 
strategies [12-15]. However, ErbB2 is thought to be either impaired in endocytosis or to 
rapidly recycle back to the cell-surface [16, 17], which can significantly dampen the 
efficacy of ErbB2-targeted drug delivery. Such altered trafficking dynamics is believed to 
be due to its constitutive association with HSP90 [18], [17-22] which can be anticipated 
to significantly dampen the efficacy of ErbB2-targeted drug delivery. We therefore 
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hypothesized that HSP90-inhibition will enhance ErbB2-targeted drug delivery by 
promoting the endocytic uptake of ErbB2-bound nanoencapsulated cargo and facilitating 
its re-routing from a recycling pathway to the lysosomes. Using Trastuzumab-conjugated 
nanogels (Trast-NG) encapsulating the DNA-damaging drug Doxorubicin (DOX) as a 
model chemotherapeutic, we demonstrate through both in vitro and in vivo studies that 
HSP90-inhibition can indeed lead to an enhancement of targeted delivery of DOX 
specifically into ErbB2-overexpressing breast cancer cells. As a consequence, a sub-
therapeutic and non-toxic dose of the HSP90 inhibitor 17AAG markedly improves the 
efficacy of ErbB2-targetd nanogels in vivo.  
4.2. Materials and methods:  
4.2.1. Materials.   
Trastuzumab was obtained from UNMC pharmacy. PEG-b-PMA diblock copolymer 
(Mw/Mn = 1.45) was purchased from Polymer Source Inc., Canada. The block lengths 
were 170 and 180 repeating units for PEG and PMA respectively. The concentration of 
carboxylate groups in the copolymer samples was estimated by potentiometric titration. 
FMOC-PEG-NHS was purchased from Creative PEGWorks, NC. Calcium chloride, 
Ethylenediamine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) 
and Ethylenediaminetetraacetic acid (EDTA) were obtained from Sigma-Aldrich (St 
Louis, MO). Doxorubicin hydrochloride was kindly provided by Dong-A Pharmaceutical 
Company, South Korea. Fetal bovine serum (FBS) (both dialyzed and heat inactivated), 
DMEM and RPMI 1640 media and Lysotracker
TM
 (green) were purchased from 
Invitrogen Inc (Carlsbad, CA). Bovine serum albumin (BSA) and NUNC
TM
 chambered 
glass coverslips for live cell imaging were purchased from Fisher Scientific (Waltham, 
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MA). MTT reagent (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was 
purchased from Research Products International (Prospect, IL). All other chemicals were 
of reagent grade and used without further purification. The following primary antibodies 
were used in this study:  anti-human-ErbB2 mouse monoclonal (ErbB2) raised against the 
C-terminal amino acid residues (1242-1255), used for Western blotting studies, were 
purchased from BD Pharmingen™ (San Diego, CA); for flow cytometry and 
immunofluorescence studies, the goat anti-human-ErbB2 polyclonal antibody (AF1129) 
was from R&D Systems (Minneapolis, MN); the mouse monoclonal anti-
phosphotyrosine (anti-pY; 4G10) was kindly provided by Dr. Brian Druker (Oregon 
Health & Science University, Portland, OR); the mouse monoclonal anti-Hsc70 antibody 
were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). 
4.2.2. Synthesis of the NGs.  
The general procedure for the synthesis of NGs has been described earlier [23, 24]. 
Briefly, PEG-b-PMA/Ca
2+
 complexes were prepared by mixing an aqueous solution of 
PEG-b-PMA with a solution of CaCl2 at a molar ratio of [Ca
2+
] / [COO−] = 1.3. The 
chains were cross-linked overnight at room temperature (r.t.) using 1,2-ethylenediamine 
and EDC ([EDC]/[1,2-ethylenediamine] = 2; [COOH]/[EDC] = 5). The NGs were 
dialyzed (MWCO 3.5 kDa) extensively against a) 0.5% aqueous ammonia in the presence 
of EDTA and b) bi-distilled water.  
4.2.3. Synthesis and characterization of mAb-modified DOX-loaded NGs.  
MAb (Trast and mouse IgG) were attached to the NGs via streptavidin-biotin complex 
(Fig. 1). Details of conjugation procedure are as follows. 
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PEGylation of streptavidin. Streptavidin was diluated with 50 mM sodium bicarbonate 
buffer till concentration becomes 1 mg/mL (total volume: 6 mL). Separately, Fmoc-PEG-
NHS (Mw = 10 kDa, 1.5 mg, 1.5 eq with respect to streptavidin) was also diluted with 
same buffer. Solution of streptavidin was added dropwise to Fmoc-PEG-NHS solution. 
The mixture was incubated for 2 h followed by Fmoc group deprotection. Fmoc groups 
were removed by adding 0.5 µL of 20% piperidine/DMF (5 eq piperidine) and incubating 
the reaction mixture for 10 min. Resulting construct (NH2-PEG-streptavidin) was purified 
using repeated ultrafiltration (MWCO 30,000, Millipore) at 3000 rpm for 15 min (3 
washes) to remove unreacted PEG. Absence of free PEG was confirmed by size 
exclusion chromatography (SEC) using an ÄKTA FPLC (Amersham Biosciences) 
equipped with Sepharose CL-6B-based column. 
Insertion of NH2-PEG-streptavidin into NGs. Carboxylate groups of NG were activated 
with EDC (0.3 mg, 10 eq with respect to the amount of NH2-PEG-streptavidin) followed 
by insertion of NH2-PEG-streptavidin into NGs through the reaction between free NH2 
groups of PEG with EDC-activated carboxyl acid core of NGs. Mixture was allowed to 
react for 2 h followed by purification of streptavidin-NG conjugate using repeated 
ultrafiltration (MWCO 100,000, Millipore) at 4500 rpm for 30 min (3 washes) to remove 
unreacted PEG-Streptavidin. Absence of free PEG-Streptavidin was confirmed by SEC. 
Amount of streptavidin present in the streptavidin-NG conjugate was measured by 
Bradford method using BioRad assay kit (BioRad, Richmond, CA, USA) and bovine 
serum albumin as the standard.  
Preparation of mAb-NG via streptavidin biotin complex and drug loading. Streptavidin-
NGs were further mixed with biotinylated mAb (ratio of streptavidin to biotin was 1:2). 
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The mixture was incubated for 2 h at r.t.. The mAb-NG was purified SEC. This 
purification procedure allowed removing all unbound mAb, while the unmodified NG 
and mAb-NGs were not separated. Amount of mAb present in the mAb-NG conjugate 
was measured by Bradford method using streptavidin-NG as control. mAb-NG/DOX was 
prepared by adding DOX to an aqueous dispersion of NGs at the feeding ratio of R= 
[DOX]/[COO
-
] = 0.25, for 24 h at pH 7.0. Unbound DOX was separated by repeated 
ultrafiltration (MWCO 30,000, Millipore) at 3000 rpm for 15 min (3 washes).  
4.2.4. Determination of particle size and zeta-potential.  
Intensity-mean Z-averaged particle diameter (Deff) and -potential of NG were determined 
using a Malvern Zetasizer (Malvern Instruments Ltd., Malvern, UK). All measurements 
were performed in automatic mode, at 25C. Software provided by the manufacturer was 
used to calculate size, polydispersity indices and -potential of NGs. The values were 
calculated from the measurements performed at least in triplicate. 
4.2.5. Cell culture conditions.  
The ErbB2-overexpressing cell lines used in this study were SKBr-3, 21MT1 and BT-
474. MCF-7 cells were used as a representative ErbB2-low cell line for comparison. All 
cell lines were maintained as previously described [19, 70]. The ErbB2-overexpressing 
breast cancer cell line 21MT-1 was established by Band et al [71] and has been 
previously described. BT-474 and MCF-7 cell lines were purchased from ATCC. 
4.2.6. Confocal microscopy.  
Cellular uptake and localization studies of Trast-NG were conducted using confocal 
microscope (Carl Zeiss LSM 510 Meta, Peabody, MA). SKBr-3 breast cancer cells 
(1×10
6
) were plated on glass coverslips. Trast-NG (without drug) were incubated with 
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ErbB2-overexpressing SKBr-3 cells for 1h. 17-AAG (100 nM) was added for the 
different times (2, 4 and 8h), after which the slides were washed and fixed in 4% 
parafolmaldehyde. Nanogels were visualized by staining the Fc-portion of the conjugated 
Trast on the NG using FITC-conjugated anti-Human antibody (green). ErbB2 was stained 
either using the goat anti-ErbB2 polyclonal antibody (AF1129) directed against the N-
terminal extracellular domains of ErbB2 or a mouse monoclonal antibody directed 
against the C-terminal tail of ErbB2 (BD Pharmingen) followed by Alexa594-conjugated 
secondary antibody (anti-goat or anti-mouse respectively). The lysosomal marker LAMP-
1 was stained using mouse anti-human LAMP-1 mAb, followed by Alexa-594-
conjugated anti-mouse secondary.  
4.2.7. Cell cycle analysis.  
We evaluated the ability of 17-AAG to enhance the delivery of DOX encapsulated within 
the NG in 21MT-1 and MCF-7 cells by a cell cycle analysis [70]. Briefly, cells were 
seeded in 6-well plates and allowed to adhere for 24 h prior to drug treatment. Cells were 
then exposed to various concentrations of Trast-NG/DOX (1.7 – 13.3 μM Dox) for 6 
hours, following which cells were either left alone (control) or treated with 100 nM 17-
AAG for 18 hours. Cell cycle distribution was then evaluated by using standard protocol 
for FACS analysis of propidium iodide (PI)-stained cells. 
4.2.8. Animal Studies.  
All animal studies were conducted in accordance with an approved protocol by the 
University of Nebraska Medical Center Institutional Animal Care and Use Committee 
(IACUC).  10
7
 BT-474 cells (an ErbB2 overexpressing human breast cancer cell line) 
reconstituted in 50% Matrigel (BD Biosciences, California) in media were injected 
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directly into the mammary fat pad of 4-6 week old female Athymic NCr-nu/nu mice 
(NCI, Fredrick National Lab, Fredrick, MD). 17--Estradiol pellets (0.72mg/pellet; 60 
day release; Innovative Research of America, Sarasota, Fl) were implanted 
subcutaneously on the lateral side of the neck of the mice, three days prior to the injection 
of the tumor cells.  The mice were stratified into treatment groups 14 days after tumor 
inoculation, when the average tumor size reached 100-200 mm
3
.  Treatment groups 
included: 1) 5 % dextrose (Control); 2) Trast alone (3 mg/kg); 3) IgG-NG/DOX (6 
mg/kg); 4) IgG-NG/DOX (6 mg/kg) + free 17AAG (1 mg/kg); 5) Trast-NG/DOX (6 
mg/kg); 7) Trast-NG/DOX (6 mg/kg) + free 17AAG (1 mg/kg). Treatments were 
administered via tail vein injections at 4-day intervals. 17-AAG doses were given 2 h 
after NG formulation administration. Animal body weight and tumor volume were 
monitored every second day. Tumor volume (V = 0.5 x L x W
2
) was estimated by 
measuring two orthogonal diameters (longer dimension: L, and smaller dimension: W) of 
the tumor using electronic calipers. Animals were sacrificed when tumor volume 
exceeded 3000 mm
3
, greatest tumor dimension exceeded 20 mm, tumor became necrotic, 
or animal exhibited a body weight loss of more than 20%. All other animals were 
sacrificed by day 78. 
4.2.9. Apoptosis and proliferation.  
Tumors from mice that received different treatments were excised at day 14 (2–3 mice 
per group). The tumors were dissected and fixed in 10% neutral buffered formalin. Then, 
the tissues were processed routinely into paraffin, sectioned at a thickness of 4 μm. 
Proliferating and apoptotic cells were detected using an antibody against Ki-67 and 
caspase-3, respectively. Visualization was done by incubation with DAB + (brown, for 
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Ki-67) and Permanent red (for caspase-3) (DAKO) for 2 min. After rinsing with distilled 
water, the sections were counterstained with hematoxylin. For quantification of Ki-67 
and caspase-3 expression, the area of positive cells was determined (Image J) in 5 
random high power fields (20× magnification) and divided by the total area of cells for 
each field of slice. 
4.2.10. Histopathology analysis.  
Specific tissues (liver, spleen, heart kidney and lung) were fixed in buffered formalin and 
were sectioned, inserted into tissue cassettes, dehydrated in 70% ethanol overnight, and 
paraffin embedded (UNMC Tissue Sciences  acility, Omaha, NE). Serial 5 μm sections 
were stained with hematoxylin and eosin (H&E). For histopathological diagnosis, H&E-
stained slides were examined by light microscopy. 
4.2.11. Statistical analysis.  
Statistical comparisons for evaluating biological effects for the various treatment groups 
were carried out using Student t-test using a type I error (α) = 0.05 .  or the antitumor 
study and toxicity studies, in vivo, group means for tumor volume and body weights were 
evaluated using repeated measures analysis of variance.  Survival was estimated using 
Kaplan–Meier analysis and compared using log-rank test. P values less than 0.05 were 
considered significant. Analysis of variance and Kaplan–Meier analysis with log-rank 
test were performed using GraphPad Prism 5 (GraphPad Software, Inc.). Median survival 
time for the various groups and the associated Confidence Interval limits were derived by 






4.3.1. Preparation and characterization of Trast-NG.  
Core-shell NG studied here were synthesized as previously described [23, 24] via self-
assembly of doubly hydrophilic poly(ethylene glycol)-b-poly(methacrylic acid) (PEG-b-
PMA) block copolymers in the presence of the condensing agent (CaCl2) followed by  
chemical crosslinking of the polyion chains and removal of the condensing agent. The 
resulting NGs were of ca. 110 nm in diameter and had a net negative charge (ζ-potential 
= -22 mV). The core of such NGs comprised a swollen network of the cross-linked 
polyion chains bearing carboxylic groups and is surrounded by the shell of hydrophilic 
PEG chains. These (PEG-b-PMA)-based NGs can incorporate very large amounts (~30% 
wt.) of water-soluble drugs such as DOX through combination of electrostatic and Van 
der Waals interactions [24], The preparation of Trast-NG is depicted in Fig. 4.1 and 
detailed in the methods section. NGs were first functionalized with streptavidin by 
inserting an NH2-PEG-streptavidin linker. Since 7.5 kDa PEG chains comprise NGs 
shells, we chose PEG with a longer chain length, Mw = 10 kDa, to reduce potential steric 
interference with receptor binding. The average particle size of streptavidin-conjugated 
NGs was 137 ± 4 nm (polydispersity Index = 0.09, ζ-potential = -19.0 ± 2.3 mV), which 




is only slightly larger than that of precursor NGs. Biotinylated Trast or control IgG was 
then coupled with streptavidin-modified NGs. Final product was purified using fast 
protein liquid chromatography (FPLC) (Fig. 4.2). FPLC chromatogram confirmed very 
high yield of reaction with little residual Trast or IgG (Fig. 4.2).  
 
Figure 4.2. Purification of Trast-NG by FPLC 
Purified Trast-NG had an average particle size of 173 ± 3 nm (polydispersity Index = 
0.08, ζ-potential = -20.2 ± 3.1 mV), whereas the control IgG-NG had a size of 177 ± 2 
nm (polydispersity Index = 0.07, ζ-potential = -19 ± 2.2 mV). After DOX loading, the 
average particle size of Trast-NG decreased to 154 ± 4 nm (polydispersity Index – 0.19, 
ζ-potential = -4.1 ± 0.9 mV), whereas the particle size of IgG-NG was 157 ± 8 
(polydispersity Index = 0.24, ζ-potential = -2.7 ± 1.3 mV). Reduction in particle size and 
net negative charge of NGs after DOX loading was consistent with neutralization and 
condensation of PMA segments by DOX. 
The conjugation of Trast to NG did not compromise its ability to specifically bind to 
ErbB2 receptors overexpressed on human breast adenocarcinoma SKBr-3 cells was 
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confirmed by flow cytometry (FACS) (Fig. 4.3A) and confocal immunofluorescence 
microscopy (Fig. 4.3B). By using two-color imaging, the latter analyses showed complete 
colocalization of ErbB2 staining with Trast (stained in red) with signals form the bound 
Trast-NG (stained in green) (Fig. 4.3B), demonstrating ErbB2-specific binding of the 
NG. 
 
Figure 4.3. Trast-NG retains its ability to specifically bind to ErB2. A. ErbB2-
overexpressing breast cancer cell line.  SKBr-3 was left untreated or treated with 
biotinylated Trast or Trast-NG on ice. The bound Trast or Trast-NG was detected using a 
Cy5-labeled anti-human secondary Ab alone.  Samples were subjected to FACS analysis. 
Untreated cells stained with the Cy5-labeled secondary Ab served as a negative control, 
whereas biotinylated Trast served as a positive control. B. Binding of Trast-NG to 
ErbB2-overexpressing breast cancer cells was confirmed by confocal microscopy. 
ErbB2-was visualized using a mouse monoclonal antibody directed against the C-
terminal antigenic region of ErbB2 (BD Pharmingen), followed by Alexa594-conjugated 
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anti-mouse secondary antibody. The Trast-NG bound to the ErbB2 was detected using a 
FITC-conjugated goat anti-human secondary antibody to detect the Fc portion of the 
Trast-conjugated to the NG. 
To further explore the specificity of Trast-NG towards ErbB2-overexpressing breast 
cancer cells, we compared the cancer cell growth inhibition induced by DOX 
encapsulated within untargeted NG vs. Trast-NG (Table 4.1). The ErbB2-
overexpressing BT-474 and the ErbB2-low MCF-7 breast cancer cell lines were 
used as models for comparison of targeting specificity. The biological effects were 
assessed using MTT dye incorporation assay.  
Table 4.1 . Comparison of IC50 values for targeted Vs non-targeted DOX-loaded 
nanogels ErbB2 high and ErbB2 low cells as determined by the MTT assay. 








        0.43 ± 0.13                   0.29 ± 0.1 
        0.07 ± 0.08                   0.19 ± 0.07 
The IC50 value of DOX against ErbB2-overexpressing BT-474 cells was 6-fold lower 
using DOX-loaded Trast-NG (Trast-NG/DOX) compared to DOX-loaded NG 
(NG/DOX). On the other hand, no appreciable difference in the IC50 against ErbB2-
low MCF-7 cells was seen between Trast-NG/DOX and NG/DOX (Table 4.1). These 
experiments confirmed the ability of Trast-NG to deliver chemotherapeutic payloads 
to ErbB2-overexpressing breast cancer cells with high specificity.  
4.3.2. Kinetics of endocytic uptake of Trast-NG into ErbB2-overexpressing breast 
cancer cells.  
Next, we compared the kinetics of the endocytic uptake of Trast-NG into ErbB2-
overexpressing cell line SKBr-3, using confocal immunofluorescence analysis in absence 
or presence of an HSP90 inhibitor. For this set of experiments, we used the empty Trast-
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NG. Cells seeded on glass-coverslips were either left untreated or treated with 10 µg/mL 
of free Trast or the equivalent protein concentration of Trast-NG for 2, 4 or 8 hours in 
absence or presence of the HSP90 inhibitor 17-AAG (100 nM) followed by confocal 
imaging (Fig. 4.4). In the absence of 17AAG, Trast-NG (stained in green) was found at 
the cell surface throughout the 8h time course, with relatively little internalized pool, 
comparable to that seen with free Trast (Fig. 4.4, second vs. first column). In contrast, 
cells incubated with Trast-NG in the presence of 17-AAG demonstrated the rapid 
internalization of ErbB2 (stained in red) with notable internal staining at 2 h and nearly 
complete intracellular staining at 4h; as expected, ErbB2 levels decreased by 8h, 




Figure 4.4. The HSP90 inhibitor 17AAG promotes the internalization and lysosomal 
degradation of Trast-NG. ErbB2-overexpressing SKBr3 cells were plated on glass 
coverslips and incubated with Trast-NG without any encapsulated drug for 1h to allow 
binding to the cell surface. 17-AAG (100 nM) was then added for the indicated time 
points, after which the slides were washed and fixed, stained as described in the legend 
for Fig. 4.3. The slides were analyzed by confocal immunofluorescence microscopy. The 
inset within panel C shows Trast-NG accumulating in punctate intracellular vesicles 
following 17-AAG treatment. 
The loss of the green signal from Trast was concomitant with the loss of red signal from 
ErbB2 (due to lysosomal degradation of both ErbB2 and Trast), suggesting that the 
targeted NG cargo follows the endocytic itinerary of the ErbB2 receptor upon HSP90 
inhibition [17-22]. To confirm if HSP90 inhibition indeed promoted the NG cargo 
trafficking into the lysosomal compartment, which is desirable to facilitate the NG 
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disintegration and release of encapsulated drugs [17-22], we examined the colocalization 
of internalized NG (stained in green) with the lysosomal marker LAMP-1 (stained in red) 
in SKBr-3 cells. Confocal Immunofluorescence analysis (Fig 4.5) confirmed that the NG 
was indeed targeted to found in LAMP-1-positive compartments in the presence of 
17AAG. These analyses demonstrate the strong positive impact of HSP90 inhibition to 
promote the internalization and lysosomal targeting of Trast-NG.  
 
Figure. 4.5. SKBR-3 cells grown on glass coverslips were treated with Trast-NG 
followed by 17-AAG as described in the legend for Fig 3 A. The internalized Trast-NG 
(seen in green) was visualized as described in the legend for Fig 2. The lysosomal marker 
LAMP-1 (seen in red) was stained using mouse anti-human LAMP-1 mAb, followed by 
Alexa-594-conjugated anti-mouse secondary. Co-localization of Trast-NG with LAMP-1 
can be seen as regions in yellow/orange. 
 
4.3.3. In vitro analysis of HSP90 inhibitor-facilitated delivery of DOX into ErbB2-
overexpressing breast cancer cells.  
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Having verified our central hypothesis that HSP90-inhibition facilitates the routing of 
Trast-NG (without drugs) into lysosomes, we evaluated the ability of 17-AAG to enhance 
the delivery of NG-encapsulated DOX. The ErbB2-overexpressing 21MT-1 cell or the 
ErbB2-low MCF7 cells (specificity control) were incubated with increasing 
concentrations of Trast-NG/DOX for 6 h, after which the cells were either left alone 
(control) or treated with 100 nM 17-AAG for 18 h to trigger the internalization and 
lysosomal routing of the targeted NG cargo. Biological effects were assessed by 
evaluating DOX-induced G2/M arrest using a FACS-based assay.  
 
Figure 4.6. HSP90 inhibition potentiates the effect of Trast-NG/DOX on ErbB2-
expressing breast cancer cells. The ErbB2-overexpressing 21MT-1 or ErbB2-low MCF-7 
cells were plated in 6-well plates and triplicate wells were treated with the indicated 
concentrations of Trast-NG/DOX for 6h. Unbound Trast-NG/DOX was washed out and 
cells were cultured further in DOX-free media without or with 17-AAG (100 nM) for 18 
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h followed by the incubation with nanogel-free media. Cell cycle analysis was performed 
after 48 h of treatment. Shown are the fold increase in the % of cells in G2/M phase of 
the cell cycle for each treatment condition over DMSO control (the color coding is 
indicated inside the histogram). The number of asterisks indicates increasing significance 
(*, p<0.05; **, p<0.005; ***, p<0.0005); NS, not significant. 
While Trast-NG/DOX treatment showed a dose-dependent increase in the % cells in 
G2M in ErbB2-overexpressing 21-MT1 cells, little effect was seen on ErbB2-low 
MCF7 cells, especially at lower concentrations (Fig. 4.6). Inclusion of 17AAG had no 
impact on the effect of lower concentrations of Trast-NG/DOX on the % of MCF7 cells 
in G2/M, but a statistically significant increase was noted in 21-MT1 cells treated with 
identical concentrations of Trast-NG/DOX (Fig. 4.6). Thus, inclusion of 17AAG 
markedly increased the biological impact of Trast-NG/DOX, relatively selectively 
against the ErbB2-overexpressing cell line.  
4.3.4. Potentiation of the antitumor efficacy of Trast-NG/DOX by 17 AAG in an 
ErbB2-overexpressing breast cancer cell xenograft model in mice.  
To examine if HSP90 inhibition potentiates the antitumor efficacy of Trast-NG/DOX 
in vivo, we treated mice bearing ErbB2-overexpressing breast cancer cell line (BT-474) 
xenografts with Trast-NGs carrying DOX with or without sequential treatment with 
17AAG. In vivo experiments with BT-474 xenografts were conducted twice (with n= 
10 mice/group). In the first set only tumor volume changes were measured, while in the 
second, the mice were also followed for survival analyses.  For comparison, we also 
examined the impact of these treatments on xenografts of the ErbB2-low cell line MCF-
7. Control treatments included: 1) 5 % dextrose solution (negative control); 2) Trast 
alone (positive control); 3) IgG-NG/DOX (non-targeted NG) and; 4) IgG-NG/DOX 
plus 17-AAG. A total of four treatments (intravenous injections) were given at 4-day 
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intervals at a NG dose equivalent to 6 mg of DOX/kg (determined as the maximum 
tolerated dose for this treatment schedule). The NG doses administered were equivalent 
to 6 mg/kg DOX and 3 mg/kg Trast per injection. In cohorts that included the 17-AAG 
treatment, this drug was administered at 1 mg/kg, 2 h after the Trast-NG/DOX or IgG-
NG/DOX injection.  
The changes in the relative tumor volume for mice bearing BT-474 (ErbB2-high) 
tumors are shown in Fig. 4.7A (data combines results from two independent 
experiments). To confirm the in vivo selectivity of the targeted NG to deliver DOX to 
ErbB2-overexpressing tumors, we also evaluated the effect of treatments with Trast-
NG/DOX in comparison to the untargeted IgG-NG/DOX, on mice with MCF-7 
(ErbB2-low) xenografts ( ig 4.8). Student’s t-test was run on the tumor relative volume 
change data at day 16, comparing each treatment groups against 5% Dextrose control.  
 
Figure 4.7. In vivo antitumor efficacy of Trast-NG/DOX and enhancement by concurrent 
administration of 17-AAG against ErbB2-overexpressing breast cancer xenografts. BT-
474 xenografts were established by orthotopic injection of cells in mammary glands of 
female Nude mice, and the following treatments intravenous administered after tumors 
had grown between 200 and 300 mm
3
 in volume: Trast-NG/DOX + 17-AAG (■) or 
Trast-NG/DOX (●) or IgG-NG/DOX + 17-AAG (▼) or IgG-NG/DOX (▲) or Trast 
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alone (♦) or Control.. Drug formulations were injected in100 μL at a dose of 6 mg DOX 
or 3 mg Trast equivalents/kg body weight 4 times at 4-day intervals as indicated by the 
arrows. 17-AAG at a dose of 1mg/kg was given 2 h after NG formulation administration. 
Changes in tumor volume (A) are presented as a fold-ratio compared baseline for each 
animal on day 0 of treatment.  Values represent mean ± SEM. Kaplan–Meier analysis of 
the overall survival is shown (B). * and ** indicates a statistically significant difference 
between the indicated groups. *** indicates a statistically significant difference between 
Trast-NG/DOX and Trast alone. 
In mice carrying BT-474 xenografts, treatment with Trast-NG/DOX alone led to a 
statistically significant (p < 0.05) tumor growth inhibition when compared to the 
control groups (p-value = 0.0159) (Fig. 4.7A). Sequential treatment with 17AAG led to 
further enhancement of anti-tumor activity of the targeted nanoformulation, as 
compared to the Trast-NG/DOX alone group. Statistical analysis confirmed that the 
potentiation of the tumor inhibitory effect of Trast-NG/DOX by 17AAG was highly 
significant (p = 0.0005). Remarkably, the Trast-NG/DOX + 17AAG treatment led to an 
actual reduction in tumor volume (shrinkage) compared to the tumor volume at the 
beginning of the treatment and is clearly observed at later time points (Fig. 4.7A). 
However, the p-values (p = 0.293) between the Trast-NG/Dox vs. Trast-NG/DOX + 17-





Figure 4.8.  Relative changes in tumor volume after administration  of ErbB2-targeted 
Trast-NG/DOX in ErbB2 - breast cancer mice model. Trast-NG/DOX (●) or IgG-
NG/DOX (▲) or Control (Ø). 
Compared to our results with the BT-474 xenograft model, mice bearing MCF-7 
xenografts exhibited a small albeit statistically significant reduction in tumor volume 
upon treatment with Trast-NG/DOX (p = 0.03 vs. control); however, the difference in 
tumor volume between the IgG-NG/DOX and Trast-NG/DOX groups was not 
significant (p-value = 0.397) (Fig. 4.8).  Comparative analysis of BT-474 vs. MCF-7 
xenografts establish the advantage of Trast-based targeting against an ErbB2+ tumor, 
and clearly demonstrate the enhancement of the Trast-NG/DOX efficacy by sequential 
post-treatment with a small dose (which by itself has no measurable effect on tumor 
growth; not shown) of the HSP90 inhibitor 17AAG.   
Kaplan-Meier analysis of survival was carried out among various treatment groups 
to assess the potential survival advantage of the treatment regimen combining 
17AAG and DOX-loaded NGs in the BT-474 xenograft model. The median 
survival (in days), the associated Confidence Intervals and the p-values are shown 
in Table 4.2.  
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Table 4.2: Comparison of Median survival (in days), the associated Confidence Intervals 







Interval (days)  






% Survival at 
censoring date  
(76 days) 
Saline 40 26 - NE   0 
Trast 48 36 - NE 0.1794 0 
IgG-NG/Dox 52 26 - NE 0.3221 0 
IgG-NG/Dox + 
17-AAG 
40 32 - NE 0.2827 0 
Trast-NG/Dox NE 68 - NE 0.0032 56.8 
Trast-NG/Dox 
+ 17-AAG 
NE NE - NE <0.0001 88.8 
  NE - Estimate not reached 
This analysis clearly shows that, at the end of the experiment (76 days; censoring 
date), the mice treated with Trast-NG/DOX + 17-AAG had a substantially longer 
survival (>88%) compared to the Trast-NG/DOX group (56.8%) (Fig. 4.7 B). No mice 
survived until the censoring date (0% survival) in all other treatment groups (5 % 
dextrose, Trast alone, IgG-NG/DOX and IgG-NG/DOX + 17-AAG) (Fig. 4.7 B). The 
data clearly indicates the superiority of Trast-NG/DOX treatment and suggests that 
combined treatment with HSP90 inhibitors can vastly improve survival times. 
Measurement of animal body weight during treatment with various regimens indicated 
that the treatment-related toxicities associated with the administration of Trast-
NG/DOX or Trast-NG/DOX + 17-AAG were generally mild (<10%). In contrast, the 
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same dose of DOX or the free drug combination (DOX + 17-AAG) produced a 
considerable body weight loss (18-20%, p< 0.05) (Fig. 4.9).  
 
Figure. 4.9. Changes in body weight are presented as a fold-ratio compared baseline for 
each animal on day 0 of treatment.  Values represent mean ± SEM. 
.Light microscopic examination of the H&E-stained tissue sections of liver, lung, 
kidney, spleen and heart among the mice euthanized at the end of the experiment 
showed no histopathological changes in the organs of Trast-NG/DOX or Trast-
NG/DOX + 17AAG treatment groups compared to the 5% dextrose control (data not 
shown), confirming the relatively low toxicities of the targeted NGs.  
As further evidence of enhanced antitumor activity of Trast-NG/DOX or Trast-
NG/DOX administered in combination with 17-AAG, we performed 
histopathological analyses of the tumors excised post-treatment (on 2nd day after 





Figure 4.10. Administration of Trast-NG/DOX reduces the cell proliferation and 
promotes the apoptosis in BT-474 xenograft tumors and its activity is enhanced by 
17AAG.  Post-treatment tumor sections were stained for Ki-67 and caspase-3 and % Ki-
67-positive (A) and % caspase-3-positive (B) cells in were calculated based on 
enumeration of at least 1000 cells. Tumors from three mice per group were analyzed. 
Data are presented as mean ± SD (n = 5 random microscopic fields for each tumor). The 
treatment groups are indicated.  
 As expected, treatment with Trast alone caused a significant reduction in Ki67+ 
cells (p = 0.0033) but little increase in caspase-3+ cells, consistent with the primarily 
cytostatic effects of Trast [25, 26](Fig. 4.10). Treatment with untargeted NG (IgG-
NG/DOX) also reduced the percentage of Ki67+ cells (p = 0.0105) but with little 
impact on caspase-3+ cells (Fig. 4.10), consistent with a cytostatic mechanism of 
action of DOX [27, 28].  Notably, Trast-NG/DOX treatment led to a significant 
reduction in Ki67+ cells (p = 0.0023) and an increase in caspase-3+ cells (p = 
0.0059), and combined treatment with 17AAG further increased the impact on both 
parameters (p = 0.0011 for Ki67+ cells and p = 0.0012 for caspase-3+ cells) (Fig. 
4.10), indicating that the combination is superior and promotes substantial 
cytotoxicity in addition to a pronounced cytostatic effect. 17AAG also improved the 
pro-apoptotic efficacy of IgG-Trast/DOX but its impact on the anticancer activity of 
Trast-NG/DOX was substantially more pronounced, especially on caspase-3 activity 
148 
 
in tumors (Fig. 4.10). To mechanistically link the enhanced anti-tumor response of 
Trast-NG/DOX + 17-AAG combination with the effects of 17-AAG on ErbB2, we 
performed immunohistochemistry (IHC) and Western blot analyses of ErbB2 levels 
in tumors of mice treated with various regimens. Indeed, lower ErbB2 levels were 
seen in tumors of Trast-NG/DOX + 17-AAG treated mice (Fig. 4.11), correlating with 
the superior antitumor efficacy of a combination of HSP90 inhibitor and ErbB2-
targeted drug-loaded NG strategy.    
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Figure 4.11. ErbB2 levels analyzed in the tumor sections using A) western blot and 
B) ErbB2-IHCs. 
4.4. Discussion 
Introduction of targeted cancer nanomedicines into clinical practice has provided 
substantial momentum for the development of similar approaches against a variety of 
cancers. Most nanosized therapeutic agents require internalization and traffic into acidic 
endocytic compartments to ensure the delivery of drug cargo into the appropriate 
subcellular target [29, 30]. While much consideration has been given to the polymer 
design and the nature of drug to ensure successful delivery, the importance of the 
endocytic traffic routes of cell surface receptors that provide the basis for targeting of 
nanocarriers has received little attention. Here, we develop a proof-of-principle strategy, 
using ErbB2 as a targeting receptor, to help facilitate the entry of a model nanogel-
encapsulated therapeutic agent Doxorubicin into the lysosomes of breast cancer cells by 
tampering with the biological mechanism that retards the delivery of ErbB2 into 
lysosomes. Our studies demonstrate the feasibility of this novel approach in achieving 
superior in vitro targeting and in vivo anti-tumor efficacy in a xenograft breast cancer 
model. We suggest that this approach could significantly potentiate the efficacy of 
existing ErbB2-targeted nano-therapeutic agents against breast cancer. Furthermore, 
adaptation of this approach to facilitate the lysosomal delivery of other receptors 
currently used or considered for targeting cancer could substantially improve the efficacy 
of targeted cancer nanomedicines in general. 
Our choice of ErbB2 receptor for our proof-of-principle studies was based on 
several key considerations: ErbB2 is the driver oncogene for over 20% of breast cancers 
and smaller subsets of many other malignancies [31-33]; ErbB2 is the target of an 
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clinically-approved Trastuzumab-emtansine conjugate, Kadcyla, whose conjugated 
drug must be released to allow access to its cytosolic target [34]; ErbB2 is a prototype 
receptor that is biologically impaired in lysosomal entry [17, 18, 33]; studies by us and 
others have demonstrated that tampering with the function of a major biological partner 
of ErbB2 and key to its inability to enter the lysosome, the molecular chaperone HSP90, 
promotes rapid lysosomal sorting and eventual degradation of ErbB2 [17, 18, 33]. ErbB2 
is constitutively associated with HSP90, and multiple lines of investigation have 
demonstrated that HSP90 function is required for ErbB2 stability and ErbB2-driven 
oncogenesis [35-37]. Availability of specific HSP90 inhibitors has allowed a dissection 
of the mechanisms of ErbB2 instability upon HSP90 inhibition, and have revealed roles 
for lysosomal degradation [17-22]. Careful cell biological studies have however revealed 
the lysosomal targeting of ErbB2 upon HSP90 inhibition to be a relatively early event, 
and one likely to be important for the rapid downregulation of ErbB2 from the surface of 
HSP90 inhibitor-treated cancer cells [17-22]. In contrast, lysosomal delivery of ErbB2 
upon the treatment of ErbB2+ cancer cell lines with Trast is distinctly slower and 
incomplete [17, 19], apparently due to the maintenance of a recycling itinerary of Trast-
bound ErbB2 [38]. Our previous studies demonstrated that low concentrations of an 
HSP90 inhibitor, 17AAG, could however promote Trast-induced lysosomal delivery of 
ErbB2 and produce synergistic anti-tumor killing in vitro [19]. Indeed, Trast + 17AAG 
exhibit enhanced antitumor activity in vivo [19]. However, 17AAG and other HSP90 
inhibitors have been slower to be adopted clinically as they produce significant 
toxicity[39-44]. The focus of such studies has been on the using of maximally-tolerated 
doses of HSP90 inhibitors, even when these are combined with other therapeutic 
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agents[40-43, 45-49]. Our studies help establish a new paradigm in which HSP90 
inhibitors at sub-therapeutic doses can substantially improve the efficacy of a 
nanoformulated therapeutic agent without significant added toxicity. 
Our studies provide support for a potentially novel use of HSP90 inhibitors to 
facilitate the endolysosomal delivery of ADCs or antibody-conjugated drug nanocarriers 
(ANPs) that rely on targeting receptors that are HSP90 clients. A number of such targets 
have been identified, including the mutant EGFR in non-small cell lung cancer [50-53], a 
receptor we have shown to constitutively enter the endocytic recycling pathway [3, 53]. 
Similarly, glioblastoma-associated EGFR-vIII which lacks the normal EG R’s ability to 
undergo ligand-triggered lysosomal traffic [54]. Recent studies also suggest that 
overexpressed EGFR in gastric cancer cells is efficiently targeted by HSP90 inhibitors for 
degradation [55]. Thus, our approach using low doses of an HSP90 inhibitor is likely to 
be applicable to other malignancies as ADCs or ANPs against other HSP90-dependent 
receptors are developed for clinical use. While our studies relied on 17AAG as an HSP90 
inhibitor, a number of other HSP90 inhibitors are being evaluated in clinical trials, 
including ones with oral bioavailability [42, 45, 46], and testing of such drugs in the 
context of ANPs is highly desirable. Since HSP90 inhibition eventually promotes the 
degradation of receptors such as ErbB2 [19, 35, 56, 57], the scheduling of the ANP and 
HSP90 inhibitor is likely to be of key importance. In our studies, we considered this issue 
upfront and demonstrated the ability of HSP90 inhibition to facilitate the internalization 
and lysosomal targeting of Trast-NG in vitro (Fig 3). Accordingly, our preclinical therapy 
was designed to administer the HSP90 inhibitor 17AAG 2h hours after the nano-therapy, 
allowing time for the latter to reach its target. It remains possible that further studies to 
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optimize the scheduling of the HSP90 inhibitor relative to the ANP will help improve the 
efficacy of regimens targeting ErbB2 or other HSP90 client receptors. 
Our studies also provide evidence that sub-therapeutic doses of an HSP90 
inhibitor (1 mg/Kg 17AAG in our studies, which has little efficacy against BT-474 
xenografts; unpublished data), dramatically enhances tumor killing by DOX-loaded 
ErbB2-targeted NGs (Fig. 5A). Such a combination led to not just inhibition of xenograft 
tumor growth but in fact a significant shrinkage of tumor masses from their pre-treatment 
volume (Fig 5A). This was associated with a significant shift from a merely cytostatic to 
a significantly cytotoxic effect on tumors as demonstrated by Ki67 and caspase-3 staining 
of tumors among surviving mice at the end of therapy. Not surprisingly, combination 
with low dose 17AAG markedly improved the survival of tumor-bearing mice (Fig. 5B). 
We must point out that DOX was used in our proof-of-principle studies as the polymer 
design we have previously established allows efficient loading of this clinically-used 
chemotherapeutic agent [23]. However, DOX enhances cardiotoxicity associated with 
ErbB2-targeted antibody therapeutics, including Trastuzumab [58-60], and as such the 
approach will need modifications to incorporate more appropriate agents for ErbB2+ 
cancers. Such studies are currently ongoing in our laboratories. The current nanocarrier 
design should however be applicable to other tumors where a targeting antibody or other 
moiety is available. 
Based on our studies, we suggest that the endocytic traffic itinerary of receptors 
selected for targeting of ADCs and ANPs should receive careful consideration. An 
understanding of mechanisms that may impair the endolysomal traffic of a targeted 
receptor (as with ErbB2) may help overcome an efficacy barrier on newer agents in 
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development and potentially improve the efficacy of agents already in the clinic. In this 
regard, the potential combination of HSP90 inhibitors that are already in clinical trials 
together with the ErbB2-targeted TDM-1 will be of considerable interest and is under 
study in our group. A recently FDA-approved ADC, Brentuximab-Vedotin, targets CD30 
receptor in Hodgkin’s lymphomas [61, 62] which requires lysosomal traffic for its 
efficacy [63], although the mechanisms of lysosomal trafficking of CD30-bound ADC 
remains unknown. 
It is of interest that HSP90 is also thought to regulate the activity of Rab GTPase-
dependent endocytic recycling by its association with a Rab Guanine Nucleotide 
Displacement Inhibitor (GDI) [64, 65], and HSP90 inhibitors could potentially help 
attenuate Rab-dependent recycling of transmembrane receptors that are not direct HSP90 
clients to enhance ADC or ANP delivery inside the tumor cell. Other factors that may 
control trafficking of oncogenic cell-surface receptors such as the non-receptor tyrosine 
kinase c-Src, endocytic adaptor proteins, E3 ubiquitin ligases, deubiquitinating enzymes, 
RAB GTPases, ESCRT proteins and EHD family proteins [66, 67],[68, 69] may offer 
future opportunities to develop facilitators of ADC and ANP traffic to endolysomal 
compartments as approaches of therapeutic potentiation. 
4.5. Conclusion. Our study demonstrates the potential of therapeutically exploiting the 
vulnerabilities in cancer cell-specific trafficking behavior of receptors used to selectively 
deliver nanoencapsulated therapeutic agents, and highlights the importance of identifying 
such vulnerabilities in targeting receptors in order to fully realize the potential of ADCs 
and targeted nanomedicines in cancer and other diseases. 
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POLYPEPTIDE-BASED NANOGELS CO-ENCAPSULATING A SYNERGISTIC 
COMBINATION OF DOXORUBICIN WITH 17-AAG SHOW POTENT ANTI-
TUMOR ACTIVITY IN ErbB2-DRIVEN BREAST CANCER MODELS2 
5.1. Introduction: 
The receptor tyrosine kinase ErbB2 (also known as Her2/Neu) is overexpressed in 
20-25 % of breast cancer patients [1-5]. Oncogenic ErbB2 signaling results in 
hyperproliferation of the cells, increases cell survival and promotes invasion and 
metastasis [6, 7]. The anti-ErbB2 monoclonal antibody, Trastuzumab (Herceptin™)[8], in 
combination with chemotherapy is currently used for treatment of ErbB2-overexpressing 
breast cancers, following surgical removal of the primary tumor [5, 8, 9]. However, many 
patients either do not respond to Trastuzumab-based therapies or relapse during the 
course of the treatment, necessitating the development of newer therapeutics [8]. ErbB2 
depends on heat shock protein 90 (HSP90) association for stability and, among client 
proteins of the chaperone, ErbB2 is perhaps the most sensitive to HSP90 inhibition [10]. 
HSP90 inhibitors (such as the ansamycin antibiotic, Geldanamycin and related molecules 
like 17-AAG) have shown significant promise in pre-clinical models of ErbB2-driven 
breast cancer as well as initial phase I/II clinical trials [11-13]. The mechanism involves 
attenuation of oncogenic signaling via degradation of ErbB2 as well as other critical 
downstream signaling mediators in the pathway, which include phospho-Akt and c-Raf. 
                                                             
2 Reproduced with permission from Desale SS, et al. "Polypeptide-based nanogels co-encapsulating a 
synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven 
breast cancer models." J Control Release 208 (2015): 59-66.Copyright 2015 Elsevier B.V. 
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In a cancer cell, these signaling molecules are strongly dependent on HSP90 to maintain 
their stability [14-16]. Since numerous oncoproteins have been identified as HSP90 
clients, inhibition of Hsp90 functions affects multiple oncogenic substrates 
simultaneously and represents an appealing molecular target for combination drug 
therapy [17]. In a recently completed phase II study of 17-AAG and trastuzumab, an 
overall clinical benefit  (including stable disease) was seen in 57% of the patients with 
ErbB2-positive metastatic breast cancer progressing on trastuzumab [13].  It has also 
been reported that inhibition of Hsp90 with 17-AAG sensitizes different cancer cell lines 
to DNA damage response mediated cellular senescence [18]. It was shown that the 
17AAG pre-treatment followed by doxorubicin (DOX) treatment exhibited senescence-
like characteristics such as increased nucleus to cytoplasm ratio and cell cycle arrest in 
the pre-clinical evaluation [18-20]. These data suggest that combination chemotherapy 
using co-administration of 17-AAG with a DOX-based regimen can be a potential 
therapy for cancer especially ErbB2-positive breast cancer [18].  
Combining drugs in one delivery carrier is a well-suited strategy for controlling 
the pharmacokinetics and co-delivery of the desired drug ratio in vivo [21, 22]. The drug 
loading and structure of such carriers can be tuned to control the drug release rates, 
maximize the therapeutic potency and minimize drug-associated toxicities. However, co-
incorporation of drug molecules with different physicochemical properties, such as 
hydrophilic DOX and hydrophobic 17-AAG, has been challenging. We have recently 
described biodegradable polymeric nanogels (NGs) based on poly(ethylene glycol)-b-
poly(L-glutamic acid) (PEG-b-PGlu) with pendant phenylalnine functionalities [23]. 
Such NGs have multiple hydrophobic domains formed by phenylalanine moieties within 
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the cross-linked PGlu polyion cores surrounded by a hydrophilic PEG shell.  Herein, we 
explored these novel NGs for co-encapsulation of 17-AAG and DOX. The potency of this 
co-delivery system was evaluated in a panel of human breast cancer lines and in an 
ErbB2-driven orthotopic xenograft model. We demonstrate that NGs-based co-delivery 
of synergistic combination of 17-AAG and DOX exhibited superior antitumor efficacy 
compared to a combination of free drugs. The implications of our results may support a 
new platform for delivery of combinations of HSP90 inhibitors with cytotoxic agents for 
treatment of various types of cancers. 
5.2. Materials and Methods 
5.2.1 Materials 
Poly(ethylene glycol)-b-poly(L-glutamic acid) (PEG-b-PGlu) diblock copolymer (Mw/Mn 
= 1.38, MW 27,500) was purchased from Alamanda Polymers, Inc (Madison, AL, USA). 
The block lengths were 114 and 150 repeating units for PEG and PGlu, respectively. L-
phenylalanine methyl ester (PME), calcium chloride, cystamine, 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and 
ethylenediaminetetraacetic acid (EDTA) were obtained from Sigma-Aldrich (St Louis, 
MO). Doxorubicin hydrochloride was kindly provided by Dong-A Pharmaceutical 
Company, South Korea. Fetal bovine serum (FBS) (both dialyzed and heat inactivated), 
DMEM and RPMI 1640 media and Lysotracker
TM
 (green) were purchased from 
Invitrogen Inc (Carlsbad, CA). Bovine serum albumin (BSA) and NUNC
TM
 chambered 
glass coverslips for live cell imaging were purchased from Fisher Scientific (Waltham, 
MA). MTT reagent (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was 
purchased from Research Products International (Prospect, IL). All other chemicals were 
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of reagent grade and used without further purification. The following primary antibodies 
were used in this study:  anti-human-ErbB2 mouse monoclonal (ErbB2) raised against the 
C-terminal amino acid residues (1242-1255), used for Western blotting studies, were 
purchased from BD Pharmingen™ (San Diego, CA); for flow cytometry and 
immunofluorescence studies, the goat anti-human-ErbB2 polyclonal antibody (AF1129) 
was from R&D Systems (Minneapolis, MN); the mouse monoclonal anti-
phosphotyrosine (anti-pY; 4G10) was kindly provided by Dr. Brian Druker (Oregon 
Health & Science University, Portland, OR); the mouse monoclonal anti-Hsc70 antibody 
was from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). 
5.2.2 Synthesis of nanogels 
The hydrophobic phenylalanine functionalities were introduced in PEG-b-PGA 
copolymer by polymer-analogous modification of the PGA segment with PME using 
carbodiimide chemistry as we previously described [23]. The degree of PME grafting in 
resulting PEG-b-PPGlu copolymer was 30% as determined by 1H-NMR analysis. 
Nanogels were prepared as described earlier [23] by using block ionomer complex PEG-
b-PPGA/Ca
2+




] = 1.5 with further cross-linking by 
cystamine and EDC ([EDC]/[cystamine] = 2; [COOH]/[EDC] = 5) at r.t., overnight. 
Byproducts of the cross-linking reaction and metal ions were removed by exhaustive 
dialysis of the reaction mixtures, first against 0.5% aqueous ammonia with EDTA and 
then against distilled water.  
5.2.3 Drug loading 
Dox-encapsulated nanogels (DOX/NG) were prepared by adding Dox to an aqueous 
dispersion of NGs at the feeding ratio of R= [DOX]/[COO
-
] = 0.25, for 24h at pH 7.0. 
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Unbound Dox was separated by centrifugal filtration on drug-pretreated Amicon YM-30 
filters. 17-AAG was solubilized into the hydrophobic domains of NGs using an 
extraction method [24]. According to this method, a thin film of 17-AAG (prepared by 
evaporation of a methanol solution of 17-AAG) was incubated with aqueous dispersion 
of NGs or DOX/NG (24 h, r.t.). Unincorporated 17-AAG was removed by filtration. Dox 




 in water) [25]. The 
amount of 17-AAG incorporated into NGs was quantified via reverse-phase HPLC using 
an Agilent Eclipse XDB C18 5 μm column (250 mm × 4.6mm) and Agilent 1200 HPLC 
system. Mobile phase was composed of 10 mM ammonium acetate containing 0.1% (v/v) 
acetic acid (pH 4.8) and 50% acetonitrile and was applied at a flow rate of 1 mL/min. 
Detection wavelength was 334 nm. Drug loading capacity was calculated as percent ratio 
of mass of incorporated drug to total mass of drug-loaded NGs without water.  
5.2.4 Physicochemical characterization of the NGs.   
The effective hydrodynamic diameter (Deff) and -potential of NGs were determined using 
a Malvern Zetasizer (Malvern Instruments Ltd., Malvern, UK). All measurements were 
performed in automatic mode at 25C. Software provided by the manufacturer was used to 
calculate size, polydispersity indices and -potential of NGs. All measurements were 
performed at least in triplicate to calculate the mean values ± SD.  
5.2.5 Drug release studies.  
Drug release from NGs was examined in PBS (pH 7.4, 0.14M NaCl) by dialysis method 
using a membrane with 3500 Da cutoff. The concentrations of 17-AAG and Dox released 
were determined by HPLC and UV spectrophotometry, respectively, and expressed as a 
percentage of the total 17-AAG or Dox available vs. time. 
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5.2.6 Cell culture. 
The ErbB2-overexpressing cell lines used in this study were 21MT-1 and BT-474. MCF-
7 cells were used as a representative ErbB2-low cell line for comparison. The ErbB2-
overexpressing breast cancer cell line 21MT-1 was established by Band et al [26] and has 
been previously described. BT-474 and MCF-7 cell lines were obtained from the 
American Type Culture Collection (ATCC). All cell lines were maintained as previously 
described [27, 28].  
5.2.7 Confocal microscopy on live cells. 
Cellular uptake and localization studies of (DOX+17-AAG)/NG were conducted using 
live cell confocal microscope (Carl Zeiss LSM 510 Meta, Peabody, MA). 21MT-1 human 
breast cancer cells (1×10
6
/chamber) were grown in live cell chambers (Fischer Scientific, 
Waltham, MA) for two days (37
o
C, 5% CO2) and exposed to (DOX+17-AAG)/NG for 30 
min followed by incubation with Lysotracker Green for 5 min. After exposure cells were 
washed with PBS and kept in complete media prior to visualization by live cell confocal 
imaging (Carl Zeiss LSM 510 Meta, Peabody, MA). 
5.2.8 ErbB2 degradation. 
ErbB2-overexpressing cells plated in 6-well plates were treated with free 17-AAG or the 
drug-loaded NG formulations, following which the samples were lysed using RIPA lysis 
buffer, supplemented with protease and phosphatase inhibitors. Analysis of the kinetics 
and dose-response of ErbB2 degradation induced by free 17-AAG or 17-AAG/NG 
formulations were done using SDS-PAGE/WB [27, 28]. 
5.2.9 In vitro cytotoxicity studies. 
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Cytotoxicity of drug-loaded NGs was assessed in 21MT-1, BT-474, and MCF-7 cells by 
a standard MTT assay [29]. Briefly, cells were seeded in 96-well plates (5,000 cells/well) 
and allowed to adhere for 24 h prior to the assay. Cells were exposed to various 
concentrations of free drugs (0 - 10 μg/mL Dox or 0 - 17.2 µM 17-AAG), drug-loaded 
NGs for 48 h at 37 °C. Cells were then washed with PBS and MTT indicator dye (25 μL, 
5 mg/mL) was added to each well and the cells were incubated for 2 h at 37°C in the 
dark. A solution of 50% DMF-20% SDS (100 μL) was added to each well and kept 
overnight at 37 °C. Absorbance was read at 570 nm using a plate reader (SpectraMax 
M5, Molecular Devices Co., USA). Cell survival rates were calculated as normalized to 
control untreated wells. All measurements were taken eight times. Based on the results of 
the test, the IC50 values and synergic effects of DOX and 17-AAG in these cells were 
calculated by using CampuSyn Software (Combosyn, USA). Combination index (CI) 
values less than 1 indicate synergism while CI values equal or more than 1 represent 
additive and antagonistic effects of drug combination, respectively. 
5.2.10 Animal Studies. 
All animal studies were conducted in accordance with an approved protocol by the 
University of Nebraska Medical Center Institutional Animal Care and Use Committee 
(IACUC).  10
7
 BT-474 cells (an ErbB2 overexpressing human breast cancer cell line) 
reconstituted in 50% Matrigel (BD Biosciences, California) in media were injected 
directly into the mammary fat pad of 4-6 week old female Athymic NCr-nu/nu mice 
(NCI, Fredrick National Lab, Fredrick, MD). 17--Estradiol pellets (0.72mg/pellet; 60 
day release; Innovative Research of America, Sarasota, Fl) were implanted 
subcutaneously on the lateral side of the neck of the mice three days prior to the injection 
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of the tumor cells.  The mice were randomized when the average tumor size reached 100-
200 mm
3
 (14 days after tumor inoculation) into treatment groups (n = 10), and treated 
with DOX/NG or 17-AAG/NG or (DOX+17-AAG)/NG or combination of free Dox and 
17-AAG in the same ratio as in (DOX+17-AAG)/NG at an equivalent dose of 6 mg/kg 
DOX, or 1 mg/kg 17-AAG or (6 mg/kg DOX + 1 mg/kg 17-AAG) or 5% dextrose 
solution. 17-AAG was formulated in Chemophor-EL : propylene glycol : ethanol (2:3:5 
by volume) mixture for injections as a component of the free drug combination.  
Treatments were administered via tail vein injections at 4-day intervals. Animal body 
weight and tumor volume were monitored every second day. Tumor volume (V = 0.5 x L 
x W
2
) was estimated by measuring two orthogonal diameters (longer dimension: L, and 
smaller dimension: W) of the tumor using electronic calipers. The T/C values were 
determined from changes in average tumor volumes of drug-treated groups relative to 
control group. Animals were sacrificed when tumor volume exceeded 3000 mm
3
, greatest 
tumor dimension exceeded 20 mm, tumor became necrotic, or animal exhibited a body 
weight loss of more than 20%. All other animals were sacrificed by day 23. 
5.2.11 Cell proliferation assay. 
Tumors from mice that received different treatments were excised at day 14 (3 mice per 
group). The tumors were dissected and fixed in 10% neutral buffered formalin. Then, the 
tissues were processed routinely into paraffin, sectioned at a thickness of 4 μm. 
Proliferation was detected using an antibody against Ki-67 (Biocare medical, CA) 
followed by visualization by incubation with DAB+ (brown, for Ki-67) for 2 min. After 
rinsing with distilled water, the sections were counterstained with hematoxylin.  For 
quantification of Ki-67 expression, the number of Ki-67 positive cells was determined 
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(Image J) in 5 random high power fields (20X magnification) and divided by the total 
number of cells for each field of slice. 
5.2.12 Histopathology analysis.  
Specific tissues (liver, spleen, heart kidney and lung) were fixed in buffered formalin and 
were sectioned, inserted into tissue cassettes, dehydrated in 70% ethanol overnight, and 
paraffin embedded (UNMC Tissue Sciences  acility, Omaha, NE). Serial 5 μm sections 
were stained with hematoxylin and eosin (H&E). For histopathological diagnosis, H&E-
stained slides were examined by light microscopy. 
5.2.13 Statistical analysis. 
Statistical comparisons for in vitro studies were carried out using Student t-test. For the 
antitumor study and toxicity studies, group means for tumor volume and body weights 
were evaluated using repeated measures analysis of variance. Survival was estimated 
using Kaplan–Meier analysis and compared using log-rank test. P values less than 0.05 
were considered significant. Analysis of variance and Kaplan–Meier analysis with log-
rank test were performed using GraphPad Prism 5 (GraphPad Software, Inc.).  
5.3. Results and Discussion 
5.3.1 Preparation and characterization of nanogels co-encapsulating 17-AAG and 
Dox 
PEG-b-PGlu diblock copolymer, in which about 30% of GA units were modified 
with hydrophobic phenylalanine moieties, were utilized for the synthesis of 
biodegradable NGs. NGs were prepared as previously described by template-assisted 
method involving condensation of these hydrophobically-modified block copolymers by 
Ca
2+
 ions into polyion complex micelles, followed by chemical cross-linking of the 
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polyion chains in their cores [23]. A cleavable diamine crosslinker, cystamine, was used 
for synthesis of the NGs with targeted density of cross-links of 20% (based on the molar 
ratio of cross-linker to carboxylic acid groups of the Glu residues). The resulting core-
shell NGs displayed an effective diameter of about 80 nm (ζ-potential = −45 mV) and 
were uniform (monomodal, narrow size distribution) as determined by dynamic light 
scattering (DLS). We have previously shown that water-soluble anticancer drugs such as 
DOX or cisplatin can be encapsulated with high loading efficiency into NGs ionic cores 
through electrostatic or coordination interactions [23, 30]. In addition, it was 
demonstrated that hydrophobic domains formed by phenylalanine moieties within the 
ionic cores of NGs could solubilize hydrophobic molecules and, therefore, such hybrid 
NGs provide unique opportunities for combinational drug delivery especially for the 
drugs that possess different solubility.  
It has been reported that HSP90 inhibitors including 17-AAG show additive or 
synergistic activities with agents commonly used to treat advanced malignancies [31-35]. 
Particularly, it was demonstrated that 17-AAG synergistically enhances the 
antiproliferative effect of DOX chemotherapy. The mechanism of synergy is thought to 
involve 17-AAG-mediated degradation of many of the proteins required for DNA-
damage response (such as ATM/ATR or Chk1 kinase), the activities of which are 
dependent on HSP90 chaperoning function [36]. Additionally, in the case of ErbB2-
driven cancers, given the ability of 17-AAG to attenuate hyperactive ErbB2 signaling 
(which is known to be involved in transcriptional upregulation of genes encoding DNA-
damage repair enzymes) [37], it can potentially enhance the cytotoxic effect of DOX-
induced DNA damage. Based on these considerations, we attempted to encapsulate both 
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hydrophilic DOX and hydrophobic 17-AAG into NGs with hydrophobically modified 
ionic cores.  At first, DOX was incubated with aqueous dispersion of NGs for 24 h at pH 
7.0. As expected, the net negative charge and particle size of Dox-loaded NGs (Dox/NG) 
decreased upon DOX loading due to progressive neutralization and condensation of the 
PGA segments upon DOX binding to carboxylate groups (Table 5.1).  
Table 5.1. Physicochemical characterization of NGs before and after drug loading
a
 






Empty NG 82 ± 1 0.18 -45.0 ± 5.2 - - 
DOX/NG 69 ± 2 0.20 -19.1 ± 1.5 18.1 - 
17-AAG/NG 95 ± 1 0.17 -25.7 ± 1.7 - 2.7 
(DOX+17-AAG)/NG 63 ± 5 0.16 -21.5 ± 0.47 18.1 3.1 
a
 Effective diameter (Deff), polydispersity index (PDI) and ζ-potential were determined  in water 
(pH 6.5). 
b
 Dox and 17-AAG content were determined by UV and HPLC, respectively.   
Loading capacity (LC) is expressed as mass of incorporated drug per mass of  
drug-loaded nanogels (w/w). 
 
Under these conditions DOX loading capacity of NGs was about 18% w/w as measured 
by UV-Vis spectroscopy. Binary drug formulation, (DOX+17-AAG)/NG, was prepared 
by solubilization of 17-AAG into DOX/NG using an extraction method. A similar 
procedure was used to prepare single 17-AAG/NG formulations. 17-AAG content was 
determined by HPLC. Comparable loading capacity values for 17-AAG were achieved 
for NGs with binary drug combination (3.1%) and for single 17-AAG/NG (2.7%). A total 
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loading capacity of NGs for the binary drug combination was about 21% w/w and 
corresponds to 6:1 DOX/17-AAG molar ratio.  The physicochemical characteristics of 
drug-loaded NGs are presented in Table 1. The size and ζ-potential of the (DOX+17-
AAG)/NG were comparable to those of DOX/NG indicating that an inclusion of 17-AAG 
into the NG cores did not affect the macroscopic characteristics of DOX-loaded NGs. 
Importantly, single and binary drug formulations exhibited excellent stability in aqueous 
dispersions: no changes in sizes and loading capacities were observed for at least two 
months.                                                                                                                                            
The release profile of the encapsulated drug from the nanocarrier is crucial for the 
synergy of the drugs [20]. Profound synergistic effects were observed when 17-AAG was 
administered prior to DOX while the sequence of DOX before 17-AAG had less 
cytotoxic activity in vitro [20, 34]. Figure 5.1 shows the cumulative release profiles of 
DOX and 17-AAG from the NGs at physiological pH and temperature.  
 
Figure 5.1.  Drug release profiles from single drug-loaded NGs (solid line) and binary drug 
combination-loaded NGs (dotted line) for DOX (●) and 17-AAG (■) in PBS buffer, pH 7.4.  The 
loading amount of DOX for each sample is 200 μg. The data represent averaged values and 
standard deviations calculated based on three independent experiments.  
 
As seen from these data, sustained but temporally distinct release of DOX and 17-AAG 
was observed. For example, during 12 hrs (DOX+17-AAG)/NG released ~ 90% of 
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loaded 17-AAG and only ~ 17% of loaded DOX. Notably, 17-AAG release was much 
faster than that of DOX, which is expected since 17-AAG is physically entrapped into the 
hydrophobic domains in the cores of NGs. In contrast, DOX binds with PGlu chains 
through electrostatic and van der Waals interactions and its release usually proceeds via 
ion exchange reactions, thus delaying its liberation from the NGs. Furthermore, 
intermolecular interactions between the anthraquinone moiety of DOX and phenylalanine 
hydrophobic domains of NGs in combination with more compact cross-linked core [23] 
could account for the delayed and controlled release of DOX from the NGs. It is also 
interesting that the individual drug release rates practically did not change for binary drug 
formulations compared to the single drug-loaded NGs (Fig. 5.1). 
5.2.2 Intracellular uptake of drug-loaded NGs.    
NG-based drug-carriers (made of biodegradable materials) are designed to be 
internalized by cancer cells via the endocytic pathway and disintegrate under lysosomal 
pH and reducing environment, to release the anticancer drugs into the cytosol. It was 
important to confirm that the (DOX+17-AAG)/NG uptake into the cells was indeed a 
result of internalization of intact drug-loaded NGs and subsequent drug release. We 
therefore compared the kinetics of uptake of free DOX or DOX/NG into 21MT-1 cells, 
monitoring the intrinsic fluorescence of DOX, using a fluorescence microscope. Images 




Figure 5.2. Comparison of kinetics of cellular DOX distribution in ErbB2 overexpressing 21MT-
1 cells after treatment with Free DOX or DOX/NG. Cells, grown on glass coverslips, were 
exposed to free DOX or DOX/NG (10 µg/mL DOX equivalents) for the indicated time periods 
following which the cells were washed 3X in PBS and fixed using 4% PFA for 20 min. The cells 
on the coverslips were then imaged using a regular fluorescence microscope, using a 20X 
objective. Shown here is a comparison of the distribution of DOX-fluorescence (red) within the 
cells, as a function of time, when added in the free form vs the NG-formulation. 
 
As shown in Fig. 5.2, the free DOX, which rapidly partitions across the plasma 
membrane, was found within the nuclei of cells as early as 15 min. On the other hand, the 
fluorescence of DOX followed by treatments with DOX/NG (at the same concentration 
of DOX) at early time points (15 and 30 min) was very weak and diffused throughout the 
cytoplasm; nuclear localization of DOX could only be seen at longer time points (120 
min, Fig. 5.2). Confocal microscopy tracking the DOX uptake in live cells confirmed that 
the DOX/NG accumulated in Transferrin positive early endosomes within 15 min (seen 
as co-localized yellow punctate structures in Fig. 5.3A, merged panel) and trafficked into 
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lysosomes within 30 min (as seen by colocalization with Lysotracker dye in Fig. 3B, 
merged panel). 
 
Figure 5.3. Confocal immunofluorescence analysis of cellular distribution of DOX/NG. 21MT-1 
cells grown on coverslips were loaded with 10 µg/ml Alexa488-labeled transferrin (early 
endosomal marker) or Lysotracker Green (lysosomal marker; 100nM) for 10 min at 37
0
C. 
DOX/NG (10 µg/mL Dox equivalents) was then added and the uptake and intracellular 
distribution of DOX/NG (red) within Transferrin- or Lysotacker green-positive compartments, 
was followed using live cell imaging. Shown here the distribution of DOX fluorescence (red) 
within transferrin-positive (panel A) early endosomes after 15 min, and in lysosomal 
compartment (lysotracker green positive) after 30 min (panel B). Clear nuclear localization is 
seen after 60 min of incubation. 
 
 As seen in the low-resolution microscopy images shown in Fig. 5.3, after 30 min 
incubation most of the fluorescence from DOX was within the cytosol and not the 
nucleus. However, by 60 min, the DOX fluorescence was found in the nucleus, 
confirming diffusion of DOX from the lysosomes. Lysosomal trapping of drug-loaded 
NGs is expected to modulate the release of the drug as well as control the degradation of 
the carrier. We have previously shown that DOX release rate from NGs is higher at the 
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acidic pH, which is likely due to protonation of carboxylic groups of PGlu and abating 
the drug and micelle electrostatic coupling. Since intracellular endocytotic vesicles are 
acidic (pH≈4.0 to 6.0), the transport of the NGs in these compartments can potentially 
trigger a release of a bolus of drug from the carrier. Degradation of the PGlu-based NGs 
in the presence of lysosomal proteases such as cathepsin B or cleavage of reductively 
labile disulfide bonds in the NGs ionic cores can further facilitate the Dox release.  
While the intrinsic fluorescence of DOX served as a method to follow the uptake 
of drug-loaded NGs and DOX-release, we followed ErbB2 degradation using a Western 
blot technique as a means to assess the release of 17-AAG and its ability to inhibit 
intracellular HSP90. The data shown in Fig. 5.4 clearly demonstrate that the encapsulated 
17-AAG is released into the cytosol and can inhibit HSP90 leading to ErbB2-
degradation.  
 
Figure 5.4. 17-AAG-loaded NGs can induce ErbB2-degradation in 21MT-1 cell lines as 
efficiently as free 17 AAG. Cells were treated with the indicated concentrations of free 17-AAG 
or the NG-formulations for 8h (Dose response experiment; panel A) or with fixed concentration 
(1 µM) of free 17-AAG or the NG-formulations for the indicated time periods (kinetics; panel B). 
Samples were lysed in Triton X-100 lysis buffer and 25 µg aliquot of total protein was analyzed 
by SDS-PAGE/WB. Shown here are changes in ErbB2-levels as a result of HSP90-inhibition. 
Hsc70 is shown as loading control.      
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As seen in Fig. 4A, 17AAG/NG or (DOX+17AAG)/NG induced ErbB2 
degradation at the same level as the treatment with free 17-AAG in a dose-dependent 
manner. Notably, the kinetics of ErbB2 degradation were also comparable for NG-
formulations and free 17-AAG (Fig. 5.4B).  
Previous studies from our laboratory has shown that NGs with cross-linked ionic 
cores can be selectively endocytosed into cancer cells, which lack epithelial cell tight 
junctions, in contrast to normal epithelial cells that form tight junctions [38]. The 
internalization route appeared to be predominantly via the caveolar pathway. While the 
current studies report the ability of untargeted NGs to be internalized into ErbB2-
overexpressing breast cancer cells, we anticipate that integration of targeting anti-ErbB2 
antibody on to the surface of NGs could further facilitate selective delivery of their 
payload specifically into ErbB2-overexpressing breast cancer cells. In conjunction with 
passive targeting, ErbB2-targeted drug delivery should further reduce side effects of the 
chemotherapeutics. In contrast to the untargeted NGs, the ErbB2-specific uptake of the 
targeted NGs will be dictated by the ErbB2 endocytic pathway. However, one anticipated 
caveat is that the rate of Trastuzumab-induced ErbB2 internalization is very slow [28, 
39]. Immunogold labeled electron microscopy has revealed that gold-labeled 
Trastuzumab can be detected within microvili-like protrusions and clathrin-coated pits at 
the cell surface as well as within recycling endosomes [39, 40]. We have shown that 
HSP90-inhibition induces ErbB2-ubiquitinylation, resulting in accelerated internalization, 
ubiquitin-dependent sorting into multivesicular bodies and subsequent lysosomal-
degradation [28]. Accordingly, we hypothesize that the uptake of the chemotherapeutic 
payload being delivered via ErbB2-targeted NGs can be significantly enhanced by 
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concomitant treatment with HSP90-inhibitors, which can accelerate the internalization of 
the ErbB2-bound targeted drug cargo and routing them to the lysosomes leading to 
efficient drug-release and induction of cytotoxicity. These studies are ongoing in our 
laboratories and will be reported elsewhere. 
5.2.3 In vitro cytotoxicity of DOX, 17-AAG or drug combination against ErbB2-high 
and ErbB2-low breast cancer cell lines. 
DOX is among the most active cytotoxic agents for the treatment of breast cancer. DOX 
induces DNA damage, and many DNA-repair components are HSP90 client proteins 
[41].  To test a hypothesis that 17-AAG contentment leads to sensitization of cancer cells 
to cytotoxic effects of DOX, we determined the cytotoxicity of various drug formulations 
in a panel of breast cancer cell lines with differential ErbB2 expression using MTT cell 
cytotoxicity assay (Supplementary Fig. 1-3). Calculated IC50 values (the concentration 
that inhibited cell growth by 50%) are summarized in Table 5.2.     
Table 5.2. Comparison of IC50 values for drug-loaded NGs and free drugs against various 
breast cancer cell lines as determined by the MTT assay. 
 
Formulation 
IC50 (µM) [with respect to Dox] 
BT-474 21MT-1 MCF-7 
Free DOX 0.60 ± 0.08 0.13 ± 0.17 0.65 ± 0.13 
Free 17-AAG 0.011 ± 0.003 0.005 ± 0.002 0.09 ± 0.04 
Free DOX + 17-AAG
a
 
0.09 ± 0.03 
(CI
b
 = 0.055) 
0.007 ± 0.002 
(CI = 0.043) 
0.63 ± 0.17 
(CI = 0.85) 
DOX/NG 2.40 ± 0.22 0.47 ± 0.20 1.05 ± 0.02 






0.13 ± 0.05 
(CI = 0.043) 
0.08 ± 0.03* 
(CI = 0.060) 
0.81 ± 0.18 




The molar ratio 
 
of DOX :17-AAG of 6:1 was used for the drug combination studies.  
b 
CI values were calculated at IC50.  
 
We first confirmed that the DOX and 17-AAG combination at a 6:1 molar ratio 
(corresponding to the drug content encapsulated into NGs) was indeed synergistic in its 
cytotoxicity against high-level ErbB2-expressing BT-474 and 21MT-1 cell lines after 
concomitant treatment for 48 h. An approximately 6- and 18-fold reduction in the IC50 for 
DOX was seen in BT-474 and 21MT-1 cells, respectively, after treatment with drug 
combination. Chou-Talalay analysis of the data clearly indicated a combination index 
below 1 (such as 0.055 for BT-474 and 0.043 for 21MT-1) confirming strong 
pharmacological synergy. Similarly, we found that (DOX+17-AAG)/NG combination 
was significantly more effective in killing ErbB2-overexpressing cells than single 
DOX/NG formulation and displayed very pronounced synergistic cytotoxicity. The 
corresponding CI values of (DOX+17-AAG)/NG combination at IC50 were 0.043 and 
0.06 for BT-474 and 21MT-1cells, respectively. On the other hand, no appreciable 
differences between the combination treatment and DOX alone (either free or loaded in 
NGs) were detected in similar experiments conducted on the ErbB2-low MCF-7 cells 
(Table 2), suggesting that 17-AAG plus DOX combination can induce synergistic anti-
proliferative effects selectively in ErbB2-overexpressing breast cancer cells.  
5.2.4 Anti-tumor activity of (DOX+17-AAG)/NG in ErbB2-driven xenograft model. 
Motivated by the enhanced in vitro efficacy of (DOX+17-AAG)/NG formulation, we 
evaluated its antitumor efficacy in vivo in ErbB2-driven xenograft model. Intravenous 
administrations of each formulation were given 4 times at 4-day intervals at an equivalent 
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dose of 6 mg-DOX/kg. Animals injected with (DOX+17-AAG)/NG or free drug 
combination received 6mg/kg DOX and 1 mg/kg 17-AAG equivalents per dose. The 
changes in the relative tumor volume, body weight and animal lifespan are shown in Fig. 
5.5A, 5.5B and 5.5C, respectively.  
 
Fig. 5.5.  In vivo antitumor efficacy of (DOX + 17-AAG)/NG in ErbB2+ - BT-474 breast cancer 
mice model. Relative changes in (A) tumor volume and (B) body weight were measured 
following intravenous administration of (DOX + 17-AAG)/NG (▲) or DOX/NG (●) or DOX + 
17-AAG (♦)  or  ree DOX (Ø) or 17-AAG/NG (■) or 5% dextrose (▼). Drug formulations were 
injected in 100 μL at a dose of 6 mg DOX or 1mg 17-AAG equivalents/kg body weight 4 times at 
4-day intervals as indicated by the arrows. Values indicated are means ± SEM (n = 10). (C) 
Kaplan–Meier analysis of overall survival in (DOX + 17-AAG)/NG group (1) or DOX/NG group 
(2) or  DOX + 17-AAG group (3) or  DOX alone (4) or 17-AAG/NG group (5) or control group 
(6). Tumor volume and body weight are normalized with respect to tumor volume or body weight 
at day 0. * P<0.05, ** P<0.01. 
 
Tumor growth inhibition ratio between treated versus control groups (T/C value) was 
calculated on day 14 after treatment initiation according to the formula: T/C = (Vt-
Vo)treated tumor/(Vt-Vo)control tumor, where Vt and Vo represent the mean tumor volume on the 
evaluation day and at the start of the experiment, respectively.   Consistent with the in 
vitro findings, combination treatment with (DOX+17-AAG)/NG formulation resulted in a 
more significant tumor volume reduction (T/C = 0.13), which translated into increased 
overall survival of the animals compared to the animal groups treated with a combination 
of free drugs (DOX+17-AAG) at equivalent drug concentrations (P<0.05, Fig. 5.5A & 
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5.5C). Although not as prominent as (DOX+17-AAG)/NG formulation, tumor burden 
was also decreased by treatments with DOX alone (T/C = 0.54) or combination of free 
drugs (DOX+17-AAG, T/C = 0.47) or Dox/NG (T/C = 0.39) compared to control (Fig. 
5.5A). Notably, survival of the animals treated with DOX/NG was higher than in animals 
treated with the combination of free drugs or DOX alone, which could be attributed to the 
pronounced systemic toxicity of (DOX+17-AAG) and DOX treatments (Fig. 5.5C). 
Figure 5.5B shows that animals treated with either single or binary drug-loaded NGs only 
lost ~5% body weight during the 2-week study period compared to control group while 
the same dose of Dox or the free drug combination (DOX+17-AAG) produced a 
considerable body weight loss (>15%, P < 0.05). These results indicate that DOX-loaded 
NGs have a much-improved therapeutic index when compared with free DOX. Notably, 
treatment with 17-AAG/NG did not have any substantial effect on the tumor growth (T/C 
= 0.87) and only minor increase in survival was observed over controls. To further 
corroborate the superior antitumor efficacy of binary drug combination in NGs, the 
tumors were excised post-treatment (on 10
th
 day after last injection) and processed for 




Fig. 5.6: Ki-67-caspase-3 apoptosis assay of excised tumors from mice treated with free drugs or 
NG-formulations. Panel A - Quantification of Ki-67 positive cells in tumor tissue from mice from 
various groups. Data are presented as mean ± SD (n = 5 random microscopic fields for each 
tumor slice). * P<0.05, *** P<0.001. Panel B shows a comparison of the tumor size for each 
treatment condition. 
The number of Ki-67 positive cells were significantly lower in tumors from mice that 
received (DOX+17-AAG)/NG compared to tumors in control (P<0.001) or DOX+17-
AAG (P<0.01) or DOX/NG (P<0.05) (Fig. 5.6A), which reflected the decrease in the size 
of the excised tumors (Fig. 6B). Light microscopic examination of H&E-stained tissue 
(liver, spleen, heart kidney and lung) sections from sacrificed animals (day 22) did not 
show any evidence of toxicity (data not shown). Collectively, these data provide in vivo 
evidence that biodegradable PEG-polypeptide NGs carrying DOX and 17-AAG drug 
combination exerted superior antitumor efficacy, both in terms of tumor inhibition and 






Using an ErbB2-driven breast cancer model, we demonstrated the potential of PEG-
polypeptide nanogels as novel nanocarriers for the delivery of synergistic combinations 
of chemotherapeutics with the HSP90 inhibitor, 17-AAG. Importantly, the binary drug 
combination of 17-AAG and DOX simultaneously delivered using NGs exhibited 
superior antitumor efficacy compared to a combination of free drugs and single drug NGs 
analogues. Inhibition of HSP90, which leads to degradation and down-regulation of 
several oncogenic client proteins, is a strategy being extensively explored as treatment for 
various types of cancers. HSP90 inhibitors, such as 17-AAG, which can synergize with 
various currently used anticancer agents has shown significant potential in initial phase II 
clinical trials, including in ErbB2-driven breast cancers. We have previously 
demonstrated the potential of 17-AAG to synergize with Trastuzumab and induce 
cytotoxicity in ErbB2-driven breast cancer models. Our studies with biodegradable and 
biocompatible polymeric NGs provide an alternative to the formulation issues that have 
impeded the development of 17-AAG. Moreover, these nanocarriers provide an 
opportunity to encapsulate multiple drugs with various physicochemical properties and 
modes of action. While doxorubicin was chosen as a model chemotherapeutic in this 
study, we anticipate that the multidrug loaded NGs represent an attractive platform for 
the development of potent combinations of HSP90 inhibitors with cytotoxic agents and, 
thus, further investigations of these NGs are warranted. 
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Combination chemotherapy is preferred over treatment with single agents to combat most 
cancers as it targets multiple cell-survival pathways at the same time and delays the onset 
of resistance. This helps in achieving long-term tumor remission and increases median 
survival. Cisplatin (CDDP)-based therapy has been the standard treatment for ovarian 
cancer since its discovery. After paclitaxel (PTX) was shown to be effective in ovarian 
cancer, multiple clinical trials studied the overall efficacy of CDDP and PTX and found 
significant benefit over the pre-existing treatments. Since then, this combination has been 
the treatment of choice for both early stage as well as advanced cases of ovarian cancer. 
However, administration of two different agents comes with the inconvenience of 
repeated or extended duration of drug infusion in patients. Moreover, the most 
extensively used conventional formulation of paclitaxel, Taxol®, utilizes Cremophor EL 
(polyethoxylated castor oil) that has been linked to significant toxicities including 
allergic, hypersensitivity and anaphylactic reactions during infusion that require 
premedication and prolonged peripheral neuropathy. Combining such drugs in one 
delivery carrier is therefore a well-suited and convenient strategy for controlling the 
pharmacokinetics and co-delivery of the desired drug ratio in vivo, to maximize the 
therapeutic potency and minimize drug-associated toxicities.  
      Cross-linked nanogels have been found to be promising drug carriers to achieve this 
goal. Being mostly hydrophilic in nature, nanogels are highly biocompatible with a high 
loading capacity for guest molecules. The nanogel structure can be readily adjusted to 
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integrate features of different materials and, thus, offer advantages for combinatorial 
encapsulation of drugs with varying physicochemical properties. One of the widespread 
synthetic techniques for the synthesis of nanogels is the crosslinking of preformed core-
shell self-assemblies such as polymer micelles that allows introducing a high degree of 
spatial organization into the nanogels. Cross-linking is known to impart control over the 
swelling behavior of the nanogels and thus helps in achieving controlled release of the 
incorporated cargo, which is an added advantage over the structural integrity imparted to 
the carrier system upon in vivo administration. The enhanced stability also makes the 
prolonged circulation of the nanogels possible, which in turn allows for increased drug 
accumulation at the target site by enhanced permeability and retention effect (EPR). We 
report in Chapter II design of multi-compartment cross-linked nanogels based on hybrid 
triblock copolymers, poly(ethylene glycol)-block-poly(L-glutamic acid)-block-poly(L-
phenylalanine) (PEG-b-PGlu-b-PPhe) for simultaneous loading and delivery of binary 
CDDP and PTX combination. Such nanogels have 1) a hydrophobic core formed by PPhe 
chains, which serves as a reservoir for PTX solubilization, 2) an anionic layer, which 
incorporates CDDP through coordination with the carboxylic groups of PGlu, and 3) an 
outer PEG shell stabilized, which stabilizes micelles in aqueous dispersion. The 
crosslinks incorporated into PGlu block layer ensure that the PEG-b-PGlu-b-PPhe 
micelles remain stable until they encounter proteases, which degrade the micelles by 
cleaving the polypeptide chains of the block copolymers. This work demonstrates that 
such biodegradable hybrid micelles carrying CDDP and PTX drug combination exert 
superior antitumor efficacy in treatment of ovarian cancer in xenograft mouse tumor 
model.   
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      Regardless of the importance and popularity of EPR effect-based drug delivery, this 
strategy has some limitations related to the inter- and intra-tumor heterogeneity, 
variations in the density as well as permeability of the tumor vasculature that can affect 
the accumulation of nanocarriers. One of the popular approaches to circumvent these 
problems is by surface-functionalization of the drug carrier with ligands that can target 
receptors with differential expression on the cancer cell surface, which helps in 
increasing the mean residence time of the delivery system at the tumor site and improving 
target cell uptake. One such receptor of interest is the folate receptor (FR). Malignant 
cells, due to their high rate of cell division, have an increased requirement of folic acid 
(FA), since it is essential component of cell metabolism and DNA synthesis and repair. 
To fulfill this higher need of FA, FR is known to be over-expressed in a large number of 
malignant tissues, including ovarian cancer, compared to normal tissues with the 
exception of the kidney and choroid plexus. Furthermore, this receptor becomes 
accessible via the plasma compartment only after the cells lose their polarity owing to 
malignant transformation which makes it a differential target for cancer tissue that is 
easily accessible for intravenously administered FA conjugated systems. Its natural 
ligand, FA, comes with the advantages of high binding affinity, stability and a simple 
chemical structure together with ease of availability, making it a suitable targeting ligand 
for ovarian cancer therapy. FA can thus be successfully conjugated to macromolecular 
systems without loss of binding affinity to its receptor. Many different agents targeting 
the folate pathway are currently in clinical development. To date, FA-targeted agents 
showed significant promise in phase II clinical trials but it has not been confirmed in 
phase III studies. Accordingly, there is a need for further identification of new therapeutic 
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combinations and refinement of patient selection. To this end, FA-conjugated imaging 
agents could be used for pre-selection of patients based on the expression of FR and 
several methods have been already developed for this purpose.  
      Our group has previously demonstrated a tumor-specific delivery and improved anti-
cancer effect in vivo of CDDP-loaded nanogels decorated with FA targeting groups. In 
our Chapter III, we designed FA-linked nanogels incorporating platinum-taxane 
combination, and examined whether FR-targeted concurrent delivery of synergistic 
combination of CDDP and PTX can lead to enhanced therapeutic efficacy compared to 
nontargeted NG system. 
      The oncogenic receptor tyrosine kinase ErbB2, overexpressed in over 20% of breast 
cancers, has served as a major target for the development of targeted drug delivery 
strategies. However, ErbB2 is thought to be either impaired in endocytosis or to rapidly 
recycle back to the cell-surface, which can significantly dampen the efficacy of ErbB2-
targeted drug delivery. Such altered trafficking dynamics is believed to be due to its 
constitutive association with HSP90 which can be anticipated to significantly dampen the 
efficacy of ErbB2-targeted drug delivery. We therefore hypothesized that HSP90-
inhibition will enhance ErbB2-targeted drug delivery by promoting the endocytic uptake 
of ErbB2-bound nano-encapsulated cargo and facilitating its re-routing from a recycling 
pathway to the lysosomes. Using Trastuzumab-conjugated NGs (Trast-NG) encapsulating 
the DNA-damaging drug Doxorubicin (DOX) as a model chemotherapeutic, we 
demonstrate in Chapter IV through both in vitro and in vivo studies that HSP90-
inhibition can indeed lead to an enhancement of targeted delivery of DOX specifically 
into ErbB2-overexpressing breast cancer cells. As a consequence, a sub-therapeutic and 
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non-toxic dose of the HSP90 inhibitor 17AAG markedly improves the efficacy of ErbB2-
targetd nanogels in vivo. In a follow up study, we attempted to co-encapsulate DOX and 
17-AAG since combining drugs in one delivery carrier is a well-suited strategy for 
controlling the pharmacokinetics and co-delivery of the desired drug ratio in vivo. 
However, co-incorporation of drug molecules with different physicochemical properties, 
such as hydrophilic DOX and hydrophobic 17-AAG, has been challenging. In Chapter 
V, we have described biodegradable polymeric nanogels (NGs) based on poly(ethylene 
glycol)-b-poly(L-glutamic acid) (PEG-b-PGA) with pendant phenylalnine functionalities. 
Such NGs have multiple hydrophobic domains formed by phenylalanine moieties within 
the cross-linked PGA polyion cores surrounded by a hydrophilic PEG shell.  Herein, we 
explored these novel NGs for co-encapsulation of 17-AAG and DOX. The potency of this 
co-delivery system was evaluated in a panel of human breast cancer lines and in an 
ErbB2-driven orthotopic xenograft model. We demonstrate that NGs-based co-delivery 
of synergistic combination of 17-AAG and DOX exhibited superior antitumor efficacy 
compared to a combination of free drugs in ErbB2-positive breast cancer cells. The 
implications of our results may support a new platform for delivery of combinations of 









LIMITATIONS AND FUTURE DIRECTIONS 
The data reported in chapter II showed the preclinical evaluation of platinum-taxane-
loaded nanogels. Our work demonstrated that such biodegradable hybrid nanogels 
carrying CDDP and PTX drug combination exert superior antitumor efficacy in treatment 
of ovarian cancer in xenograft mouse tumor model. However, our system relied solely on 
the EPR effect to facilitate the delivery of the drug combination to the tumor site. No 
matter what the importance and popularity of EPR effect-based drug delivery is, this 
strategy has some limitations related to the inter- and intra-tumor heterogeneity, 
variations in the density as well as permeability of the tumor vasculature that can affect 
the accumulation of nanocarriers. One of the popular approaches to circumvent these 
problems is by surface-functionalization of the drug carrier with ligands that can target 
receptors with differential expression on the cancer cell surface, which helps in 
increasing the mean residence time of the delivery system at the tumor site and improving 
target cell uptake. In our Chapter III, we designed FA-linked nanogels incorporating 
platinum-taxane combination, and examined whether FR-targeted concurrent delivery of 
synergistic combination of CDDP and PTX can lead to enhanced therapeutic efficacy 
compared to nontargeted NG system. Many recent studies have shown that the particulate 
system with the size less than 50 nm has profound effect on its tumor accumulation. 
Although we were able to generate particles with the size less than 100 nm, it wasn’t 
small enough for the very effective tumor accumulation as per recent reports. Another 
limitation of current triblock copolymer-based nanogels system is loading same drug 
combination at different ratios. Although our current drug ratio is very synergetic, we are 
also exploring the different block length ratios which would allow us to have system with 
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different ratios of same drug combination. Current and future studies planned in our 
group include design and fabrication of sub-100 nm particulate system. One such a 
system under investigation is based on diblock copolymers of PEG and poly(L-leucin). 
This copolymer assembles into a uniform micellar aggregates in aqueous solutions. The 
resulting micelles have size of less than 50 nm. It also allows for loading to highly 
synergistic combination of hydrophobic drug molecules including paclitaxel.  
      The binding of FA-(CDDP + PTX)/NG to and/or their uptake by FR+ cancer cells 
can retain them within the tumor for a longer period of time, prevent their rapid re-
entering into systemic circulation and, thus, provide some benefits over passively 
targeted formulations. The introduction of FA moieties can also have an effect on 
pharmacokinetics and biodistribution of NGs and influence tumor uptake. Our future 
efforts include detailed pharmacokinetic study which may help to elucidate the 
relationship between the therapeutic effect of the FR-targeted NGs and distribution at the 
tumor and the whole body. FA targeting achieved desirable tumor inhibition in our 
present study but its distribution in other organs especially kidney (main site of platinum 
toxicity) which still remains a concern. Selecting an alternative targeting moiety with a 
better selectivity to tumor target is therefore desirable. We also would like to try our 
treatment regimen on the cisplatin-resistant cell line to see if targeted combination 
therapy can induce a therapeutic response in them.  
      Current clinical therapy for ErbB2-positive breast cancer includes the administration 
of Trastuzumab monoclonal antibody (Herceptin™). This therapy suffers from several 
limitations. Firstly, its long-term clinical use is questionable because tumor cells acquire 
resistance to the therapy and secondly, ErbB2 is either impaired in endocytosis or rapidly 
192 
 
recycles back to the cell surface. In chapter IV, our studies demonstrated, both in vitro 
and in vivo, that HSP90 inhibition facilitates the uptake and delivery of trastuzumab-
based ErbB2-targeted nanoparticle therapy carrying a model chemotherapeutic agent, 
Doxorubicin, specifically into ErbB2-overexpressing breast cancer cells. These novel 
findings highlight the importance of considering oncogene-specific alterations in receptor 
dynamics towards the design of targeted drug delivery strategies. We suggest that 
combination of ADCs or ANPs with therapeutic agents that enhance receptor endocytosis 
and lysosomal routing can provide a novel strategy with significantly higher therapeutic 
benefit. Based on our studies, we suggest that the endocytic traffic itinerary of receptors 
selected for targeting of ADCs and ANPs should receive careful consideration. An 
understanding of mechanisms that may impair the endolysomal traffic of a targeted 
receptor (as with ErbB2) may help overcome an efficacy barrier on newer agents in 
development and potentially improve the efficacy of agents already in the clinic. In this 
regard, the potential combination of HSP90 inhibitors that are already in clinical trials 
together with the ErbB2-targeted TDM-1 will be of considerable interest and is under 
study in our group. It is of interest that HSP90 is also thought to regulate the activity of 
Rab GTPase-dependent endocytic recycling by its association with a Rab Guanine 
Nucleotide Displacement Inhibitor (GDI), and HSP90 inhibitors could potentially help 
attenuate Rab-dependent recycling of transmembrane receptors that are not direct HSP90 
clients to enhance ADC or ANP delivery inside the tumor cell. Other factors that may 
control trafficking of oncogenic cell-surface receptors such as the non-receptor tyrosine 
kinase c-Src, endocytic adaptor proteins, E3 ubiquitin ligases, deubiquitinating enzymes, 
RAB GTPases, ESCRT proteins and EHD family proteins may offer future opportunities 
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to develop facilitators of ADC and ANP traffic to endolysomal compartments as 
approaches of therapeutic potentiation.  
      Our studies also provide evidence that sub-therapeutic doses of an HSP90 inhibitor (1 
mg/Kg 17AAG in our studies, which has little efficacy against BT-474 xenografts; 
unpublished data), dramatically enhances tumor killing by DOX-loaded ErbB2-targeted 
NGs. Such a combination led to not just inhibition of xenograft tumor growth but in fact 
a significant shrinkage of tumor masses from their pre-treatment volume. This was 
associated with a significant shift from a merely cytostatic to a significantly cytotoxic 
effect on tumors as demonstrated by Ki67 and caspase-3 staining of tumors among 
surviving mice at the end of therapy. Not surprisingly, combination with low dose 
17AAG markedly improved the survival of tumor-bearing mice. We must point out that 
DOX was used in our proof-of-principle studies as the polymer design we have 
previously established allows efficient loading of this clinically-used chemotherapeutic 
agent. However, DOX enhances cardiotoxicity associated with ErbB2-targeted antibody 
therapeutics, including Trastuzumab, and as such the approach will need modifications to 
incorporate more appropriate agents for ErbB2+ cancers. Such studies are currently 
ongoing in our laboratories. The current nanocarrier design should however be applicable 
to other tumors where a targeting antibody or other moiety is available. We have tested 
the efficacy of our regimen on the Trast-sensitive cell lines. Our ongoing efforts are to 
test the efficacy of our regimen on trast-resistant cell lines and also choose a transgenic 
mouse model to test our treatment regimen. 
 
 
